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Abstract 1 
ABSTRACT 
An investigation of the marine sponge Halisarca sp. was carried out following 
the discovery of strong activities in antiviral and P388 murine leukaemia 
assays of an extract from this sponge. A polyether type of compound is 
suspected as the cause of this activity. The investigation of Ha/isarca sp. 
made a significant contribution to the development of a chemical screening 
process. 
The absolute configuration of pateamine has been elucidated by a 
combination of degradative and synthetic chemistry utilising formation of 
diastereoisomers with Mosher's acid. Several other derivatives of pateamine 
are reported. 
The algal metabolite thyrsiferol has been isolated from the digestive gland of 
the marine mollusc Aplysia parvula. The egg masses of A parvula have also 
been examined. 
The NMR characterisation of the thyrsiferol has been extended through the 
extensive use of one- and two- dimensional spectroscopic experiments. 
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1.1 Natural Products as Potential Drug Sources 
As the human population has developed and expanded, the demands for 
food, space and good health have increased. The increasing importance of 
treating new or sedentary diseases has outstripped the capabilities of 
empirical ethnobotanical knowledge, traditionally derived from terrestrial flora 
and fauna, to provide new treatments and cures for diseases that were not 
critical to those cultures developing natural remedies. The increasing 
demand for good health has also led to the problem of supply for existing 
herbal or naturally based remedies. This is compounded by the destruction 
of habitat and loss of cultures capable of disseminating or adding to the 
present ethnobotanical store of knowledge. The use of crude preparations 
from plants and animals can have several disadvantages 1 such as climatic, 
ecological, morphological and geographical variations in the quantities of the 
active constituent(s). Other drawbacks include the possible co-occurrence of 
undesirable components with detrimental side effects and the loss of 
biological activity due to the variability of preparation or storage of the crude 
material. It is therefore desirable to isolate the individual natural products 
which give rise to the observed biological activity. 
Williams et a/.2 define a natural product as "a substance that has no known 
role in the internal economy of the producing organism!! and that the function 
of natural products is to " ... confer any survival advantage on the producing 
organism due to the structure of the natural product itself." This contrasts 
with other natural organic products such as sugars, amino acids, and nucleic 
acids, which are primary metabolites and are both essential and ubiquitous. 
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The metabolic cost of producing bioactive natural products can be justified by 
having a protective role in the organism: protection from overgrowth, 
protection from predation, protection from competition for space, light and 
nutrients, and protection from infection by micro-organisms. Williams et a/.2 
point out that natural products are sparse in those organisms possessing an 
immune system and are common in those lacking an immune system such 
as plants, fungi, micro-organisms and invertebrate animals. Natural 
compounds isolated from species that lack an immune system are therefore 
a rich source of biologically active compounds. The origin of biologically 
active natural products associated with an organism can be obscure as they 
may be synthesised de novo by the organism itself, or they may be 
sequestered from a dietary or symbiotic source, or be a product of joint 
metabolism. 
1.1 .1 Marine Natural Products 
The seas and oceans of the world cover a vast area of the earth and contain 
a huge diversity of relatively unexplored flora and fauna. It has been 
estimated that four-fifths of the Earth's animal life live in or on the water.3 
Coupled with the growing accessibility of the marine environment, such as by 
SCUBA diving, marine organisms now represent a valuable, and largely 
intact, resource for the discovery of novel bioactive natural products with 
pharmaceutical potential. 
Data from the National Cancer Institute (NCI) in the USA, compiled by Dr. 
Peter Murphy of the Australian Institute of Marine Sciences (AIMS) in 1992,4 
further illustrates the utility of screening marine natural products as potential 
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drug sources. Figure 1.1 displays the number of anticancer leads from 
various sources in the NCI in vitro preclinical antitumour drug screen. It can 
be seen that although, relative to terrestrial sources, a low number of 
compounds of marine origin have been screened, there is a high proportion 
of anticancer leads originating from marine animal sources. 
Absolute number screened in italics 
Terrestrial Animals 
Terrestrial Plants 18923 
Marine Animals 
Marine Plants 
Microorganisms 
0 2 
Percentage 
Figure 1.1 Anticancer Leads with Significant Cytotoxic Activity in the NCI 
Preclinical Antitumour Drug Discovery Screen.4 
Australian results from AIMS4 indicate more specifically, that the marine 
invertebrate phylum Porifera (sponges) provides a rich source of cytotoxic 
marine natural products, with over 11 % of specimens in this phylum 
displaying significant cytotoxicity (viz JC5o <4 J.Lg/mL). The marine world is a 
very competitive and hostile environment. Therefore it is not surprising that 
so many marine species have diverted greater amounts of resources to the 
development of secondary metabolic pathways, as part of their chemical 
survival strategy, than those species of the terrestrial world. 
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1.1.2 Sponges5 
Sponges belong to the phylum Porifera and there are in excess of 5000 living 
species ranging is size from around 5 mm to as large as 2 metres across. 
Sponges are sessile animals (although larvae can be crawling or free 
swimming entities) permanently attaching themselves to hard surfaces, such 
as rocks or mollusc shells. These are usually found in relatively shallow salt 
water but they are also found in deep ocean water, or in fresh water lakes 
and streams. Sponges are hollow filter feeders and extract food particles 
such as bacteria, algae and dinoflagellates from a flow of water that is 
pumped through their bodies by flagella. This flow of water enters the 
sponge through perforations called incurrent pores, the water is strained of 
food particles and exits the atrium or body cavity through excurrent pores 
called osculi. Sponge cells face different environments according to their 
position in the body, some face the external world, some are surrounded by 
other sponge cells. This difference in position has allowed cell groups to 
evolve different functions and forms. Sponges are the most primitive animals 
to show tissue level of organisation. Some cells, the amoebocytes, are 
responsible for the formation of the supporting structure of the sponge. This 
supporting structure can be made of material such as a type of collagen that 
forms a fibrous "skeleton !I or calcium carbonate or silica which forms spicules 
offering rigidity, support and protection. The spicule shapes are used to help 
classify sponge species into taxonomic groups. 
1.1.3 Molluscs6 
There are about 1 00 000 living species of Mollusca and members show a 
wide range of diversity. Molluscs include such varied forms as chitons, 
Chapter 1 "Introduction 8 
slugs, clams and octopuses and live in such diverse habitats as terrestrial 
areas, marine or fresh water systems or a combination of both as found in 
the littoral zone. Chitons and slugs have a radula, a tongue"like strap 
covered with horny teeth that scrape off small bits of algae and other marine 
plants living in the littoral zone. Clams lack the radula and tend to be filter 
feeders that use cilia to flow water over sieve"like gills. Squid and octopuses 
are the most advanced molluscs and have modified the radula to contain 
jaws. Their behaviour is also the most advanced with limited learning 
capability. The molluscan body has several distinctive regions, a muscular 
foot used for locomotion, a visceral mass containing internal organs such as 
the heart, digestive system and excretory system, a head housing the 
sensory organs, brain and mouth, and the mantle cavity that houses the gills. 
Molluscs have a true circulatory system with a heart, a few closed blood 
vessels associated with the gills and an open, blood filled cavity which baths 
internal tissues. 
1.2 The Marine Chemistry Group 
The Marine Chemistry Group at the University of Canterbury was formed in 
1975 with the main objective being to isolate and identify the structures of 
biologically active compounds derived from marine sources. 
Screening of extracts for a particular biological activity, for example antiviral 
activity, from plant, animal, microbial or fungal sources with a disease" 
specific biological assay provides an invaluable guide for the separation and 
isolation of bioactive natural products. In this way important leads in drug 
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discovery and development can be revealed for the potential treatment of 
specific diseases. 
A wide range of extracts are screened in the Marine Chemistry Group's in-
house in vitro antimicrobial, antiviral and antitumour assays (see Appendix 1). 
Those organisms producing extracts with a pertinent biological response are 
re-extracted on a larger scale in a bioassay-directed chromatographic 
isolation and the active components identified. The P388 antitumour assay 
is discussed in detail below and examples of bioassay-directed "hitsn (ie the 
isolation of biologically active compounds} are described in Section 1.2.2 
which serves to highlight the success of the Marine Chemistry Group's 
approach. 
1.2.1 The P388 Antitumour Assay 
The in vitro "antitumourll assay uses the P388 cell line (murine leukaemia 
cells} and it is up to a hundred times more sensitive to cytotoxicity effects 
than the antiviral BSC-1 cell line (see Appendix 1). The P388 assay is 
therefore a cytotoxicity-based assay against a specific leukaemia cell type. 
The ICso result obtained from this assay represents the concentration of the 
test compound at which the number of viable cells is reduced by fifty per cent 
relative to the control. 
A two-fold dilution series of the sample of interest is incubated with P388 
cells in 96-well microtitre plates. After seventy-two hours of incubation the 
concentration of the sample required to reduce the number of viable cells by 
fifty per cent relative to a control (P388 cells, MTT, a positive control such as 
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mitomycin C, media and solvent) is calculated. This is achieved by adding 
MTT, a yellow tetrazolium salt to each well and incubating for a further 4 
hours. The mitochondria of viable leukaemia cells can reduce the yellow dye 
MTT to a purple formazan derivative? By measuring the light absorbance at 
540 nm in each well, a direct quantification of formazan formation and 
therefore the number of viable cells is able to be determined. The 
absorbance is expressed as a percentage cell viability relative to the control, 
and is plotted against the logarithm of the sample concentration in the well to 
generate a sample concentration vs cell viability curve. The antilogarithm of 
the concentration producing a fifty per cent reduction in the number of viable 
cells gives the ICso result, which is usually expressed in units of ng/ml 
(Figure 1.2). Those samples not intersecting the fifty percent line are either 
too dilute (always above, compound "g") or too concentrated (always below, 
compounds "c" and ue") to return an ICso value. 
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Figure 1.2 A Typical Graph Generated From the P388 Assay 
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The P388 cell line represents a rapidly dividing cell type, thus its efficacy in 
finding products with activity in the predominantly occurring slow growing 
solid tumours of humans such as lung, colon, breast, skin and kidney 
cancers is strictly limited.8 However, it is important to note that a P388-active 
compound may still display a selective activity against these types of 
tumours. 
1.2.2 Bioassay-Directed Isolations 
The antiviral and antitumour compounds mycalamide A (1) and mycalamide 
B (2) were isolated in a bioassay-directed extraction of a New Zealand 
species of Mycale found in the Otago Harbour. 9• 10 
CH2 
R=H mycalamide A (1) 
R=CHs mycalamide B (2) 
The mycalamides later proved to be too cytotoxic to be effective as antiviral 
agents but at present they represent important anticancer leads and 
synthesis of analogues is currently being undertaken. 
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Pateamine (3) was isolated from a Myca/e species of marine sponge from 
Fiordland and is of potential importance as an immunosuppressant agent. 11 
The planar structure of pateamine (3) was resolved in 1990,12 but the 
stereochemistry of the four stereocentres was not elucidated. 
28 
s 
11 
10 ~ ~ ~ 17 /29 
26 N 
5 0 I 
0 18 27 30 
H2N 3 
25 
0 0 24 31 
pateamine (3) 
Attempts to synthesise pateamine (3) are currently in progress and the 
elucidation of the stereochemistry, to enable the synthesis of the correct 
stereoisomer, is discussed later in this thesis. 
A bioassay-directed extraction of the New Zealand sponge Latruncu/ia sp. 
led to the isolation of the structurally related iminoquinones, discorhabdins A 
(4), B (5) and C (6) as the major cytotoxic components. 13• 14 These 
displayed strong antiviral activity in vitro; high activity in the in vitro P388 
assay and selected antimicrobial activity. Discorhabdin C (6), like the 
mycalamides, currently represents an important anticancer lead. 
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0 H 
N 
')s 
0 
discorhabdin A (4) 
Br 
H 
N ~s 
0 
discorhabdin B (5} 
13 
Br 
discorhabdin C (6) 
Bioassay-directed isolation of the active constituents from a sample of the 
deep-water Kaikoura sponge, Lissodendoryx sp., yielded several novel 
members of the halichondrin series of antitumour compounds and relatively 
"large" amounts of two known halichondrins. The halichondrins were first 
reported in 1985 by Uemura et a/.15 followed by a related paper in 1986 by 
Hirata and Uemura.16 Eight halichondrins were isolated and identified, the 
most active being halichondrin B (7) with an ICso of 0.093 ng/mL. Other 
members of the halichondrin series, viz. norhalichondrins, homohalichondrins 
or isohomohalichondrins, differ in structure beyond the C49 position. The 
families A, Band C designate the degree of oxygenation at the C12 and C13 
positions. 
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' H rx 53 H OH 
R=R'=H halichondrin B {7) (23 ' 
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OH 
55 
OH H 
,, 
,, 
,, 
,, 
R=R'=H B series 
R=H, R'=OH C series 
R=OH, R'=OH A series 
0 OH 0 ,,, 
H 
HO,, cr49 0
L ~ TI ~ ~ ,, s 1 4 7 ~,,, 0 -
H : 
homohalichondrin series isohomohalichondrin series 
H 
HO,,,,cr49 0
51 47 ,, 
'"' 0 HO~O H ~ 
norhalichondrin series 
14 
Currently, halichondrin B (7) has NCI Decision Network Committee (DNC) 
"IIA status", awaiting preclinical development and the implementation of an 
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effective, sensitive method of analysis for halichondrin B (7) in body fluids. 
At the IIA stage in preclinical development, isolation and/or synthesis of the 
drug is optimised and studies on the feasibility and cost of scale-up are 
carried out. The DNC allows approximately ten compounds per year past 
this point. At stage Ill level, "Investigational New Drug Application" approval 
is sought, then clinical trials may commence. 
1.3 Supply of Marine Natural Products 
The bulk supply of a potential anticancer drug is an essential requirement for 
entry into the clinical trial stage and many of these compounds are isolated in 
small quantities. There are several options for obtaining large amounts 
(gram quantities) of a bioactive natural marine product: collection; 
aquaculture; microbial or tissue culture; genome transfer; or the total 
synthesis of the compound. Tissue culture and genome transfer are long 
term options and the viability of a bioactive natural product would have to be 
well established before these options would be economic. Although the 
starting points for synthesis typically rely upon inexpensive compounds of 
known absolute stereochemistry, the synthesis usually includes many 
reaction steps for any molecule of reasonable size. Multiple reaction steps 
involving stereospecific reactions lower the yield of the desired enantiomer, 
making this path a long term option only. Collection, even with its ecological 
ramifications, or aquaculture remain the options of choice for obtaining 
significant amounts of bioactive natural marine products. 
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1.4 The Importance of Absolute Stereochemistry 
The pharmaceutical industry has had to address the requirement by 
regulatory authorities that they must market chiral drugs as pure 
enantiomers. 17 The majority of marine natural products are isolated as 
enantiopure compounds due to their specific biosynthesis. However bulk 
supplies of these potential drugs, which do not rely on biosynthesis, are likely 
to have different characteristics due to the presence of stereoisomers. 
Examples of the different pharmacological response of two enantiomers are 
common: (S)-warfarin (8) is six times more active as an anticoagulant than 
the R enantiomer, while (S)~propranolol (9) is an antihypertensive and 
antiarhythmic used in the treatment of heart disease while the R enantiomer 
acts as a contraceptive.17 
~ 0 
# H 
''''CH2C0Me 
OH Ph 
( S)-warfarin (8) ( S)-propranolol (9) 
Only the 2R, 3R isomer of 2-fluorocitric acid (1 0), a metabolite of the citrate 
synthase pathway from sodium fluoroacetate (1080) poisoning, is active as a 
cell poison while the other three stereoisomers (11, 12, 13) can be 
successfully metabolised by the ce11. 18 
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C02H / H02C H / H 
'' / 
F'''' OH HO 
/ 
,, 
H ,,,,C02H / H02C'',,,. HR 
/ I I 
C02H / H02C 
'''Hs 
/ 
(2S, 3R)-2-fluorocitric acid (11) / (2R, 3$)-2-fluorocitric acid (12) 
/ 
/ 
C02H / H02C F / F 
H'' '' 
,, 
OH / HO 
,, 
'''H 
H 
,, 
''''C02H 
/ 
/ 
H02C',,,·' HR 
,, ,, 
H~· / '''Hs 
C02H / H02C 
(2R, 3R)-2-fluorocitric acid (1 0) (2S, 3$)-2-fluorocitric acid (1 3) 
Perhaps the most infamous example of an enantiomer causing undesirable 
side effects is that of thalidomide. (B)-thalidomide (14) is a powerful 
tranquilliser while the (R} form is a potent teratogen. 19 
0 0 ~N· .. U 
0 0 
(B)-thalidomide (14) 
It should be realised that, where only one enantiomer is the desired bioactive 
compound, a racemic mix is in reality two drugs with differing properties. 
Chapter 1 -Introduction 18 
1.5 Determination of Absolute Stereochemistry 
The determination of absolute stereochemistry has become an important 
aspect of the characterisation of natural products. Elucidating the absolute 
stereochemistry allows any synthetic effort to target the correct isomer. 
The method of choice for the determination of absolute stereochemistry is 
single crystal X-ray crystallography. This typically provides an unambiguous 
assignment of the absolute stereochemistry for the molecule. If the R factors 
for the enantiomers are ambiguous, crystal engineering, where a molecule of 
known absolute stereochemistry is cocrystallised with the molecule in 
question, may allow the configuration of the unknown molecule to be 
assigned. A major drawback for single crystal X-ray crystallography is the 
requirement for adequate monocrystals. Such monocrystals may be 
unobtainable. 
Gas chromatography (GC),20 or high performance liquid chromatography 
(HPLC)21 methods employing chiral stationary phases, or more rarely chiral 
solvents, can also be employed with great precision. Compounds of 
unknown absolute stereochemistry are compared with samples of known 
absolute stereochemistry or with a series of compounds that are similar in 
structure with known absolute stereochemistry. 
Comparison of optical properties of a compound of unknown stereochemistry 
with the optical properties of a series of compounds of known absolute 
stereochemistry is another method for determination of absolute 
Chapter 1 M Introduction 19 
stereochemistry. The compounds that the unknowns are to be compared 
with also need to be closely related. 
The exciton chirality method is also a reliable method for the determination of 
absolute stereochemistry. This relies on the chiral interaction between two or 
more isolated, but spatially close, chromophores which gives rise to 
Davydov-split Cotton effects. 22 
The GC, HPLC and optical methods that rely on comparison with other 
compounds are open to interpretation as to the structural similarity of the 
compounds. The use of optical rotation is also subject to the uncertainty of 
contamination with an optically active impurity. This is particularly serious 
when the impurity has a high rotation or a rotation of opposite sign to that of 
the compound of interest.17 
1.5.1 NMR Determination of Absolute Stereochemistry 
As enantiomers cannot be distinguished in an achiral medium, a chiral 
auxiliary must be employed to convert the enantiomers into a 
diastereoisomeric mixture. This leads to NMR chemical shift 
nonequilvalance (L.\8) of groups adjacent to the chiral centre which can then 
be correlated to give the absolute stereochemistry of the chiral alcohol or 
amine.23 There are three types of chiral auxiliary in use. Chiral lanthanide 
shift reagents and chiral solvating agents form diastereotopic complexes in 
situ with the enantiomers and may be used directly in the NMR tube. 
Derivatisation of enantiomers with an enatiomerically pure compound is the 
most widely used technique and there are a number of such agents available 
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{Table 1.1 ). This requires the separate formation of discrete 
diastereoisomers prior to NMR spectroscopic analysis without racemisation 
or kinetic resolution. The advantage of chiral derivatising agents is that the 
observed chemical shift nonequilvalance Ao is typically five times greater 
than for related complexes with a chiral solvating agent.17 
Table 1.1 A Selection of the Most Useful Chiral Derivatising 
Agents for 1 H NMR Spectroscopic Analysis 
F?h Ph P.h 
A'''C02H H~'''C02H A'''COH F3C OMe AcO 2 OMe H 
(S)-MTPA (15) ( S)-a-methoxy-a- (R)-0-acetyl 
phenylacetic acid (16) mandelic acid (17) 
F?h f?h P.h ~'''C02H F~'''CH2NH2 H~'''NH2 H OH H Me 
(S)-methyl (R)-2-fluoro-2- ( S)-a-phenyl 
mandelate (18) phenylethylamine (19) ethylamine (20) 
0 
($)-a-naphthyl 
ethylamine (21) 
camphanic acid (22) 
The most widely used chiral derivatising agent is a-methoxy-a-
(trifluoromethyl)phenylacetic acid (MTPA) in what is known as the Mosher 
method.24 For MTPA esters, the preferred conformation adopted is where 
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the carbinyl hydrogen, carbonyl oxygen and a-trifluoromethyl group are all 
eclipsed (Figure 1.3 and Figure 1.4).17, 24 
Figure 1.3 Conformational Models for (R) and (S)-MTPA Esters23 
Figure 1.4 Extended Newman Projections of the Conformational Models for 
( R) and ( S)-MTPA Esters 
For (R)-MTPA esters and am ides, this places one group (L 2 in Figure 1.4) 
consistently close to the shielding influence of the phenyl ring. This group, 
(L 2), consequently resonates upfield of the L 2 resonance in the (S)-MTPA 
ester or amide (where the OMe and phenyl ring have exchanged sites) as 
this shielding is not present in the latter case. The reverse is true for L 3 . 
Careful analysis of the chemical shifts for the same groups ~ to the chiral 
centre for the two diastereoisomers, allows assignment of L 2 as having A8(R)-
(S)<O and L 3 as having A8(R)-(S)>O. 19F NMR chemical shifts of the MTPA 
trifluoromethyl group can also be used for the determination of absolute 
stereochemistry. 25 
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The Mosher method relies on few data points, just those of the ~ position. 
Ohtani et a/.26, 27 have pointed out that they, o, and£ positions may cause a 
greater steric interaction with the MTPA group and hence display a greater 
difference in the Ao chemical shifts. These workers use this observation in a 
modified Mosher's method that enables the examination of as many protons 
as can be assigned and, due to the number of data points, may be more 
reliable. 
a-Methoxy-a-phenylacetic acid (MPA) is another chiral derivatising agent 
assessed by Dale and Mosher23. Riguera28 has suggested that MPA has 
advantages over MTPA due to the lower number of possible conformers, 
therefore giving rise to greater time-averaged chemical shift differences. 
The conformation proposed by Dale and Mosher23 for the MPA moiety is one 
in which the torsional angle between the Ca-OMe and the C=O bonds is syn-
periplanar but this is only one of the two stable conformers, the other (anti-
periplanar) being one in which the methoxy group comes close to the ester 
carbonyl (Figure 1.5).29 
A~H 
MeO 0 
R 
Figure 1.5 Syn-periplanar and Anti-periplanar Rotamers for 
Methoxyphenylacetates 
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If the anti-periplanar conformation has a significant population, the time-
averaged t\8 will be reduced, possibly to a point where distinction is no 
longer observed. Because the energies of the anti-periplanar and the syn-
periplanar rotamers are very close, the equilibrium between them can be 
significantly altered by temperature effects if required.30 
The direction of the chemical shift differences between diastereotopic MTPA 
am ides and esters are the same. However the direction of the chemical shift 
differences between diastereotopic MPA amides are opposite to that 
observed for esters of similar absolute configuration.23 •31 The 
conformational preferences of amide and ester functional groups do show 
clear differences. The COC=O skeletal fragment shows a preference for the 
Z conformation, while the conformational distribution of CNHC=O is more 
complex, with ZIE ratios ranging from 90/10 to 50/50 known (Figure 1.6).32 
The anti-periplanar-Z conformer is the most populated followed by the syn-
periplanar-Z conformer. 
H l?h 0 H MeO - N ~ 
2 I -f,,,L 
H L1 
Figure 1.6 Some of the Conformational Models for Anti-periplanar-Z, 
Anti-periplanar-E and Syn-periplanar-Z (R)-MPA Amides32 
For the (R)-MPA amide this places one group (L2 in Figure 1.7) close to the 
shielding influence of the phenyl ring which consequently resonates upfield of 
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L2 in the corresponding (S)-MPA amide due to the shielding influence not 
being present in the latter case. The reverse is true for L 1. 
Figure 1.7 Extended Newman Projections of the Conformational 
Models for (R) and (S)-MPA Amides31 
The esters adopt a syn-periplanar conformation where the carbinyl hydrogen, 
carbonyl oxygen and a-methoxy group are all eclipsed (Figure 1.8).29 
MeO~ 
L 
Figure 1.8 Extended Newman Projections of the Conformational Models for 
(R) and (S)-MPA Esters30 
Due to the differing dipole moment of the syn-periplanar and anti-periplanar 
rotamers, 31 solvent polarity has a marked effect on the ratio of the two 
rotamers. The more polar, unwanted conformers are less stabilised in 
nonpolar solvents, such as CDCI3 and CCI4, allowing some optimisation of 
the chemical shift differences for MPA amides.32 
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The change in the conformation between MPA esters and amides may result 
from an intramolecular hydrogen bond between the amide hydrogen and the 
methoxy substituent.31 MTPA is not subject to this directional chemical shift 
difference due to the electronegative CFs group aligning with the carbonyl 
rather than the methoxy group for MP A 
The validity of the Mosher method has been well established17 with 
numerous examples of the use of MTPA esters to demonstrate the 
stereochemistry of compounds with previously known absolute 
stereochemistry.29 The Mosher method however, is not infallible. 
Sipholenoi-A (23) is one such case. The MTPA esters of position 4 were 
prepared but it was found that the positive and negative 83 values were 
irregularly placed on the left and right sides of the MTPA plane.33 
sipholenoi-A (23) 
Steric hindrance around the MTPA moiety, which in this case is in the axial 
position, forced the conformation of the MTPA group from an ideal 
orientation. As a result, alternative competing conformations were possible 
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which reduced the chemical shift differences between the diastereoisomers 
to a level where a decision was not possible. Steric hindrance, such as cited 
here, has been claimed to be the cause of such failures.34 
1.6 Project Aims 
The objectives of this project were as follows: 
1) The isolation of biologically active natural products from the marine 
sponge Halisarca sp. This sponge displayed activity in the P388 assay at 
2322 ng/mL in the chemical screening process of a small (2 g) sample. 
2) The determination of the stereochemistry of pateamine. 
3) To ascertain if the sea-hare Ap/ysia parvula, a herbivorous shell-less 
mollusc, sequesters selected metabolites from the red alga Laurencia 
thyrsifera. A. parvula is thought to use such compounds, or derivatives, for 
its own defence against predators higher up in the food chain and also to 
protect its egg masses. 
Chapter 2 ~ Halisarca sp. 27 
Chapter 2 
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2.1 Introduction 
Halisarca sp. is a member of the family Halisarcidae. This family is placed in 
the order Dendroceratida which Bergquist35 describes as "lack[ing) siliceous 
spicules and which have a skeleton composed entirely of spongin fibres 
arranged in a dendritic pattern... In one family the spongin skeleton is lost 
completely .11 Halisarcidae is the family characterised by a complete lack of 
both spongin and mineral skeleton. This lack of a skeleton hinders greatly 
the classification of members of this family as sponge taxonomic descriptions 
typically rely on skeletal characteristics. The classification of specimens of 
Halisarca species must rely on ecological, histological and reproductive 
information. 35 
A search in the marine chemistry literature database, MarinLit,36 revealed 
that no compounds had previously been isolated from the Ha/isarca genus. 
The specimens used in this study were collected from three deep water (80 
m} dredging operations in Otago harbour from which 2.54 kg of Halisarca sp. 
was collected. Guided by the strong activity displayed in the initial in-house 
antiviral and P388 murine leukaemia assays of an extract of a small (2 g) 
sample (HSV, ?; Hcyt 3+ (1 0, 4); PV1, ?; Pcyt, 4+, (4); P388, 4230 1 o-6 dil, 
see Appendix I for an explanation of the assays), an investigation of this 
sponge was initiated. 
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2.2 Attempted Isolation of Active Material 
2.2.1 1st Extraction 
Solvent partitioning of the crude organic extracts from Halisarca sp. (1 kg} 
was undertaken. This concentrated the activity into the non-polar fraction 
and a small amount of this was used for chemical screening. 
2.2.2 Chemical Screening 
Chemical screening is the term given to taking a small amount of crude 
extract and eluting aliquots1 of this material off a variety of cartridges to 
assess the physical, chromatographic and stability properties of an extract on 
various sorbents. 37 This process enables dereplication of extracts so as to 
avoid the considerable effort expended in purifying the active component(s) 
to a stage where spectroscopic properties allow comparison with known 
compounds. Chemical screening also allows rapid identification of 
chromatographic methods suitable for the purification of the active 
component(s) present in the extract. This investigation of the Halisarca sp. 
extract was part of the chemical screening development effort. 
An aliquot of the active fraction was dissolved in methanol/water and loaded 
onto a 500 mg reverse-phase octadecyl (C18} cartridge. Four fractions were 
collected with the activity eluting in the last two fractions (methanol and 10 % 
dichloromethane/methanol}. Another aliquot of the same active fraction was 
dissolved in benzene and loaded onto a DIOL cartridge. Not all of the 
material was soluble but the insoluble material was transferred onto the frit, 
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enabling subsequent solvents to dissolve material. Five fractions were 
collected with the activity solely in the final, methanol fraction. Finally 
another aliquot of the same active fraction was dissolved in methanol and 
loaded onto a CBA cartridge. Three fractions were collected from a "pH" 
gradient with the active material eluting in the initial methanol wash. 
The chemical screening carried out suggested that the P388 active material 
was a moderately non-polar, acidic compound and that C18 and DIOL 
sorbents would be ideal initial chromatographic methods. 
The investigation of Halisarca sp. made a significant contribution to the initial 
development of the chemical screening process. This development has 
continued through the work of others in the Marine Chemistry Group, and a 
full description of the current chemical screening protocol is included as 
Appendix II. 
2.2.3 Further Chromatography 
Solvent partitioning of the crude organic extracts concentrated the activity 
into the non-polar fraction which analysis by thin layer chromatography 
revealed contained much sterol material. In an effort to separate the active 
material from the very non-polar material, C18 reverse-phase column 
chromatography was employed. This resulted in the shedding of a significant 
amount of the mass while concentrating the active material into seven 
fractions (fractions 6 to 12, Figure 2.1 ). 
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Figure 2.1 % Mass versus % Specific Activity for the C18 Reverse-phase 
Column of Ha!isarca sp. Active Material (Specific Activity = mass/ICso) 
Thin layer chromatography using DIOL sorbent showed good separation of 
some of the components of the active fractions but some streaking was 
present. Subsequent chromatography on a normal-phase DIOL column 
further concentrated the active material while most of the mass eluted later 
off the column (Figure 2.2). 
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Figure 2.2 % Mass versus % Specific Activity for the DIOL Normal-phase 
Column of the Halisarca sp. Active Material 
Thin layer chromatography of the active fractions employing cyano, amino, 
DIOL and C18 sorbents gave little information as to the identity of the active 
spot due to streaking on all sorbents tested. The amino plate withheld a 
yellow spot on the baseline and so a trial column of this sorbent was carried 
out. The chemical screening on an extract of this sponge had indicated that 
the active material was acidic in nature so it was assumed that the active 
material was one of the components sticking to the baseline of the amino 
plate. Further chemical screening was carried out on the active material with 
amino cartridges. 
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2.2.4 Further Chemical Screening 
Amino cartridges with different preparation schemes viz. cartridge 1, MeOH 
followed by 0.01 % TFA in MeOH; cartridge 2, MeOH, 2 % NH40H/MeOH; 
cartridge 3, MeOH; cartridge 4, a used column prepared by MeOH followed 
by 0.01 % TFA in MeOH. These different cartridges were trialed with equal 
aliquots of the active material loaded and the columns eluted with neutral, 
basic and acidic solvents in varying order. None of these amino cartridges 
returned any activity. In most cases a yellow band refused to elute 
regardless of what solvent was used. Strong anion exchanger (SAX) sorbent 
was trialed with some success but this sorbent was unable to be scaled up 
as only 1 00 mg cartridges were available. Further chemical screening was 
carried out later with an amino and a CBA cartridge. The amino cartridge 
was prepared by MeOH followed by 0.1 % TFA in MeOH, then eluted with 
MeOH, followed by 2 % NH40H/MeOH, and 2 % TFA/MeOH. The CBA 
cartridge was prepared by MeOH followed by 0.1 % TFA in MeOH, then 
eluted with MeOH, 2% NH40H/MeOH. The amino cartridge returned activity 
early (F1, MeOH, 1.5 mg, 97.5 ng/mL) and the CBA cartridge returned 
activity late (F2, 2 % NH40H/MeOH, 3.9 mg, 200 ng/mL). 
This result was at odds with the previous amino cartridge chemical screening 
but the higher concentration of TFA in the preparation was thought to have 
deactivated the amino cartridge sufficiently to allow the active material to 
pass through. The late elution of the active material off the CBA cartridge 
was also at odds with the initial chemical screening as this latest result 
suggested that the active material was basic. 
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2.2.5 Further Chromatography 
Sephadex LH-20 gel permeation is a method of chromatography that can be 
based on size separation or polarity, depending on the eluent selected. The 
ability of gel permeation to differentiate the size of molecules is 
advantageous when active compounds consistently coelute with other 
compounds with similar polarity by adsorption chromatography.38 Gel 
permeation is of particular importance in the isolation of large bioactive 
compounds as those with a molecular weight of greater than around 500 
a.m.u. are typically not retained by the gel and rapidly elute with the solvent 
front. Compounds that degrade on silica or other sorbents are also 
candidates for gel permeation and this method typically returns good 
recovery of mass. Sephadex LH-20 was selected for further chromatography 
of the active material from Ha/isarca sp. A column of this material was 
prepared (20 g) with methanol, so as to utilise the size separation properties 
of LH-20 with a minimum adsorption chromatography, and loaded with the 
active material (40 mg). Eighty three fractions were collected and the P388 
assay results showed that the activity was concentrated in the first 29 
fractions. Combination of the 29 active fractions gave 43.4 mg of material. 
However, the resultant 1 H NMR spectrum indicated that the combined 
fractions contained much plasticiser. Subsequent chromatography of this 
material on a DIOL column saw a significant loss of activity. Just one fraction 
(1.5 mg) was active. A second extraction was initiated. 
2.2.6 2nd Extraction 
One of the problems with the previous extraction was the persistent streaking 
of some spots on the TLC that obscured other, more resolved spots. 
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Halisarca sp. is a very slimy sponge and the streaking was thought to be due 
to this mucus. In an attempt to overcome this, the sponge (740 g) was twice 
sonicated in water and the resulting solutions drained and freeze dried. The 
sponge was then extracted with methanol and dichloromethane. All the 
activity was found in the methanol extract (14 g) with no activity in the water 
wash or in the dichloromethane extract. Chromatography of the methanol 
extract on a C18 reverse-phase column yielded five fractions with minimal 
activity and one fraction (667 mg) with substantial specific activity. Another 
attempt at size separation using LH-20 gel permeation was undertaken 
utilising the four fractions containing minor activity without success, none of 
the 41 fractions returning detectable activity. The fraction with the greatest 
specific activity from the C18 reverse-phase column was loaded onto a DIOL 
column and eluted with a stepped gradient from hexane to methanol. Only 8 
% of the activity was recovered, all in one fraction which eluted with 
dichloromethane. The activity recovered off this column eluted much later 
than on the DIOL column of the previous extract. The active fraction (14 mg) 
was consumed in attempting to develop an analytical HPLC method using 
various sorbents for the separation and isolation of individual peaks. At this 
point the third and final extraction of Halisarca sp. was initiated. 
2.2.7 3rd Extraction 
The sponge (800 g) was sonicated as in the previous extraction. The 
methanol extract (8.6 g) was partitioned between dichloromethane and water 
with the activity found in the organic phase. Partitioning between hexane 
and methanol/water equally divided the activity and mass so the partitions 
were recombined. Chromatography by C18 was again employed as the 
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previous extractions had shown this to be an ideal and rapid method to 
concentrate the activity. DIOL chromatography was used again to shed a 
large proportion of the mass from the active fractions. At this point in the 
isolation cyano TLC indicated that this sorbent could be a possible route for 
further purification of the active component. However, a cyano cartridge was 
trialed with a large loss of mass and activity. 
The use of a preparative HPLC C18 reverse-phase column was employed in 
an attempt at further purification due to the fact the active material had 
already come into contact with C18 packing material on numerous occasions 
with good results and the much larger number of theoretical plates of the 
HPLC column would give rise to greater resolution of components in the 
mixture. The column was eluted with acetonitrile/water (55:45, isocratic) with 
detection at 200 nm. Upon solvent removal the mass of the six fractions 
collected did not sum to the mass loaded onto the column. Subsequently the 
column was stripped with stronger solvents but this additional mass still did 
not explain the missing material. The 1 H NMR spectra of the fractions and 
the strip did not show any of the character of the material that was injected 
onto the column and it can only be assumed that the octadecyl moiety of the 
C 18 packing material had in some way been damaged or leached so as to 
expose fresh Si-OH groups to which the active material irreversibly bound or 
degraded. No further sponge was available for extraction. 
The 1 H NMR spectrum of the material combined and loaded onto the 
reverse-phase C18 HPLC column (Figure 2.3) displayed some character 
however. One of the notable characteristics of this spectrum is the similarity 
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to the 1 H NMR spectrum of polyether type compounds such as okadaic acid 
(24) (Figure 2.4) and halichondrin B (7) (Figure 2.5). 
fLU 5.5 5.0 4.5 4-.D <1.5 3.0 
Figure 2.3 1H NMR Spectrum of Pre-HPLC Fraction 
Figure 2.4 1 H NMR Spectrum of Okadaic acid (24) 
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2.3 Conclusion 
The 1 H NMR spectra of various active fractions from the three extractions did 
not yield any conclusive evidence on the structure of the compound that was 
causing the cytotoxicity. The most active fraction, one of those combined for 
injection onto the C18 preparative HPLC column, was assayed at 17 ng/mL, 
which when compared to the value pure okadaic acid (24) returned in our 
assay (11 ng/mL 39), gives an idea of the extreme cytotoxicity of the 
compound(s) that was present in the samples of Halisarca sp. used in this 
study. The activity of the extract is indeed reminiscent of that recorded for 
tedanolide (25), another polyether cytotoxin. 
tedanolide (25) 
Tedanolide (25) was first isolated by Schmitz et af0 from Tedania ignis and 
was recorded to have an EDso against lymphocytic leukaemia (P388 assay) 
of 16 pg/mL. In earlier, unpublished work from this laboratory,41 Dr. John 
McCombs expended considerable effort in following the activity of an extract 
from Tedania n. sp. B also from Otago Harbour. In the final analysis some 
1 00 J.Lg of material was obtained from 25 kg of sponge. Virtually all the 
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activity was concentrated into that fraction, which was still grossly impure. 
From mass spectral arguments it was concluded that Tedania n. sp. B. 
contained tedanolide (25) and a new monochlorinated analogue. More 
recently Dr. Laurent Ettouati encountered a similar problem working on 
extracts from a Fiordland sample of Chondropsis kirkii. In this case the 
polyether cytotoxin was most likely okadaic acid (24).42 In each of these 
cases a large quantity of sponge had to be processed to even start to detect 
the cytotoxin, let alone isolate the compound pure and determine the 
structure. The current work on the Halisarca sp was limited by the small 
amount of this deep water sponge that was available. Perhaps if a larger 
amount of the sponge had been available there may have been a more 
conclusive result. These three cases serve to emphasis and highlight the 
problems associated with this aspect of marine natural products chemistry. 
When the emphasis is on finding potent cytotoxins from a natural source, 
sometimes the compounds discovered are so toxic that the concentration in 
the marine species is so minute that vast quantities of source material are 
needed, accompanied by a prodigious effort to reduce the mass of the 
extracts to a point that conventional laboratory based approaches can be 
used to isolate and purify the target compound. The recent isolation of 
spongistatins 8 (26) and 9 (27) by the Arizona group of Professor G R Pettit 
is an excellent example.43 In this work 2409 kg of Spirastrella spinispirulifera 
was extracted to yield 1.8 mg and 5.4 mg of spongistatin 8 (26) and 
spongistatin 9 (27) respectively. 
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Other examples of large extractions with small amounts of active material 
isolated can be found in the literature, such as the isolations of the 
bryostatins,44 ciguatoxin,45 the goediastatins,46 okadaic acid {24)47 and the 
halichondrins. 48 Many of these examples originate from laboratories 
equipped to deal with routine extraction of material in excess of 1 tonne, with 
the expertise to carry out preliminary extraction and isolation work involving 
large quantities. The maximum batch quantity that our laboratory here at the 
University of Canterbury can cope with is about 20 kg. 
Collection of vast quantities of marine organisms from a localised habitat is 
fraught with risk. If insufficient data as to the extent of the habitat, 
Chapter 2 - Halisarca sp. 42 
recruitment from other areas, and growth rates is collected, or available, the 
organism may become extinct, not only locally, but completely, if the entire 
population inhabits only the one area. This extinction may, in turn, affect 
specialist organisms that are dependent upon the collected species for food, 
or as a source of defensive chemicals. In addition to environmental impact 
considerations, biodiversity issues also need to be considered. This, 
however, is a moral issue and as such lies beyond the direct scope of this 
thesis. None-the-less, biodiversity issues increasingly have an impact on 
marine natural products chemists be it at the national level as governments 
become involved (eg Manila Convention, Melaka Accord, and the Rio 
Treaty), or as Editors of journals seek comment on such issues.18 The 
accusation of bio-piracy is now a distinct possibility for anyone making large-
scale (> 1 tonne) collections anywhere in the world without having first 
examined the environmental issues and obtained the appropriate collection 
permits from the country concerned. 
The work outlined above has provided the basis for further work on the 
Halisarca sp. The method of purification of the active material evolved over 
the course of the three extractions of Halisarca sp. has concentrated the 
activity from the initial activity of 8103 10"6dil to the low ng/mL level. Once it 
is possible to obtain significantly more material to work on, with the insights 
provided by these exploratory approaches, it should be possible to move 
quite rapidly to obtaining the pure cytotoxic polyether compound present in 
this sponge. The initial bioactivity results, and what was found subsequently, 
suggest that this is a potent compound and should be pursued actively by the 
Marine Chemistry group as the opportunity arises. 
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Chapter 3 
Pateamine 
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3.1 Introduction 
Pateamine (3) is an extremely potent cytotoxin isolated from a Myca/e 
species of marine sponge from Fiordland. This 19-membered macrocyclic 
diamino dilactone is of potential importance as an anticancer agent and 
some biological assay data suggest it might have applications as an 
immunosuppressant agent.11 The planar structure of pateamine (3) was 
resolved in 1990,12 but the stereochemistry of the four stereocentres was not 
elucidated. 
28 
17 
31 
pateamine (3) 
Although pure samples of pateamine (3) have been available and despite 
numerous attempts to date, 42• 49 crystals or crystalline derivatives have so 
far been unobtainable. Molecular modelling carried out by Shane Blincoe as 
part of his M.Sc. thesis50 showed that the most likely diastereoisomer was 
38, 5R, 1 OS, 24R or its enantiomer. The molecular modelling was carried 
out with the side chain of pateamine {3) substituted by a methyl group. This 
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reduced the amount of computer time taken to minimise the large number of 
conformers generated while still retaining chirality at C1 0. 
In this section of work the aim was to elucidate, in a systematic fashion, the 
chirality at each of the four stereocentres in pateamine (3). The approach 
taken was to create optically active analogues of products by the selective 
degradation of pateamine (3) followed by derivatisation of the fragments with 
chiral derivatisation agents. 
3.2 Strategy 
The philosophy was to use chemical methods of sufficient mildness that the 
chirality at the critical centres was not destroyed or racemised. The 
approaches considered were primarily targeted at opening the dilactone ring 
that would release one stereocentre, that at C24, and if the major fragment 
(C1-C17) survived without elimination this would allow a direct examination 
of C1 0. The only stereocentre that was directly accessible in pateamine (3) 
itself was that at C3. It was never envisaged that it would be possible to 
directly probe the chirality of the C5 stereocentre. The chirality at this centre 
would have to be ascertained by modelling. In principle, elements of the 
chirality of pateamine (3) could have been obtained from exciton methods. 
However the lack of information on the relative stereochemistry around the 
ring would still have required application of Mosher's methodology. 
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3.3 Stereochemistry at C24 
3.3.1 Initial Approaches: 4-Hydroxy-pentan-2-one 
Position 24 was the first to be examined. In this first attempt the target was 
to extract 4-hydroxy-pentan-2-one (28) from pateamine (3) and compare this 
directly, by chiral GC methods, with synthetic samples of the chiral and 
racemic hydroxy ketone. Selective degradation of pateamine (3) by a 
combination of hydrolysis and osmylation would give rise to 4-hydroxy-
pentan-2-one (28), retaining the original chirality of position 24 (Figure 3.1 ). 
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Figure 3.1 Proposed Method for Isolation of 4-Hydroxy-pentan-2-one (28) 
This fragment was then to be compared with synthetic 4-hydroxy-pentan-2-
one (29) of known chirality. 
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3.3.2 Synthesis of 48-Hydroxy-pentan-2-one (29) 
48-Hydroxy-pentan-2-one (29) was prepared by the selective yeast reduction 
of 2,4-pentandione.51 • 52 As there is no corresponding microbiological 
method for the production of the (R) isomer, racemic 4-hydroxy-pentan-2-one 
(30) was obtained by a crossed aldol condensation (Figure 3.2).53 
base 9H <;? 
5~1 
Figure 3.2 Synthesis of Racemic 4-Hydroxy-pentan-2-one (30) 
3.3.3 1 H NMR Spectroscopic Assignment of 48-Hydroxy-
pentan-2-one (29) 
The assignment of the 1 H NMR spectrum (Figure 3.3) of 48-hydroxy-pentan-
2-one (29) started with the unambiguous assignment for a proton a to an 
hydroxy group at DH 4.22 ppm as H4. Irradiation of H4 collapsed the pair of 
doublet of doublets at DH 2.62 ppm and OH 2.52 ppm to a pair of doublets and 
also collapsed a doublet at DH 1 .16 ppm. The DH 2.62 ppm and DH 2.52 ppm 
resonances were assigned as the diastereotopic H3 protons. Coupling 
constants allowed these to be assigned as H3s (Js,4=3.4 Hz) and H3R 
(Js,4=8.6 Hz) respectively. The remaining doublet at DH 1.16 ppm was 
assigned as CHs-5. This left the singlet at DH 2.15 ppm to be assigned as 
CHs-1. 
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Figure 3.3 1 H NMR Spectrum of 48-Hydroxy-pentan-2-one (29) 
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The stereochemistry of the stereocentre was confirmed by the use of (R) and 
( 8)-a-methoxy-a-(trifluoromethyl)phenylacetic acid {MTPA) (31, 15). 
R=OH {R)-MTPA (31) 
R=CI (8)-MTPACI (32) 
R=OH ( 8)-MTPA (15) 
R=CI {R)-MTPACI {33) 
48-Hydroxy-pentan-2-one (29) was derivatised with ( 8)-MTPA (15) via the 
acid chloride (33) to give 48((8)-MTPA)-pentan-2-one (34). 
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The racemic mixture was derivatised with (R)-MTPACI (33) to give 4S((S)-
MTPA)-pentanonate (34) and 4R((S)-MTPA)-pentan-2-one (35). 
3.3.4 1 H NMR Spectroscopic Assignment of 4S((S)-MTPA)-
pentan-2-one (34) 
The 1 H NMR spectroscopic assignment of 4S((S)-MTPA)-pentan-2-one (34) 
began with the unambiguous assignment of the multiplet resonance for a 
proton a to an ester group at OH 5.56 ppm as H4. The singlet at OH 3.53 ppm 
was assigned as the MTPA methyl ester due to the chemical shift value. The 
complex multiplet signals at OH 7.49 and 7.40 ppm were assigned as the 
phenyl protons of the MTPA moiety. The remainder of the molecule was 
assigned by comparison to 4S-hydroxy-pentan-2-one {29). 
Comparison of the 1 H NMR spectrum of 4S((S)-MTPA)-pentan-2-one (34) 
(Figure 3.4) with that of the products from the racemic (Figure 3.5) reaction, 
allowed the 1 H NMR spectroscopic assignment of 4R((S)-MTPA)-pentan-2-
one (35). 
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Figure 3.4 1 H NMR Spectrum of 
48( ( S}wMTPA)Mpentan-2-one (34} 
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Figure 3.5 1 H NMR Spectrum of 
Diastereotopic 4( ( S}wMTPA)-pentan-2-ones (34, 36) 
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Table 3.1 1 H NMR Spectroscopic Data for (S)-MTPA Esters of (R) and (S) 
4-Hydroxy-pentan-2-one (34, 36) 
Proton ( S, R)=( R, S) (S,S) ( S, R)-( S, S) 
o ppm (J in Hz) o ppm (J in Hz) Aoppm 
CHs-1 2.04 2.13 -0.09 
H3a 2.85 (7.8, 17.1) 2.91 (8.3, 17.1) -0.06 
H3b 2.56 (5.1, 17.1) 2.60 (4.3, 17.1) -0.04 
H4 5.56 5.56 
CHs-5 1.39{5.9) 1.31 (5.9) 0.08 
MiPAOMe 3.55 3.51 
Phenyl 7.40 7.40 
Phenyl 7.49 7.49 
As enantiomers are isochronous in the NMR spectrometer, 4R((S)-MTPA)-
pentan-2-one (35) has a 1 H NMR spectrum equivalent to that of 48( (R)-
MTPA)-pentan-2-one (36) and so the 1 H NMR spectrum of the product from 
the racemic reaction can be treated as having present 4S((S)-MTPA)-pentan-
2-one (34) and 4S((R)-MTPA)-pentan-2-one (36) allowing the use of the 
Mosher method. 
From Table 3.1 the (R)-(S) values show a distinct pattern. All Ao values 
listed of ( R)-( S) are negative except for the protons of CHs-5 which are 
positive. From Mosher's chemical shift tables23 for MTPA esters, all positive 
Ao values are assigned the designation L 3 and all negative Ao are assigned 
L 2 (Figure 3.6). 
Figure 3.6 Mosher Assignment Model 
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Substituting CH3-5 for L 3 and CH2-3 for L2, the stereochemistry of the MTPA 
esters of 4-hydroxy-pentan-2-one and therefore the yeast reduction derived 
4-hydroxy-pentan-2-one (29) itself can be confirmed as (8}. 
3.3.5 Chiral GC Analysis of Yeast Reduction Product 
Analysis by chiral GCMS of the yeast reduction product gave the retention 
time for 48-hydroxy-pentan-2-one (29) while the racemic aldol product 
showed the retention times of both the (8) and the (R) isomers (Figure 3.7). 
A co-injection of ( 8) and racemic 48-hydroxy-pentan-2-one confirmed the 
order of elution . 
.. 
Figure 3.7 Chiral GCMS of Racemic 4-Hydroxy-pentan-2-one (30) 
On comparison of these retention times with the pateamine-derived fragment 
the absolute chirality of C24 could have been assigned. 
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3.3.6 Base-Catalysed Hydrolysis of Pateamine (3) 
Small scale partial degradation of pateamine (3) by potassium hydroxide 
hydrolysis or lithium aluminium hydride reduction to give the hydroxydiene 
moiety failed to open the dilactone ring in a clean manner and led to the 
degradation of the entire molecule. The subsequent approach explored (see 
below) was to open the dilactone ring by methanolysis and to recover the 
hydroxydiene moiety as the hydroxydienoate ester (37).54 
3.3.7 Methanolysis of Pateamine (3) 
This approach was again based on the anticipated use of the hydroxyketone 
(37) to ascertain the chirality at the C24 stereocentre of pateamine (3). 
Methanolysis of pateamine (3) by sodium methoxide successfully cleaved the 
dilactone with the hydroxydienoate (37) easily extracted from the reaction 
mix by having the characteristic of being soluble in CH2CI2, while the 
remainder of the reaction mix was only MeOH soluble. The hydroxydienoate 
(37) was further purified by small scale chromatography. 
HO 
7 
1 OMe 
0 
HO H 
7 
MeO 1 
0 
6 
Z,E-hydroxydienoate (37) and E,Eisomer (38) 
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3.3.8 1 H NMR Spectroscopic Assignment of the 
Hydroxydienoate (37) 
The assignment of the 1 H NMR spectrum (Figure 3.8) of the natural Z,E-
hydroxydienoate (37) started with the unambiguous assignment for a proton 
a to an hydroxy group at OH 4.02 ppm as H7. Irradiation of H7 collapsed the 
doublets at OH 1.23 ppm and OH 2.32 ppm. These were assigned as CH3-8 
and H6 respectively. Irradiation of the doublet at OH 7.23 ppm collapsed the 
triplet at OH 6.88 ppm to a doublet and also collapsed the fine doublet at OH 
1.89 ppm. The doublet at OH 7.23 ppm was assigned as H4, the triplet at OH 
6.88 ppm as H3 and the fine doublet at OH 1.89 ppm as H9. Irradiation of H3 
collapsed both H4 and the doublet at OH 5.63 ppm which was assigned as 
H2. The resonance at OH 3.72 ppm was assigned as the methyl ester. The 
coupling constant between H2 and H3 (J2,3=11.7 Hz) arises from a Z 
arrangement across the double bond. An NOE difference experiment 
irradiating CH3-9 led to an enhancement of H3 which assigned this double 
bond as E. Present in this sample of hydroxydienoate (37) was a small 
amount of the E,E isomer (38) (minor peaks in Figure 3.8) which could be 
distinguished from the Z,E isomer by the coupling constant between H2 and 
H3 (J2,3=15.6 Hz). 
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Figure 3.8 1 H NMR Spectrum of the Hydroxydienoate (37) 
3.3.9 Osmylation of the Hydroxydienoate 
Attempts to cleave the double bonds of this fragment by osmylation to yield 
4-hydroxy-pentan-2-one failed and led to degradation of the hydroxydienoate 
(37). 
3.3.1 0 Final Method 
An alternative route to the determination of the stereochemistry at C24 was 
the preparation of diastereoisomeric Mosher's esters utilising both 
enantiomers of MTPA (31, 15). The hydroxydienoate (37) was derivatised 
with (R)-MTPA {31) via the acid chloride55 to give one of the Mosher 
esters.24 
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A sample of synthetically-derived ( S)-hydroxydienoate was obtained from 
Professor Daniel Romo, Texas A & M University, whose group has been 
undertaking the total synthesis of pateamine (3). This synthetic 
hydroxydienoate was derivatised with both enantiomers of MTPA and all 
proton resonances in the 1 H NMR spectra of the resultant diastereoisomers 
were assigned (Figure 3.9, 3.1 0). 
3.3.11 1 H NMR Spectroscopic Assignment of 24((R)-MTPA)-
dienoate (39) 
The 1 H NMR spectroscopic assignment of the natural 24((R)-MTPA)-
dienoate (39) began with the unambiguous assignment of the multiplet 
resonance for a proton a to an ester group at OH 5.37 ppm as H7. The fine 
doublet (J=1.0 Hz) at OH 3.53 ppm was assigned as the MTPA methyl ester. 
The pair of doublets of doublets at OH 2.52 ppm and OH 2.36 ppm were 
assigned as the diastereotopic protons at C6. These protons resonated as a 
doublet in the hydroxydienoate (37). The derivatisation with MTPA appears 
to have restricted rotation around the C6-C7 bond making the resonances for 
the H6 protons anisochronous. The remainder of the molecule was assigned 
by comparison to the hydroxydienoate (37). 24((S)-MTPA)-dienoate (40) 
was assigned in an identical manner. 
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Figure 3.9 1 H NMR Spectrum of 24((R)-MTPA)-dienoate (39) 
7 5 4 2 ppm 
Figure 3.10 1 H NMR Spectrum of 24((8)-MTPA)-dienoate (40) 
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Table 3.2 1 H NMR Spectroscopic Data for (R) and (S)-MTPA Esters of 
Natural and Synthetic Hydroxydienoates (39, 40) 
Proton (R)-MTPA Nat (R)-MTPA Syn ( S)-MTPA Syn (R)-(S) 
o ppm (J in Hz) o ppm (J in Hz) o ppm (J in Hz) Aoppm 
H2 5.60 (11.7) 5.60 (11.7) 5.64 (11.2) -0.04 
H3 6.76 (11.5) 6.76 (11.7) 6.84 (11.5) -0.08 
H4 7.14 (12.2) 7.14 (11.7) 7.23 (11.7) -0.09 
H6s 2.52 (8.0, 14.0) 2.52 (7.8, 13.7) 2.59 (8.0, 14.0) -0.07 
H6R 2.36 (5.1' 14.0) 2.36 (5.6, 13.9) 2.40 (5.4, 14.0) -0.04 
H7 5.37 5.37 5.38 -0.01 
CHs-8 1.36 (6.3) 1.36 (6.4) 1.28 (6.4) 0.08 
OMe 3.70 3.70 3.71 -0.01 
CHs-9 1.77 (1.0) 1.77 (1.5) 1.87 (1.5) -0.10 
MTPAOMe 3.53 (1.0) 3.53 (1.0) 3.53 (1.5) 
Phenyl 7.46 7.49 7.50 
Phenyl 7.36 7.36 7.36 
Figure 3.11 Mosher Assignment Model with L 2 and L 3 Replaced with CH2-6 
and CHs-8 Respectively 
All Ao values listed of (R)-(S) are negative except for the protons of CHs-8 
which are positive (Table 3.2). From Mosherls chemical shift tables23 for 
MTPA esters, all positive Ao values are assigned the designation L 3 and all 
negative Ao are assigned L 2. Substituting CHs-8 for L 3 and CH2-6 for L 2 
(Figure 3.11 ), the chirality of position 24 can be designated as ( S). This also 
confirmed that the synthetic material was indeed (S). 
Comparison of the 1 H NMR spectroscopic data for the (R)-MTPA ester of the 
natural hydroxydienoate with the data obtained from the 24S((R)-MTPA)-
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dienoate ester (39) of synthetic origin showed identical chemical shifts and 
coupling constants. 
The retention times of both MTPA esters of the synthetic hydroxydienoate 
(3 9, 40) were determined on a Supelcosii-LC-(R)-UREA phase HPLC 
column. These were compared with the retention time for the {R)-MTPA 
ester of the pateamine-derived hydroxydienoate. The retention times for 
both {R) diastereoisomers were virtually identical. As a further check a co-
injection of the synthetically derived (R)-MTPA ester and the pateamine-
derived (R)-MTPA ester was performed (Figure 3.12). This gave widths at 
half peak height and retention times identical to those for the individually 
injected chromatograms. This result from the chiral HPLC of the 
diastereoisomers produced agreed with the conclusion that the chirality at 
C24 of pateamine (3) was (S).56 
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Figure 3.12 HPLC traces of 1) the pateamine-derived (R)-MTPA ester and 2) 
co-injection with synthetically derived (R)-MTPA ester 
Chapter 3 ~ Pateamine 61 
3.4 Stereochemistry at C3 
3.4. i Preparation of MTPA Am ides 
The first attempt at solving the stereochemistry of this centre was made by 
N,N'-dicyclohexylcarbodiimide (DCC) mediated coupling of the primary amine 
at C3 with (R) and (S)~MTPA. This should have given rise to resonances in 
the 1 H NMR spectrum which were distinct for each diastereoisomer. 
Mosher's method could then have been used to elucidate the chirality of C3. 
With considerable difficulty ( R) and ( S)-MTPA am ides of pateamine ( 41, 42) 
were prepared. High resolution fast atom bombardment mass spectrometry 
(Lewis Pannell, NIDDK, NIH, U.S.A.) of 3((R)-MTPA)-pateamine (41) gave a 
parent ion (MH+) at 772.3622 a.m.u. which was within experimental error of 
the calculated mass (C41 HssFsNs06S calc. 772.3607). 
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3.4.2 1H NMR Spectroscopic Assignment of 3((R)-MTPA)-
pateamine (41) 
The 1 H NMR spectroscopic assignment of 3((R)-MTPA)-pateamine (41) 
started with the multiplet at DH 3.67 ppm. This resonance had a correlation in 
an HMQC experiment to 3c 46.9 ppm. Comparison of this correlation to that 
of the totally assigned HMQC experiment on pateamine (3) led to this 
resonance being assigned as H3. While H3 resonates at 3H 2.58 ppm for 
pateamine (3) compared with DH 3.69 ppm for 3((R)-MTPA)-pateamine (41), 
the carbon chemical shift for C3 in both molecules is similar (8c 45.5 and 
46.9 ppm respectively). A 1 0-TOCSY experiment (20 ms mixing time) 
selectively exciting H3 revealed correlations to DH 6.85, 2.65, 2.36, 1.97, and 
1.26 ppm. Comparison of these correlations to those of the HMQC 
experiment on pateamine (3) led to these resonances being assigned as NH, 
H2a, H2b, H4 and H26 respectively. This combination of data confirmed the 
identity of the resonance at 3H 3.67 ppm as being H3. A 1 0-TOCSY (1 00 ms 
mixing time) selectively exciting H3 revealed a further correlation to a 
multiplet at DH 2.89 ppm which was assigned as H5. The multiplet 
resonances at DH 7.38 and 7.51 ppm correlated to 3c 127.5 and 128.3 ppm 
in the HMQC experiment and were assigned as the MTPA aromatic protons. 
The fine multiplet resonance at 3H 3.40 ppm correlated to 3c 54.6 ppm in the 
HMQC experiment and was assigned as the OMe of the MTPA moiety. All 
other resonances were assigned by comparison to the HMQC experiments of 
pateamine (3) and 3((R)-MTPA)-pateamine (41). 
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Table 3.3 Selected 1H NMR Spectroscopic Data for (R) and (S)-MTPA 
Amides of Pateamine (41, 42) 
Proton (R)-MTPA pateamine (S)-MTPA pateamine (R)-(S) 
8 ppm (Jin Hz) 8 ppm (Jin Hz) ~8 ppm 
2a 2.64 ( 11.3, 16.6) 2.58 (11.2, 16.6) 0.06 
2b 2.36 (3.8, 16.6) 2.40 (3.8, 16.6) -0.04 
3 3.67 3.70 n/a 
4 1.97 1.98 -0.01 
5 2.89 2.80 0.09 
7 6.80 6.72 0.08 
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Upon comparison of the ~8 data for the H2 and H4 protons a clear-cut result 
was not obtained (Table 3.3). This inconclusive result was thought to be due 
to either the constraining nature of the macrolide ring system or due to the 
number of conformations possible for MTPA amides28 which may have been 
preventing the MTPA moiety from adopting the conformation required to 
observe the necessary time-averaged chemical shift differences. Examples 
of the failure of the Mosher method can be found in the literature (see 
Introduction Section 1.5).33 
As a method had already been established for the cleavage of the 
hydroxydienoate from the major fragment of pateamine (3), this was seen as 
a way of removing any possibly unfavourable constraints put upon this part of 
the molecule, if this indeed was the cause of the lack of discrimination 
between these derivatives. The methanolysis was carried out on these two 
MTPA amide derivatives but due to the low yield from the reaction and the 
small amount of starting material, 1 H NMR spectroscopy revealed neither 
reaction mixture contained the cleaved MTPA major fragments. 
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3.4.3 Formation of MPA Amides 
In an attempt to circumvent the problems mentioned above, an alternative 
form of chiral auxiliary, a-methoxyphenylacetic acid (MPA), was employed for 
the second attempt at obtaining the stereochemistry at C3. MPA amides 
adopt different conformations to those of both MTPA esters and amides. It 
was thought that an alternative conformation may yield an answer (see 
Introduction Section 1.5). 
MeQ R P7-{ 
H 0 
R=OH (R)-MPA (45) 
R=CI (R)-MPACI (46) 
Ph R 
MeO-r-1 
H 0 
R=OH (S)-MPA (16) 
R=CI (S)-MPACI (47) 
The (R) and (S)-MPA amides of pateamine (43, 44) were prepared via the 
acid chlorides (46, 47). The 1 H NMR spectra of (R) and (S)-MPA amides of 
pateamine (43, 44) were assigned through the use of HMQC, 1 D- and 20-
TOCSY experiments. 
High resolution fast atom bombardment mass spectrometry of 3((R)-MPA)-
pateamine (43) gave a parent ion (MH+) at 704.3748 a.m.u. which was within 
experimental error of the calculated mass (C4oHs4Ns06S calc. 704.3733). 
3.4.4 1 H NMR Spectroscopic Assignment of 3((8)-MPA)-
pateamine (44) 
The 1 H NMR spectroscopic assignment of 3((8)-MPA)-pateamine (44) 
started with the multiplet at OH 3.65 ppm. This resonance had a correlation in 
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an HMQC experiment to Be 46.2 ppm. Comparison of this correlation to that 
of the HMQC experiment on pateamine (3) led to this resonance being 
assigned as H3. A 2D-TOCSY experiment (80 ms mixing time) revealed 
correlations from BH 3.65 ppm to BH 6.81, 2.83, 2.61, 2.34, 1.96, and 1.21 
ppm. Due to the similarity of carbon resonances for 3((8)-MPA)-pateamine 
(44) and 3({R)-MTPA)-pateamine (41), comparison of the HMQC 
experiments led to these resonances being assigned as NH, H5, H2a, H2b, 
H4 and H26 respectively. These combinations of data confirmed the identity 
of the resonance at BH 3.65 ppm as being H3. The multiplet resonance at BH 
7.35 ppm correlated to Be 126.9 ppm in the HMQC experiment and was 
assigned as the MPA aromatic protons. The resonance at BH 3.34 ppm 
correlated to Be 56.9 ppm in the HMQC experiment and was assigned as the 
OMe of the MPA moiety. The singlet resonance at BH 4.56 ppm correlated to 
Be 83.6 ppm in the HMQC experiment and was assigned as MPA-CH. All 
other resonances were assigned by comparison of the HMQC experiments of 
pateamine (3), 3((R)-MTPA)-pateamine (41) and 3((8)-MPA)-pateamine (44). 
Table 3.4 Selected 1 H NMR Spectroscopic Data for (R) and (8)-MPA 
Amides of Pateamine {43, 44) 
Proton (R)-MPA pateamine (S)-MPA pateamine (R)-(8) 
B ppm (J in Hz) B ppm {J in Hz) ilB ppm 
H2a 2.49 (12, 16) 2.61 (1 0, 16) -0.12 
H2b 2.29 (12) 2.34 (3, 16) -0.05 
H3 3.69 3.65 n/a 
H4 1.94 1.96 (5.7) -0.02 
H5 2.81 2.83 -0.22 
H? 6.72 6.81 -0.59 
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This chiral auxiliary also failed to give a clear-cut result due to all of the 
proton ~8 values being negative (Table 3.4). 
3.4.5 Methanolysis of the MPA Amides 
Consequently, methanolysis was carried out on both MPA amides to remove 
any possible conformational restrictions imposed by the macrolide ring. 
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High resolution fast atom bombardment mass spectrometry of (R)-MPA-
pateamine Major Fragment (48) gave a MH+ parent ion at 584.3145 a.m.u. 
which was within experimental error of the calculated mass (Cs2H45Ns05S 
calc. 584.3158). 
The 1 H NMR spectra (Figure 3.13) of each of the methanolysis products (48, 
49) were complex with the resonances of H4 being buried by those for H27 
and H28. This required the use of selective 1 D- and 20- NMR experiments 
to remove any overlap from other resonances and extract relevant chemical 
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shifts and coupling constants. A 20-TOCSY experiment on 3(($)-MPA)-
pateamine major fragment (49) showed correlations from H3 to the amide 
NH, H5, the coincident H2 resonances, the multiplet of the H4 resonances 
and H26. A 1 0-TOCSY (10 ms mixing time) selectively exciting H3 (8H 3.65 
ppm) confirmed that the resonances for both the H2 protons were coincident. 
An HMQC experiment also showed a single correlation from the H2 signal to 
a carbon resonating at 8c 43.8 ppm. The 1 0-TOCSY experiment gave a 
splitting pattern for the H4 proton resonances that was not first order (Figure 
3.14). To obtain these crucial chemical shifts some simulations of the spin 
system from C2 to C5 were undertaken. 
H29,30 
OMe MPA-OMe H27 H28 
MPA-H 
H2 H26 
Phenyl H7 
H9 H17 
H13 H14 
H4 
H11, 16 
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 ppm 
Figure 3.13 1H NMR Spectrum of 3-((S)-MPA)-pateamine Major Fragment (49) 
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H3 H2 
NH 
H4 
Figure 3.1410-TOCSY NMR Spectrum of3((S)-MPA)-pateamine Major 
Fragment ( 49) Selectively Excited at H3 
Figure 3.15 Spin System of C2 to C5 Simulated to Obtain NMR Data 
3.4.6 Spectral Simulation 
Coupling constants for the C2 to C5 spin system (Figure 3.15) were initially 
extracted from the 1 D-TOCSY experiment as far as possible and were 
further refined as the simulation progressed. The spectrum eventually 
generated from the simulation was identical to the spectrum obtained from 
the 1 D-TOCSY experiment (Figure 3.16). 
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2.02 2.00 1.98 1.96 1,94 1.92 1.9() 1.88 
Figure 3.16 Simulated (above) and Experimental 1 D-TOCSY 
Spectra of the H4's of 3((S)-MPA)-pateamine Major 
Fragment ( 49) Selectively Excited at H3 
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The correctness of the simulation was tested by a 1 D-TOCSY ( 10 ms mixing 
time) experiment selectively exciting H3 with the concurrent decoupling of 
H5. The resultant spectrum was compared to a simulation with the coupling 
constants Js,4a and Js,4b set to 0.0 Hz (Figure 3.17). This absence of 
coupling constants for coupling of H5 to the H4 protons in the simulation is 
the equivalent of the decoupling of H5 in the 1 D-TOCSY experiment. Further 
testing of the simulation was carried out with the selective excitation of H5 
and the concurrent decoupling of H3 in a subsequent 1 D-TOCSY ( 1 0 ms 
mixing time) experiment and comparison of this experimental spectrum with 
the simulated spectrum, having coupling constants J3,4a and J3,4b set to 0.0 
Hz (Figure 3.18). This set of simulated and experimental spectra also 
matched. 
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Figure 3.17 Simulated (above) and Experimental1 D-TOCSY NMR Spectra 
of 3((S)-MPA)-pateamine Major Fragment (49) Selectively Excited at HS and 
· Decoupled at H3 
~· T' 1 • -;1"1"""""1~· rrr>rCTT 
2,04 2.02 2.00 1,98 1.96 1.94 1.92 1.90 1.88 1.86 ppm 
Figure 3.18 Simulated (above) and Experimenta11 D-TOCSY NMR Spectra 
of 3((S)-MPA)-pateamine Major Fragment (49) Selectively Excited at H3 and 
Decoupled at H5 
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3((R)-MPA)-pateamine major fragment (48) also gave a very complex 1 H 
NMR spectrum and was simulated following the same procedure. 
Table 3.5 Data Extracted from Simulation of C2 to C5 Spin System of 
3-( ( S)-MPA)-pateamine Major Fragment ( 49) 
Proton 8 (ppm) 8 (Hz) Couplings J (in Hz) 
5 2.99 897.12 Js,4a 9.1 
4a 1.97 591.00 Js,4b 5.2 
4b 1.89 566.00 J4a,4b 13.8 
3 4.08 1224.16 J4a,3 4.5 
NH 7.13 2139.28 J4b,3 9.3 
2a 2.43 729.10 Js,NH 9.45 
2b 2.43 729.10 Js,2a 5.5 
Js,2b 5.5 
J2a,2b 15.0 
Table 3.6 Data Extracted from Simulating of C2 to C5 Spin System of 
3-((R)-MPA)-pateamine Major Fragment (48) 
Proton 8 (ppm) 8 (Hz) Couplings J (in Hz) 
5 2.76 828.11 Js,4a 9.8 
4a 1.94 582.38 Js,4b 4.5 
4b 1.84 550.67 J4a,4b 13.6 
3 3.98 1194.16 J4a3 4.5 
' NH 7.14 2142.28 J4b3 10.0 
' 2a 2.54 761.10 Js,NH 9.5 
2b 2.47 739.60 Js,2a 5.2 
Js2b 5.2 
' J2a,2b 16.0 
Once the model was optimised, chemical shift data were extracted (Tables 
3.5 and 3.6) and the values fitted to the MPA-amide assignment model 
(Figure 3.19).31 
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Table 3.7 Selected 1H NMR Spectroscopic Data for (R) and (8)-MPA 
Amides of Pateamine Major Fragment (48, 49) 
Proton {48) 
o ppm (J in Hz) 
H2a 2.53 (5.2, 16) 
H2b 2.47 (5.2, 16) 
H3 3.98 
H4a 1.94 
H4b 1.84 
H5 2.76 
H7 6.30 
(49) 
o ppm (J in Hz) 
2.43 (6.5) 
2.43 (6.5) 
4.07 
1.97 
1.89 
2.99 
6.89 
(R)-(S) 
118 ppm 
0.10 
0.04 
n/a 
-0.03 
-0.05 
-0.23 
-0.59 
Figure 3.19 MPA Amine Assignment Diagram31 
73 
Substituting CH2-4 for L 2 and CH2-2 for L 1, the stereochemistry of C3 is 
assigned as (R). 
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3.5 Stereochemistry at C1 0 
The methanolysis of the MPA amides of pateamine (48, 49) resulted in an 
hydroxy residue at C1 0. This hydroxy group could be utilised in an attempt 
to elucidate the stereochemistry at C1 0. Portions of 3(( S)-MPA)-pateamine 
major fragment (49) were each subsequently reacted with (R)-MTPA and (S)-
MTPA. 
26 
H 
28 
10 
27 
0 OMe 
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High resolution fast atom bombardment mass spectrometry of 3((S)-MPA)-
1 O((S)-MTPA)-pateamine major fragment (51) gave a MH+ parent ion at 
800.3545 a.m.u. which was within experimental error of the calculated mass 
(C42H5sFsNs07S, 800.3556 a.m.u.). 
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3.5.1 1 H NMR Spectroscopic Assignment of 3((8)-MPA)-
1 0( ( S)-MTPA)-pateamine Major Fragment (51) 
The 1 H NMR spectroscopic assignment of both the 3((8)-MPA)-1 O(MTPA)-
pateamine major fragments (50, 51) is incomplete due to the small amount of 
material available. The 1 H NMR spectroscopic assignment of 3((8)-MPA)-
1 0((8)-MTPA)-pateamine major fragment (51) started with the multiplet at OH 
4.05 ppm. A 20-TOCSY experiment (80 ms mixing time) revealed 
correlations from OH 4.05 ppm to OH 7. 14, 2.94, 2.42, 2.40, and 1.26 ppm. 
This pattern of correlations in the 20-TOCSY led to these resonances being 
assigned as NH, H5, coincident H2's, H4 and H26 respectively. The multiplet 
resonances at OH 7.67 and 7.33 ppm were assigned as the MTPA and MPA 
aromatic protons respectively. The resonances at OH 3.58, 3.54 and 3.34 
ppm were assigned by comparison to previous compounds as the OMe of 
the MTPA, C1 methoxy ester, and MPA moieties respectively. H1 0 was 
assigned by comparison of the pattern of correlations to H9 and H11 in the 
20-TOCSY experiment to the pattern of correlations in 3((8)-MPA)-
pateamine major fragment (49). For 3((8)-MPA)-10((8)-MTPA)-pateamine 
major fragment (51) the chemical shift for H10 (oH 6.29 ppm) was 
significantly downfield from that of H10 in 3((8)-MPA)-pateamine major 
fragment ( 49) (oH 4.94 ppm) indicating that the alcohol function at C1 0 had 
indeed been converted to an ester. A trace through H10 (oH 6.28 ppm) in the 
F2 dimension in the TOCSY experiment clearly showed correlations to both 
H9's (oH 3.41 and 3.23 ppm) and to H11 (oH 5.54 ppm). Similarly a trace 
through H10 in the F2 dimension of the TOCSY experiment on 3(S)-MPA-
10(R)-MTPA pateamine major fragment (50) showed correlations to both 
H9's (oH 3.45 and 3.26 ppm) and to H11 (oH 5.39 ppm). Other resonances 
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were assigned by comparison of the HMQC and TOCSY experiments of 
pateamine (3), and all other MTPA and MPA derivatives. 
Chemical shift data were extracted from 20-TOCSY experiments carried out 
on each of the diastereoisomers produced. 
Table 3.8 Selected 1 H N M R Spectroscopic Data for ( R) and ( S)-MTPA 
Esters of 3((8)-MPA)-pateamine Major Fragment (50, 51) 
Proton (50) 
8 ppm (J in Hz} 
9a 3.45 (15.2, 7.3) 
9b 3.26 (15.2, 5.9} 
10 6.28 
11 5.39 (9.6) 
(51) 
8 ppm (J in Hz) 
3.41 ( 14.4, 5.0) 
3.23 (14.4, 5.0) 
6.29 
5.54 (9.3} 
(R}-(S) 
.6.8 ppm 
0.04 
0.03 
n/a 
-0.15 
Figure 3.20 Mosher Assignment Model with L 2 and L 3 Replaced With CH-11 
and CH2-9 Respectively. 
All positive .6.8 values are assigned the designation L 3 and all negative .6.8 
were assigned L 2 (Table 3.8). Utilising the Mosher assignment diagram by 
substituting CH-11 for L 2 and CH2-9 for L 3 (Figure 3.20), the chirality of 
position 1 0 can be designated as ( S). 
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3.6 Stereochemistry at C5 
As there is no functional group at C5 that could be derivatised with any chiral 
reagent, this stereocentre required a different approach. The proximity of C5 
to the previously assigned C3 suggested the use of NOE experiments and 
coupling constants to probe the relative stereochemistry between C5 and C3. 
To this end NOE experiments were carried out on various proton resonances 
of 3((R)-MPA)-pateamine major fragment (48) around the C2-C5-C26 spin 
system. Coupling constants extracted from the simulation of this fragment 
limited the number of conformers that needed to be considered. 
Table 3.9 Coupling Constants Extracted from NMR Simulation of C3 to C5 
Spin System of 3((R)-MPA)-pateamine Major Fragment (48) 
Coupling between J (in Hz) 
J5 4a 9.8 
J5,4b 4.5 
J4~,4b 13.6 
J4a,3 4.5 
J4b,3 10.0 
Js,NH 9.5 
Table 3.10 Selected Difference NOE Enhancements(%) for 3{(R)-MPA)-
pateamine Major Fragment (48) 
From/To H2 H3 H4a H4b H5 H7 CHs-26 NH 
H3 2.4 1.6 0.6 1.5 1.9 0.2 2.6 
H4a 1 2.4 <2a 1.2 0.3 
H4b 1 3.7 3.5 0.7 2.6 
HS 1.4 0.7 6.5 1.8 2 
CHs-26 1 1.3 0.8 9 3 
NH 0.8 1.9 0.7 1.8 0.3 
aThis value is affected by spikes 
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From Table 3.9 the coupling constant between H5 and H4a (Js,4a) is 9.8 Hz 
which suggests that H5 is predominantly anti to H4a. The coupling constant 
J4b,3 is 10.0 Hz suggesting H4b is mostly anti to H3. These coupling 
constants limit the number of rotamers around the H5-H4 bond and the H4-
H3 bond to four, two for 3R,5R and two for 3R,5S (Figure 3.21 ). 
C5~H4R C2~C6 
N~C2 C3~H48 
H48 H5 
RRa 
H48~C5 C2~C6 
N~C2 H4R~C3 
H4R R5 
RRb 
C5~H4R C6~C26 
C3LH4s 
R5 
N~C2 
H48 
RSa 
H4~C5 C6~C26 
N~C2 H4RYC3 
R4R H5 
RSb 
Figure 3.21 Newman Projections Along the C3-C4 and C4-C5 Bonds 
for the Four Possible Rotamers of C3 to C5 Spin System of 
3((R)-MPA)-pateamine Major Fragment (48). 
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Table 3.11 Allowed and Disallowed NOE Enhancements (%) for the Four 
Rclamern,RSa,RSb,RRa,RRb 
RSa From/To H2 H3 H4a H4b H5 H7 CHs-26 NH 
H3 2.4 1.6 0.6 1.5 1.9 0.2 2.6 
H4a 1 2.4 <2b 1.2 0.3 
H4b 1 3.7 3.5 0.7 2.6 
H5 1.4 0.7 6.5 1.8 2 
CHs-26 1 1.3 0.8 9 3 
NH 0.8 1.9 0.7 1.8 0.3 
RSb From/To H2 H3 H4a H4b H5 H7 CHs-26 NH 
H3 2.4 1.6 0.6 1.5 1.9 0.2 2.6 
H4a 1 2.4 <2b 1.2 0.3 
H4b 1 3.7 3.5 0.7 2.6 
H5 1.4 0.7 6.5 1.8 2 
CHs-26 1 1.3 0.8 9 3 
NH 0.8 1.9 0.7 1.8 0.3 
RRa From/To H2 H3 H4a H4b H5 H7 CHs-26 NH 
H3 2.4 1.6 0.6 1.5 1.9 0.2 2.6 
H4a 1 2.4 <2b 1.2 0.3 
H4b 1 3.7 3.5 0.7 2.6 
H5 1.4 0.7 6.5 1.8 2 
CHs-26 1 1.3 0.8 9 3 
NH 0.8 1.9 0.7 1.8 0.3 
RRb From/To H2 H3 H4a H4b H5 H7 CH3-26 NH 
H3 2.4 1.6 0.6 1.5 1.9 0.2 2.6 
H4a 1 2.4 <2b 1.2 0.3 
H4b 1 3.7 3.5 0.7 2.6 
H5 1.4 0.7 6.5 1.8 2 
CHs-26 1 1.3 0.8 9 3 
NH 0.8 1.9 0.7 1.8 0.3 
a Allowed NOE's are those within 3.5A, Disallowed refers to a situation which cannot give rise to an 
NOE because of excessive distance 
bThis value is affected by spikes 
Irradiation of H5 in the difference NOE experiment leads to an enhancement 
for the upfield H4 (H4b). From molecular mechanics modelling of rotamers 
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RRa and RSa, the enhanced H4 must be H4s. Upon irradiation of the upfield 
H4 an enhancement of CH3 -26 is observed that, from the distances 
measured from MM2 results for each rotamer, indicates an allowed NOE for 
RSa (~2.5 A), but disallowed NOE for the RRa rotamer (""3.9 A). Distance 
measurements from the MM2 results exclude both the RRa and RSb 
rotamers as the NOE enhancement of H7 by irradiation of H3 would be due 
to excessive distance (4.6 A and 5.3 A respectively). Further evidence for 
the exclusion of RSb is the irradiation of H5 that leads to an NOE 
enhancement for the upfield H4. This must be due to H4R in RSb but the 
NOE enhancement of CHs-26 observed when the upfield H4 (H4b) is 
irradiated, is disallowed (~3.8 A) due to excessive distance. Irradiation of the 
NH proton leads to an NOE enhancement of both H5 and the upfield H4. 
The NOE enhancement of H5 by irradiation of the NH proton is disallowed for 
both ARb or RSb due to excessive distance (5.0 A and 4.4 A respectively). 
The NOE enhancement of CHs-26 upon irradiation of H3 cannot be 
explained by either RRb (""4.4 A) or RSa (z4.7 A) due to excessive distance. 
These NOE experiments suggest that none of the four rotamers discussed 
exist in solution as a sole entity. 
The rotamer which allows the greatest number of significant NOE 
enhancements is RSa followed by the rotamer RRa. Invoking minor 
populations of RSb and RRb can explain all observed NOE's for both the RS 
and RR set of rotamers. For the RR set of rotamers however, RRb cannot 
be the major rotamer as the 2.4 % enhancement of H3 by irradiation of H4a 
and the 3.5 % enhancement of H5 by irradiation of H4b must be from the 
dominant rotamer. RRa is excluded from being the major rotamer by the 
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1.9 % enhancement of H7 by irradiation of H3 that must also be from the 
major rotamer. RSa has no major disallowed NOE enhancements and the 
minor disallowed enhancements can be assigned as due to a minor 
population of RSb. This evidence suggests RSa is the major rotamer. 
The experimental coupling constants show intermediate values to those 
derived from molecular mechanics modelling of the RSa and RSb rotamers 
of 3((R)-MPA)-pateamine major fragment (48) (Table 3.12). This indicates 
that there is more than one conformer present. The experimental coupling 
constants are weighted in favour of the RSa rotomer, further suggesting the 
RSa rotamer is the major contributor. 
Table 3.12 Coupling Constants for the Rotamers of 3((R)-MPA)-pateamine 
Major Fragment (48) from MM2 Modelling and NMR Simulation 
Couplings 
JH5,H4S 
JH5,H4R 
JH4S,H3 
JH4R,H3 
JH3,H2S 
JH3,H2R 
RSb 
MM2 
J {in Hz) 
12.3 
2.9 
3.5 
11.7 
2.5 
4.1 
RSa 
MM2 
J (in Hz) 
2.1 
12.3 
11.7 
2.0 
2.2 
4.3 
NMR 
J (in Hz) 
4.5 
9.8 
10.0 
4.5 
5.2 
5.2 
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Figure 3.22 The MM2 Minimised Rotamer RSa of 3((R)-MPA)-pateamine 
Major Fragment (48) (C9-C17 side chain removed) 
Figure 3.23 The MM2 Minimised Rotamer RSb of 3((R)-MPA)-pateamine 
Major Fragment (48) (C9-C17 side chain removed) 
The combination of information derived from the NOE difference experiments 
and the coupling constants derived from the NMR simulation of the 3((R)-
MPA)-pateamine major fragment (48) reveals that the major rotamer is RSa 
(Figure 3.22) with a minor population of RSb (Figure 3.23). The relative MM 
energies for RSa (23.25 kcal/mol) and RSb (25.00 kcal/mol) also support the 
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major rotamer as being RSa. From the RSa rotamer, H4a (downfield 
resonance) can be assigned as H4R and H4b (upfield resonance) can be 
assigned as H4s. This allows the assignment of (S) stereochemistry to C5. 
This relative stereochemistry between C3 and C5 is consistent with earlier 
findings based on molecular mechanics modelling for pateamine (3) itself, 
using coupling constant and NOE information determined for pateamine (3). 
This earlier work also determined that the coupling constants and NOE 
enhancements measured could not have arisen from a single conformer of 
pateamine (3).50 
3.7 Other Pateamine Derivatives 
3.7.1 Crystallisation Attempts 
Two counter ions, PFs- and ZnCI42-, were employed in separate experiments 
in the continuing attempts to obtain crystals suitable for single-crystal X-ray 
diffraction analysis. These attempts were unsuccessful and no pateamine 
(3) was recovered from either attempt. 
3.7.2 3(N-Acetyl)-pateamine (52) 
During this study of pateamine (3) it was noted that upon storage pateamine 
(3) degraded to give a neutral mix of compounds which were not retained on 
CBA cartridges. Upon methanolysis of pateamine (3) to extract the 
hydroxydiene moiety at no time could the major fragment be isolated or 
purified. 3(N-Acetyl)-pateamine (52) was synthesised with the view that this 
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may be a more stable compound than pateamine (3) itself, and the 
methanolysis of 3(N-acetyl)-pateamine (52) may lead to a more stable 
fragment which could then allow derivation of C1 0 with no chiral auxiliary 
present at C3. 
3( N-Acetyl)-pateamine (52) was the first substituted pateamine derivative to 
be methanolysed. Initially attempts were made to neutralise the NaOMe with 
the addition of H20 and TFA followed by trapping of the organic material on a 
C18 cartridge. CBA chromatographic material was considered but previous 
work had shown that salts had a detrimental effect on the effectiveness of 
this sorbent. Subsequent 1 H NMR spectroscopic analysis of the material 
trapped on the C18 cartridge and then eluted with MeOH showed a complex 
mix of compounds. As there were now no salts in the sample the material 
was further chromatographed on a CBA cartridge in an attempt to trap the 
desired basic reaction products. No material was trapped on the CBA 
sorbent indicating that the amine at C17 had eliminated. Due to the small 
amount of material available and the complexity of the mixture this section of 
work was discontinued. 
The method of isolation of the methanolysis products employed above was 
abandoned in favour of size separation on LH-20 gel permeation material 
followed by CBA chromatography. This had the advantage of not requiring 
the addition of H20 or TFA and could be carried out using dry MeOH which 
prevented the formation of NaOH and eliminated the risk of excessive 
addition of TFA. The gel permeation method was very successful and all 
subsequent work employed this method of isolation. 
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28 
17 
26 
5 
R-N 3 
H 
25 
0 0 24 31 
R= acetyl (52) 
R= p-bromobenzoyl (54) 
High resolution fast atom bombardment mass spectrometry (Lewis Pannell, 
NIDDK, NIH, U.S.A.) of 3(N-acetyl)-pateamine (52) gave a parent ion (MH+) 
at 598.3306 a.m.u. which was within experimental error of the calculated 
mass (CssH4sNs05S calc. 598.3314). 
3.7.3 3(p-BBA)-pateamine (54) 
Pateamine (3) was derivatised with p-bromobenzoic acid (p-BBA) in an 
attempt to obtain a single crystal which would be suitable for analysis by 
single crystal X-ray crystallography. The scale of the reaction precluded the 
formation of a crystal but the methodology was proved and with a further 
supply of pateamine (3) in the future it may be possible that this derivative 
will lead to an independent assignment of the stereochemistry of the four 
stereocentres of pateamine (3). 
Chapter 3 - Pateamine 86 
High resolution fast atom bombardment mass spectrometry gave a parent 
ion (MH+) at 738.2582 a.m.u. which was within experimental error of the 
calculated mass (CsaH4eNs05SBr calc. 738.2576). 
3.8 Conclusion 
Through the use of a combination of degradative and derivatisation chemistry 
the absolute stereochemistry of pateamine (3) has been determined as 
3R,5S, 1 OS,24S. 
0 
3R,5S, 10S,24S-pateamine (3) 
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Chapter 4 
Aplysia parvula 
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4.1 Introduction 
Ap/ysia spp., subclass Opisthobranchia, order Anaspidea, family Aplysiidae 
are hind gilled molluscs, lacking a cephalic shield with an internal, relatively 
small, membranous to lightly calcified shell enclosed by parapodia, or 
swimming flaps. Aplysia are herbivorous molluscs that feed preferentially on 
various red algae found in the littoral zone and the lack of a protective shell 
makes Aplysia spp. potentially vulnerable to predators.57 This lack of 
mechanical protection coupled with the absence of known predators 
suggests sea hares have a chemical defence. 
Sea hares are not the only soft bodied molluscs to appear immune to 
predation. Other Opisthobranchia, for example the shell-less, carnivorous 
nudibranchs, sequester metabolites from food sources, such as sponges and 
tunicates, and locate them in the mantle and in mucus that they exude when 
disturbed. 58 
4.2 Selected Compounds Isolated from Aplysia spp. 
A large number of compounds have been isolated from sea hares.59 The 
first compounds isolated from an Aplysia sp. were the brominated 
sesquiterpenes, aplysin (55), debromoaplysin (56) and aplysinol (57). These 
were isolated from A. kurodai by Yamamura and Hirata in 1963.60 
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X 
R 
X=Br, R=H aplysin (55) 
X=Br, R=OH aplysinol (57) 
X=H, R=H debromoaplysin (56) 
89 
lrie et a/. later isolated these compounds from the red alga Laurencia 
okamurai.6 1 lrie et a/. went on to describe laurinterol (58) and 
debromolaurinterol (59) from L. intermedia62' 63 and demonstrated that these 
compounds are able to be transformed into aplysin (55) and debromoaplysin 
(56) respectively by treatment with p-toluenesulfonic acid in refluxing 
benzene in good yield. 
X 
H3C 
X=Br, R=H laurinterol (58) 
X=H, R=H debromolaurinterol (59) 
This in vitro transformation provided a model for the in vivo conversion of 
laurinterol (58), from the sea hare's diet of the red alga Laurencia sp. 
Stallard and Faulkner64 demonstrated that sea hares are capable of 
chemically modifying dietary metabolites by feeding radio-labelled laurinterol 
(58) to A. californica and isolating radio-labelled aplysin (55). 
Whereas aplysin (55) and other brominated metabolites have been claimed 
to be antifeedants,65 there is no direct evidence to suggest that all 
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brominated metabolites are in fact antifeedant nor that the modifications 
carried out in vivo enhance any bioactivity of the sequestered metabolites. 66 
The transformation of laurinterol (58) into aplysin (55) may also be purely a 
result of the acidity of the digestive gland of Aplysia.64 
4.2.1 Antifeedant compounds from Aplysia spp. 
Kinnel et a/.67 carried out extensive studies on the antifeedant properties of 
different parts of the sea hare's body and also several compounds isolated 
from the sea hare A. brasiliana. Aplysia pieces sandwiched between fillets of 
fish and fed to sharks were invariably spat out, while the fillet was consumed. 
Smaller fish also rejected Aplysia pieces. Two of the isolated compounds 
shown to have antifeedant activity were brasilenyne (6 0) and cis-
dihydrorhodophytin (61 ). 
, ... cl 
brasilenyne (60) cis-dihydrorhodophytin (61) 
These compounds were topically coated onto beetle larvae ( Tribolium 
confusum) and offered, with controls, to swordtail fish (Xiphophous he/len). 
The controls were invariably eaten while the treated larvae were rejected 
outright or rinsed by the fish using a flow of water generated by the action of 
the gills. The rinsed larvae were still susceptible to being rejected. The 
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rinsing activity was brought about by as little as 0.1 J.Lg of brasilenyne (60). 
These compounds are similar to chlorofucin (6 2), poiteol (63) and 
obtusenyne (64) which were isolated from various species of Laurencia.68 
CL 
B 
chlorofucin (62) poiteol (63) 
B 
II 
obtusenyne (64) 
Another compound isolated from A. brasiliana, also reported to be an 
antifeedant, is the bromoallene, panacene (65).69· 70 
-•-·''Br ~H 
panacene (65) 
Further experimental evidence for Aplysia containing antifeedants was 
provided by Stallard et at71 When extracts from the digestive gland of A. 
brasiliana were painted onto the shell of a juvenile crab, Callinectes sapidus, 
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this preferred prey became repulsive to the octopus, Octopus vulgaris. From 
this study A. brasiliana yielded two compounds, brasilenol (66) and epi-
brasilenol (67), that are likely to be sequestered from a dietary source as 
they have also been isolated from the Mediterranean red alga, L. obtusa?1 
No experiments were conducted to prove that these compounds were the 
components giving rise to the antifeedant activity of the digestive gland 
extract. 
brasilenol (66) 
ft~ W ...... 
epi-brasilenol (67) 
The function of the digestive gland has attracted much interest as it is from 
this organ that many of the compounds mentioned thus far are isolated. 
Stallard and Faulkner72 offer two possibilities for the function of the digestive 
gland: the site of enzymatic digestion of polyhalogenated compounds or the 
storage of defensive chemicals. GCMS analysis of the non-polar oils 
extracted from the digestive gland of an Aplysia sp. fed solely L. coccineum 
var. pacificum revealed the presence of a large number of polyhalogenated 
constituents which were similar to those from the algae. Two halogenated 
monoterpenes isolated and identified were (38,48,78)-3,7-dimethyl-1 ,8,8-
tribromo-3,4,7-trichloro-1,5-octadiene (6 8) and (3R,4S,68)-7-chloro-3,7-
dimethyl-1 ,4,6-tribromo-1-octen-3-ol (69)72 
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B 
(38,48,7 8}-3,7-dimethyl-1 ,8,8-tribromo-3,4,7-trichloro-1 ,5-octadiene (68) 
~ Br 
Br Br 
(3 R,4 S, 68)-7 -chloro-3, 7 -dimethyl-1 ,4, 6-tribromo-1-octen-3-ol (69) 
However there were not the lipids present which might be considered to 
constitute a normal diet. This suggests, along with the antifeedant 
experiments, that the digestive gland is the site of storage for antifeedant 
compounds. Pennings and Paul58 reported that sequestered secondary 
metabolites are almost exclusively stored in the digestive gland. Some 
authors72• 58 have questioned how the antifeedants from the digestive glands 
are mobilised to effect deterrence. One explanation is that physical 
transportation of antifeedants need not occur as a naive generalist predator 
may attack what seems to be an easy meal only to discover, upon digestion 
of the body, that all is not as it seemed. The generalist predator thereby 
learns from this experience that the Aplysia sp. is not a desirable food source 
and will practice avoidance of the Aplysia sp. sampled, and most likely the 
entire genus, in the future.73 That the individual has not benefited from the 
antifeedants before death is contrary to Darwinian selection where, for a trait 
to be selectively advantageous, the individual(s) possessing the trait must 
survive to reproduce at a higher rate than individuals lacking the trait. 
However it must be mentioned that Darwinian selection also selects out 
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useless traits, so the location of the sequestered secondary metabolites in 
the digestive gland must have some selective advantage. Specialist 
predators will have coevolved with the Aplysia and will either be immune to 
the antifeedants or have some mechanism to avoid their effects. 
Another possibility is that the defensive chemicals are transported to the skin 
but are only present in amounts below the concentration at which they can 
be detected by spectroscopic properties. 
The chemical defence exhibited by Aplysia spp. has been hypothesised to 
have allowed the sea hares to dispense with the mechanical defence of a 
shell.74 The capability of sea hares for de novo synthesis of chemicals 
remains unexplored. 66 
Blunt et a/. have previously reported the isolation of thyrsiferol (70),15 a 
squalene-derived polyether metabolite, and a series of vinyl acetylenic chloro 
diols (71, 72, 73, 74f6• 77 from L. thyrsifera. 
H H 
thyrsiferol (70) 
H \, OH 
' ' 
- ' 
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(71) (72) 
(73) (74) 
4.3 Current Work 
This study was initiated to ascertain if the sea-hare Ap/ysia parvula 
sequesters selected metabolites from the red alga Laurencia thyrsifera. The 
animals used in this study were found grazing on inter-tidal fields of the red 
alga L. thyrsifera78 at Seal Reef, Kaikoura on the East Coast of the South 
Island, the same location as the specimens of L. thyrsitera were collected 
from for the Blunt eta/. 75, 76, 77 studies. 
4.3.1 Chemicallnvestigation 
The bodies of Aplysia parvu/a were drained, dissected and the digestive 
glands excised. The purple fluid given off by the animals during harvesting 
was collected and showed marked P388 activity. The fluid was passed down 
a C18 reverse-phase cartridge to trap any organic material but the trapped 
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material was not active. Due to the lack of organic-soluble activity, attention 
was focused on the bodies and excised digestive glands. The organic 
extract of the bodies (less digestive glands) was coated onto Celite and dry-
packed on to a C18 reverse-phase column. Eleven fractions were collected 
from the column. Slight antimicrobial activity existed in fractions 3 (50:50 
MeOH/H20) to 6 (80:20 MeOH/H20), but no P388 activity was observed in 
any fraction. 
C18 reverse-phase chromatography of the organic extract from the digestive 
glands yielded 12 fractions. The fraction from the C18 column that was the 
most active antimicrobial fraction was rechromatographed on DIOL sorbent 
to yield thyrsiferol (70). The extended 1 H NMR spectroscopic assignment of 
thyrsiferol (70) is the subject of the following chapter. 
Thyrsiferol (70) was initially reported to be biologically inactive?5 However, 
Suzuki et a/?9 isolated thyrsiferol (70) and thyrsiferyl acetate (75) from L. 
obtusa and reported P388 ED so values of 10 and 0.3 ng/ml respectively. In 
this study, thyrsiferol (70) returned a IC5o value of 1222 ng/ml in the P388 
assay. 
GCMS analysis of the organic fraction from the extraction of the digestive 
glands displayed eleven peaks in the total ion count trace. The mass spectra 
of these peaks revealed that the compounds present were C-12 mono-, and 
C14 di-unsaturated hydrocarbons, and a series of C-13, C-15, C-17, and C-
19 fatty acid methyl esters with various methyl substitution patterns. None of 
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the mass spectra of the peaks displayed any halogen isotopic splitting 
patterns. The analysis was not continued beyond this stage. 
4.3.2 The Egg Masses of A. parvu/a 
While collecting A. parvula, it was noted that the bright orange egg masses 
conspicuously attached to rocks, usually under small overhangs, survived 
untouched for periods of up to 14 days. There is no obvious physical 
protection for the egg mass, which in principle is an ideal food source for reef 
predators such as the numerous starfishes (Order Asteroidea) and triplefins 
(Family Tripterygidae) present. Either chemical and/or microbial protection 
was suspected. Gii-Turnes and Fenical80• 81 have reported microbial 
protection of spawned embryos of an estuarine shrimp, Palaemon 
macrodactylus, and embryos of the American lobster, Homarus americanus. 
The shrimp embryos were covered in an Alteromonas sp. from which 2,3-
indolinedione (76) was isolated and the lobster embryos were covered by a 
Gram-negative rod-type bacteria from which 2-(4'-hydroxyphenyl)ethanol (77) 
was isolated. Both these animals are external brooders with the embryos 
continuously exposed to water-borne microorganisms. 
2,3-indolinedione (76) 2-(4'-hydroxyphenyl)ethanol (77) 
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There is also the possibility of chemical defence of the egg masses arising 
from the adult animal bestowing protection in the form of chemicals which 
either leach into the surrounding water over time or are released by 
mechanical disturbance. 
To test the possibility of chemical and/or microbial protection of A. parvula 
egg masses, the majority were extracted with solvent for chemical analysis 
with the balance used for the cultivation of microbial colonies and 
examination by electron microscopy. 
A. parvula were collected and placed into a 200 litre sea water tank with 
several kilograms of fresh L. thyrsifera. Periodically the tank was inspected, 
cleaned, and newly found, wild A. parvula and fresh algae added. The egg 
masses were removed as they were found and frozen until required. The 
frozen eggs (280 g) were steeped in MeOH (600 mL) until thawed, sonicated 
for 30 minutes and then homogenised in a Waring blender. After filtering 
through Celite, extracts were combined and the solvent removed in vacuo to 
yield an orange viscous oil (12.5 g). The extract was coated onto Celite and 
chromatographed on a C18 reverse-phase column (28 mm x 400 mm, 100 
g). A large amount of material (1 0.5 g) was eluted in the first two fractions. 
Some fractions showed strong antiviral activity (Herpes simplex type 1 virus 
(ATCC VR 733) and Polio virus type 1 (Pfiser vaccine strain)) and some 
antimicrobial activity (against Bacillus subtilis and the three species of fungi). 
All fractions were compared by TLC with a genuine sample of thyrsiferol (70) 
and those with a similar Rt were partitioned between CH2CI2 and H20, while 
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the remaining antimicrobial fractions were chromatographed on a DIOL 
column (10 mm x 140 mm, 10 g). A 1 H NMR spectroscopic analysis of 
fractions 4-9 from this column displayed only signals characteristic for 
triglycerides. Fraction 3 (0.4 mg) only had 1 H NMR resonances 
characteristic of terpenoid compounds. No olefinic resonances were 
obvious. This fraction was selected for FABMS as it contained the least 
amount of triglycerides. The mass spectrum revealed an ion of 640 a.m.u. 
but the fragmentation pattern was not amenable to analysis due to the 
mixture of compounds present. 
Fractions 3-9 all had antimicrobial activity but the lack of other than 
triglyceride resonances in the 1 H NMR spectra suggested that the active 
compound was at a very low level. GCMS analysis of several of the fractions 
revealed that the compounds present were C-13 and C-18 saturated 
hydrocarbons, and a series of C-17, and C-19 fatty acid methyl esters. 
Neither the GCMS or the FABMS of fraction 3 displayed any bromine isotopic 
splitting patterns. This precludes the presence of thyrsiferol (70) or any of 
the many other brominated algal metabolites or thermally degraded products 
of these compounds. The lack of material remaining precluded further work 
in this area. 
4.3.3 Investigation of Microorganisms 
Fresh Ap/ysia embryos were located and removed from the substrate, rinsed 
and wiped over three salt water agar plates. The egg masses were then 
homogenised with a sterile tissue grinder and 1 00 J.LL of the homogenate 
streaked in a standard pattern over each of three further salt water agar 
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plates. The plates were incubated at room temperature for 7 days, examined 
daily and individual colonies lifted, cultured and restreaked until 
monocultures were obtained. Nine monocultures were obtained in this 
fashion. The successfully isolated colonies were each bulked up on several 
agar plates. These were each diluted with MeOH (200 JlL) and sonicated for 
1 0 minutes. The resultant solution was filtered and submitted for the P388 
assay in a standard assay. Of the nine colonies isolated, four showed some 
level of activity in the P388 assay. Samples of the four microorganisms that 
returned activity in this assay were forwarded to PharmaMar (Spain) and the 
Abbott Chemical Company (U.S.A.) for further assessment. However, none 
of the microorganisms met those companies' requirements for further study. 
Chapter 4 - Aplysia parvula 101 
Figure 4.1 The Eggs of Aplysia parvula 
Figure 4.2 A Magnified View Showing Micro-organisms 
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4.4 Conclusion 
The sea hare Aplysia parvula has been shown to store the cytotoxic 
metabolite thyrsiferol (70) in the digestive gland. This metabolite has been 
sequestered from the preferred food source, the red alga Laurencia 
thyrsifera. If the egg masses are indeed protected by an endowed chemical 
then the most likely compound for this role is thyrsiferol (70), supplied to the 
egg masses from the digestive gland of the adult. However, no evidence 
was found to suggest that A. parvula actually transfers thyrsiferol (70) to the 
egg mass. 
Quite clearly there are microorganisms associated with the egg masses, but 
all attempts made in our laboratory to culture microorganisms producing 
compounds with antibiotic or cytotoxic properties were not successful. Other 
workers too, have found that it is difficult to cultivate all the microorganisms 
present in or on an organism. Kang et a/.82 isolated the antibiotic enterocin 
(78), previously isolated from a microbial source,83 from a marine ascidian of 
the genus Didemnum. 
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Microscopic examination of the tunic of the Didemnum sp. revealed large 
amounts of bacteria, thought to be Arthrobacter species. Twenty strains of 
endobacteria were isolated but none could be confirmed as the origin of the 
antibiotic isolated from the entire animal. 
The whole area of culturing microorganisms from marine environments is a 
rapidly expanding field, but is one fraught with many difficulties and has a 
minimum requirement for an expert microbiologist experienced in the marine 
area. It is almost certain that success in this area will only come when that 
requirement is coupled with new, innovative approaches to the field. It has 
been estimated from extracted DNA that a typical marine source such as a 
sediment, or the interior of a sponge contains close to 1 000 different species 
of microorganism, but the best efforts in the laboratory typically yield only 1-5 
% of this number. Our efforts on culturing microorganisms from the surface 
of the egg masses of A. parvula are therefore fairly typical for what has been 
achieved to date. Clearly, a microbiological source of protection for the egg 
masses can not be ruled out. 
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In conclusion, it is suggested that the protection displayed by the egg 
masses of A. parvula is most probably biological in origin. Upon spawning 
the eggs would have a fixed supply of nutrients and these must be directed 
to cell growth processes, to allow the larvae to have the best chance of 
survival, rather than be used for the energetically expensive biosynthesis of 
defence chemicals. Consequently the embryos must either have a generous 
amount of antifeedants when spawned or have low levels of active material, 
which must be constantly renewed. The restricted volume of the eggs for the 
storage of defensive compounds would tend to suggest constant 
replacement by symbiotic microorganisms as the method of choice. 
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Thyrsiferol 
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5.1 Introduction 
The isolation of thyrsiferol (70) from Aplysia parvula afforded the opportunity 
to re-examine and extend the assignment of the NMR spectra of thyrsiferol 
(70)75 using more modern equipment and techniques. The complete 
assignment of the 13C and 1 H NMR spectra of thyrsiferyl acetate (75) and a 
partial assignment of thyrsiferol (70) was reported by Blunt et a/.84 in 1989. 
An X-ray crystallographic structure of the mono acetate, thyrsiferyl acetate 
(75), gave the relative stereochemistry, but the absolute configuration was 
not obtained unequivocally. 
H \_ OH 
:. ...... 
H \_ OH 
0 :: ', 
0 H OR 
-H H 
R=H thyrsiferol (70) 
R=Ac thyrsiferyl acetate (75) 
Venustatriol (79), a diastereoisomer of thyrsiferol (70), was isolated by 
Sakemi et at. 85 in 1986 from L. venusta. Venustatriol (79) was converted to 
venustatriol-18 acetate (80) and found by analysis of the NMR data to have 
the same conformation for the six membered rings (C1-C14) as thyrsiferol 
acetate (75). The substituents of the tetrahydrofuran ring had a different 
stereochemistry to that of thyrsiferol {70), which could not be determined by 
NMR. Consequently, venustatriol-18 acetate {80) was crystallised and the 
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absolute configuration determined by X-ray crystallography. This enabled 
Sakemi et a/. to define the absolute configuration for thyrsiferyl acetate (75) 
and hence for thyrsiferol (70). 
0 RO H 
0 
H H 
R=H venustatriol (79) 
R=Ac venustatriol-18 acetate (80) 
Venustatriol (79) was reported as having significant antiviral activity.85 
5.2 NMR Spectroscopic Assignment of Thyrsiferol 
The 1 H NMR spectrum of thyrsiferol (70) (Figure 5.1) showed much overlap 
in the methyl and methylene regions requiring the use of several 1 D- and 20-
NMR techniques viz. HMQC, HMBC, TOCSY, NOE and ECOSY86• 87• 88 
NMR experiments. Distinct resonances for several ring junction protons 
allowed access to most of the remaining protons. 
CHs-1 CHs-28 
3.8 3.6 3.4 3.2 3.0 2.8 2.6 2.4 2.2 2.0 1.8 1.6 1.4 1.2 ppm 
Figure 5.1 1 H NMR Spectrum of Thyrsiferol 
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Figure 5.2 Conformational Diagram of Thyrsiferol (70) 
Table 5.1 1 H NMR Spectroscopic Data for Thyrsiferol (70). 
Proton a Literature CDCis Protona Literature CDCis 
8 ppm84·b 8 ppm (J in Hz) 8 ppm84·b 8 ppm (Jin Hz) 
CHs-1 
H3 
H4R 
H4s 
H5R 
H5s 
H7 
H8R 
H8s 
H9R 
H9s 
H11 
H12R 
H12s 
H13R 
H13s 
H14 
1.40 
3.89 
2.24 
2.07 
1.52 
1.79 
3.04 
1.78 
1.53 
3.57 
1.58 
1.58 
3.73 
1.39 
3.89 (4,12) 
2.24 (4,13,13,13) 
2.07 (4,4, 13)c 
1.51 (4, 13) 
1.78 (4,12) 
3.04 (3,9) 
1.71 (3) 
1.40 (9) 
1.76 
1.51 
3.56 (7,11) 
1.47(11) 
1.87 (7) 
1.67 (4) 
1.82 (12) 
3.69 
H16d 
H16d 
H17d 
H17d 
H18 
H20R 
H20s 
H21R 
H21s 
H22 
CHs-24 
CHs-25 
CHs-26 
CHs-27 
CH3-28 
CHs-29 
CHs-30 
2.1 
3.45 
1.85 
1.85 
3.76 
1.12 
1.27 
1.18 
1.20 
1.15 
1.09 
1.21 
a The notation Rands represent pro-Rand pro-S geminal protons respectively 
b Literature data do not distinguish between pro-Rand pro-S 
1.37 
1.81 
1.46 
1.55 
3.44 (2, 10) 
1.57 
2.07 
1.81 
1.81 
3.76 (6,9) 
1.12 
1.26 
1.19 
1.17 
1.09 
1.15 
1.20 
c Coupling constants have been lifted from various NMR experiments but are incomplete 
d Unable to assign pro-Rand pro-S 
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Br 
RR 
Figure 5.3 C1-C7 Fragment of Thyrsiferol (70) 
The starting point for ring A (Figure 5.3) was the assignment of H3 (3.89 
ppm) from an HMQC correlation between H3 and the unambiguously 
assigned halogenated C3 (58.95 ppm). ECOSY correlations from H3 to both 
H4 protons (Figure 5.4) combined with the conformation diagram derived 
from the X-ray crystallographic study75 showing H3 to be axial, allowed the 
assignment of H4R (2.24 ppm, Js,4R=13 Hz) as being axial and H4s (2.07 
ppm, Js,4s=4 Hz) as equatorial. 
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F2 
3.78 
3.82 
3.84 
3.86 
3.90 
3.92 
3.94 
3.96 
3.98 
2.35 2.30 2.25 2.20 2.15 2.10 2.05 2.00 
F1 (ppm) 
Figure 5.4 ECOSY Correlations From H3 (3H 3.89 ppm, F2 dimension) to 
H4R 3H (2.24 ppm, Js,4R=13 Hz, large box) and H4s (3H 2.07 ppm, 
Js,4s=4 Hz, small box) 
The HMQC spectrum showed correlations between H4R and H4s protons 
and C4 (28.19 ppm). H4R showed correlations in the ECOSY to signals for 
H3, H5R (1.51 ppm) and H5s (1.78 ppm). The coupling constants revealed 
by the ECOSY experiment showed H5R to be axial (J4R,sR=13 Hz) and H5s 
to be equatorial (J4R,ss=4 Hz). The HMQC data revealed that the two 
resonances due to H5R and H5s are both connected to C5 (37.02 ppm). An 
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HMBC trace through H3 (3.89 ppm) showed correlations to 8c 74.92 ppm, 
8c 74.34 ppm, C5 (37.02 ppm), 8c 30.97 ppm, C4 (28.20 ppm) and 8c 23.65 
ppm. Irradiation of H4R in an NOE experiment enhanced two methyl signals, 
OH 1.39 ppm and OH 1.19 ppm. A trace through OH 1.39 ppm in the HMBC 
spectrum showed correlations to 8c 74.92 ppm, C3 (58.95 ppm) and 8c 
30.97 ppm. The HMBC correlation from OH 1.39 ppm to C3 (58.95 ppm) 
assigned OH 1.39 ppm to CHs-1. The HMQC experiment correlated CHs-1 
(1.39 ppm) to 8c 23.65 ppm and this resonance was assigned as CHs-1. 
The 8c 7 4.92 ppm resonance was assigned to C2 due to its chemical shift, 
correlation in the HMBC experiment to CHs-1 and lack of any HMQC 
correlation. The 8c 74.34 ppm correlation seen from H3 (3.89 ppm) was 
assigned to C6 due to its chemical shift and lack of any HMQC correlation. 
Although the H3 to C6 correlation is a 4JcH, the HMBC experiment also 
showed a correlation from H4s (2.07 ppm) to 8c 74.34 ppm. This left the 
remaining HMBC correlation from CHs-1 (1.39 ppm) to 8c 30.97 ppm to be 
assigned as CHs-25. The HMQC experiment showed a correlation from 
CHs-25 (30.97 ppm) to OH 1.26 ppm (CHs-25). The remaining NOE 
enhancement at OH 1.19 ppm from irradiation of H4R (2.24 ppm) was 
assigned to CHs-26 as H4R and CHs-26 are in a 1 ,3-diaxial conformation. 
The HMQC experiment showed a correlation from CHs-26 (1.19 ppm) to 8c 
20.02 ppm (CH3-26). An irradiation of H3 (3.89 ppm) in an NOE experiment 
enhanced CHs-25 (1.26 ppm). A 20-TOCSY experiment showed 
correlations from H3 (3.89 ppm) to H4R (2.24 ppm), H4s (2.07 ppm), H5s 
(1.78 ppm), H5R (1.51 ppm). 
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H 
Figure 5.5 C7-C11 Fragment of Thyrsiferol (70) 
An HMBC trace through CH3-26 (1.19 ppm) showed correlations to oc 86.50 
ppm, C6 (74.34 ppm) and C5 (37.02 ppm). This allowed C7 to be assigned 
to the peak at oc 86.50 ppm, and thus provided the linkage between the A 
and B rings (Figure 5.5). An HMQC correlation between C7 and OH 3.04 
ppm assigned H7. H7 (3.04 ppm) showed correlations in the ECOSY 
spectrum to H8R (1.71 ppm, Jr,aR=3 Hz, equatorial) and H8s (1.40 ppm, 
J?,as=9 Hz, axial). Both H8 protons correlated to a single carbon in the 
HMQC spectrum, C8 (22.96 ppm). The TOCSY experiment revealed that H7 
was correlated to another proton resonating at OH 1.51 ppm but any other 
protons present were overlapping with the H8 protons. An NOE irradiation of 
H7 led to enhancements at OH 3.56 ppm and OH 1.51 ppm. Due to the 
conformation of the B ring the resonance at OH 3.56 ppm was assigned to 
H11. An HMQC correlation between H11 (3.56 ppm) and oc 76.26 ppm 
assigned C11. The NOE enhancement at OH 1.51 ppm was thought to be 
due to H5R but upon irradiation of H11, an enhancement at BH 1.51 ppm was 
also seen. This led to the conclusion that the resonance at OH 1.51 ppm is 
due also to H9 s as this proton is in a 1 ,3-diaxial conformation with both H7 
and H11. Although irradiation of H7 may enhance H5R, it is coincident with 
any enhancement of H9s. A trace through H7 (3.04 ppm) in the HMBC 
experiment showed correlations to C11 (76.26 ppm), C6 (74.34 ppm), 8c 
38.49 ppm, C5 (37.02 ppm), C8 (22.96 ppm) and CHs-26 (20.02 ppm). The 
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correlation to oc 38.49 ppm was assigned as being due to C9. From the 
HMQC data, C9 (38.49 ppm) is correlated to H9s (1.51 ppm) and another 
signal at OH 1.76 ppm which could then be assigned as H9R. 
27 
H 
Figure 5.6 C1 O-C14 Fragment of Thyrsiferol (70) 
A trace through H11 (3.56 ppm) in the HMBC spectrum revealed correlations 
to C7 (86.50 ppm), oc 71.92 ppm, C9 (38.49 ppm) and a very broad 
correlation to oc 21.30 ppm. The correlation to oc 71.92 ppm was assigned 
to Ci 0 due to its chemical shift and lack of any HMQC correlation. The 
ECOSY experiment showed a correlation from H11 (3.56 ppm) to H12s (1.87 
ppm, J11.12s=7 Hz, equatorial) and H12R (1.47 ppm, J11,12H-11 Hz, axial). 
Correlation in the HMQC experiment of H12s and H12R to oc2i.12 ppm 
assigned this resonance as C12. The TOCSY experiment showed further 
correlations from Hii (3.56 ppm) to OH 3.69 ppm and to OH i .67 ppm. The 
OH 3.69 ppm correlation could be assigned to H14 due to the chemical shift, 
and the OH 1 .67 ppm correlation must be due to one or both of the H13 
protons (Figure 5.6). The HMQC experiment displayed a correlation from 
H14 (3.69 ppm) to C14 (76.05 ppm). The ECOSY showed a correlation from 
H14 (3.69 ppm) to H13s (1.82 ppm, J14,1ss=12 Hz, axial) and H13R (1.67 
ppm, J14,13R=4 Hz, equatorial). The HMQC experiment displayed a 
correlation from both Hi 3s (1.82 ppm) and H13R (1.67 ppm) to oc 20.68 ppm 
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which assigned C13. An irradiation of H11 (3.56 ppm) in an NOE experiment 
showed an enhancement of H14 (3.69 ppm), H7 (3.04 ppm}, H12s (1.87 
ppm) and H9s (1.51 ppm). The enhancement of H14 by irradiation of H11 
shows that the conformation of the C ring is of a boat form. 
H 
Figure 5.7 C13~C22 Fragment of Thyrsiferol (70} 
The trace through H14 (3.69 ppm) in the HMBC experiment showed 
correlations to oc 73.21 ppm, oc 33.51 ppm, oc 22.85 ppm and C13 (20.68 
ppm). An NOE enhancement of OH 1.09 ppm by irradiation of H14 (3.69 
ppm} located CH3~28 as this is the only methyl that can adopt the correct 
conformation to display an enhancement (Figure 5.7). The HMQC spectrum 
showed a correlation between CH3~28 (1.09 ppm} and oc 22.85 ppm 
(CH3~28}. A trace through CH3~28 (1.09 ppm) in the HMBC spectrum 
showed correlations to C14 (76.05 ppm), oc 73.21 ppm and oc 33.51 ppm. 
The oc 73.21 ppm correlation was assigned to C15 due to its chemical shift 
and lack of any HMQC correlation. This left the remaining HMBC correlation 
of oc 33.51 ppm still to be assigned. The HMQC spectrum showed a 
correlation from oc 33.51 ppm to OH 1.81 ppm and OH 1.37 ppm. This 
methylene group was assigned as C16 as no other methylene carbons 
showed a correlation to CH3~28 in the HMBC spectrum. Both H16 protons 
showed correlations in the TOCSY experiment to OH 3.44 ppm which in turn, 
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displayed a correlation to 8c 77.60 ppm in the HMQC experiment. These 
were assigned to H18 and C18 respectively, due to the chemical shifts. A 
trace through H18 (3.44 ppm) in the HMBC experiment showed correlations 
to 8c 86.01 ppm, C16 (33.51 ppm), 8c 32.31 ppm, 8c 25.43 ppm and 8c 
23.39 ppm. The resonance at 8c 86.01 ppm was assigned to C19 due to its 
chemical shift and lack of HMQC correlation. The ECOSY experiment 
revealed a correlation from H18 (3.44 ppm) to DH 1.46 ppm and DH 1.55 ppm. 
The HMQC experiment showed a correlation from 8c 25.43 ppm to DH 1 .46 
ppm and to DH 1.55 ppm and these resonances were assigned to C17 and to 
the H17 protons respectively. The HMQC experiment also showed a 
correlation from 8c 23.39 ppm to DH 1.15 ppm and due to the chemical shift 
of these correlations these signals were assigned to C29 and CHs-29 
respectively. The remaining HMBC correlation from H18 to 8c 32.31 ppm 
was assigned to C20. The HMQC experiment showed a correlation from 
C20 (32.31 ppm) to 8H 1.57 ppm and to DH 2.07 ppm, the H20 protons. The 
TOCSY experiment revealed correlations from both DH 1.57 ppm and DH 2.07 
ppm to DH 3.76 ppm and to DH 1.81 ppm. The ECOSY experiment correlated 
DH 3.76 ppm to a lone signal at DH 1.81 ppm thus establishing that the H21 
protons were coincident (8H 1.81 ppm) and that the DH 3.76 ppm signal was 
H22. The HMQC experiment showed correlations from H22 to 8c 87.40 ppm 
(C22), and from the H21 protons (8H 1.81 ppm) to 8c 26.57 ppm (C21 ). An 
NOE experiment irradiating CHs-29 (1.15 ppm) gave enhancement of H18 
(3.44 ppm), one of the H21 protons at DH 1.81 ppm and the proton at DH 1.57 
ppm (H20). H20R could now be assigned as DH 1.57 ppm due to the 
conformation of the ring, and H20s as DH 2.07 ppm. 
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Figure 5.8 C21-C24 Fragment of Thyrsiferol (70) 
An irradiation of H22 (3.76 ppm) in an NOE experiment showed an 
enhancement of one of the H21 protons at OH 1.81 ppm and an enhancement 
of two methyl signals, OH 1.20 ppm and OH 1.12 ppm. An irradiation in an 
NOE experiment of OH 1.12 ppm gave enhancements for H21 (1.81 ppm) and 
H22 (3.76 ppm). Irradiation of OH 1.20 ppm gave an enhancement for H22 
(3.76 ppm) only. These NOE experiments allowed the assignment of CH3-24 
as OH 1.12 ppm and CH3-30 as OH 1.20 ppm. The HMQC experiment 
showed correlations between CH3-24 (1.12 ppm) and oc 23.46 ppm, and 
also between CH3-30 (1.20 ppm) and oc 27.23 ppm, assigning CH3-24 and 
CH3-30 respectively (Figure 5.8). 
This left CH3-27 as the last moiety still to be assigned. The only remaining 
resonance is the methyl signal at OH 1 .17 ppm which has a correlation in the 
HMQC experiment to oc 21.42 ppm. This was assigned to CH3-27 by 
default. The HMBC correlations from H11 were of no use in the attempt to 
assign CH3-27 due to the proximity of the carbon resonances for C12 and 
C13. 
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5.3 Conclusion 
This NMR study of thyrsiferol (70) has extended and revised the previous 
assignment84 of the 1 H and 13C NMR spectra but is still incomplete. The 
flexibility of the C15-C18 chain poses a challenging problem in assigning the 
pro-S and pro-R protons for both the H16 and the H17 protons. Several 
coupling constants were unable to be measured. 
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General Methods 
Nuclear Magnetic Resonance 
All NMR spectra were recorded on a Varian Unity 300 spectrometer at 23°C, 
operating at 300 MHz for 1 H nuclei and at 75 MHz for 13C nuclei. Other 
NMR experiments described in this thesis viz. 1 D-TOCSY, 2D-TOCSY, 
ECOSY, NOE, COSY and the reverse-detected HMQC and HMBC 
experiments were recorded at 300 MHz. This instrument was fitted with a 
Nalorac Z.spec 5 mm Indirect Detection Probe, except for work described in 
Chapter 3, for which the data were obtained from the Varian Unity 300 
spectrometer fitted with a Nalorac Z.spec MID300 3 mm Indirect Detection 
Probe. Chemical shifts in this thesis were described in parts per million 
(ppm), on the 8 scale, and were referenced to the appropriate solvent peaks: 
CDCis referenced to CHCis at 8H 7.26 ppm (1 H) and CHCis at oc 77.0 ppm 
C 3C). For Chapter 3 the CDC Is solvent had 0.01 % ds-pyridine added to 
inhibit residual acidity. 1 H NMR spectra were recorded using an acquisition 
time of 2 s; 13C NMR spectra were recorded using an acquisition time of 
0.5 s. ECOSY experiments were recorded using an acquisition time of 0.7 s 
and a relaxation delay of 0.5 s. COSY experiments were recorded using an 
acquisition time of 0.24 s and a relaxation delay of 1 s. 2D-TOCSY spectra 
were recorded using an acquisition time of 0.53 s, a relaxation delay of 1 s 
and a mixing time of 80 ms. 1 D-TOCSY spectra were recorded using an 
acquisition time of 2 s, a relaxation delay of 1 s and mixing times as indicated 
in the discussion. All HMQC and HSMQC were recorded with an acquisition 
time of 0.2 s, a relaxation delay of 0.4 s and J x-H=130 Hz. HMBC 
experiments were recorded with an acquisition time of 0.21 s, a relaxation 
delay of 0.3 s, J=140 Hz and JNxH=8.3 Hz. 
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Modelling 
The simulation of spin systems described in Chapter 3 was performed on a 
Sun SPARCstation 2 using the spin simulation software which is part of the 
Varian VNMR 4.3 operating system software. The minimisation of molecular 
models described in Chapter 3 was performed on a VAX 6430 running VMS 
V5.5-2 and minimised with the MM2 option of the program MODEL version 
KS2.99. 
Mass Spectrometry 
Mass Spectrometry was performed on a Kratos MS80 Mass Spectrometer 
operated at 4 kV. FAB was performed with an lon Tech ZN11 FN ion gun 
using Xe as the reagent gas, operating at 8 kV and 2 mA with a 
m-nitrobenzyl alcohol (NOBA) matrix. 
Some samples (stated) were sent to Lewis Pannell (NIDDK, NIH, U.S.A.) for 
HRFABMS analysis. This mass spectrometry was performed on a JEOL 
SX1 02 operated at 10 kV. FAB was performed with an JEOL FAB ion gun 
using Xe as the reagent gas, operating at 6 kV and 5 mA with a 
m-nitrobenzyl alcohol (NOBA) matrix. 
High Performance Liquid Chromatography 
Most analytical HPLC was performed on a Philips PU41 00 Liquid 
Chromatograph equipped with a Philips PU4120 Diode Array Detector 
interfaced to a PC General 486 computer running Philips PU6003 Diode 
Array Detector System Software (V3.0) and a Hewlett Packard 7475A 
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Plotter. Some analytical work described in Chapter 3 was performed on a 
Shimadzu LC-4A instrument equipped with a Shimadzu UV 
Spectrophotometric Detector SPD-2AS and a Hewlett Packard 3390A 
integrator using a Supelcosii-LC-(R)-UREA column (250 mm x 4.6 mm, 
5)lm}, eluting with propan-2-ol/hexane (1 :200) at a flow rate of 750 
)lUminute. H20 was purified using a MilliQ deionising system. MeOH (J.T. 
Baker, HPLC reagent grade) and acetonitrile (BDH, HiPerSolv) solvents were 
used undistilled. All other solvent were of technical grade and were purified 
and re-distilled before use. All solvents were filtered through a Millipore filter 
apparatus equipped with a Rainin Nylon-66 filter (0.45 )lm} prior to use. All 
samples were filtered through a syringe filter (AIItech, 0.45 )lm} prior to 
injection. 
Column Chromatography 
Octadecyl (C18) reverse-phase packing used for preparative and flash 
column chromatography was prepared from silica gel (Davisil, 35-70 )lm} 
using a solution of octadecyltrichlorosilane (2% v/v, EGA-Chemie) in carbon 
tetrachloride.89 The silica gel was stirred gently with a teflon-coated 
magnetic follower overnight before washing with carbon tetrachloride (x 2). 
Unreacted chloride groups were removed by washing with dry MeOH. A 
carbon tetrachloride solution of trimethylchlorosilane (2 % v/v, Aldrich) was 
used to end-cap any unreacted hydroxyl groups. The reverse-phase material 
was finally washed with CH2CI2 (x 2} and MeOH (x 2) to remove the 
reagents. The C18 reverse-phase material was extensively washed with 
MeOH immediately before use. Small scale preparative C18 reverse-phase 
column chromatography was performed using either 200 mg Alltech 
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disposable cartridges or, more commonly, using 500 mg BondEiut 
disposable cartridges. DIOL column chromatography was pertormed using 
either Bakerbond DIOL (40 J..Lm APD) packing material in glass columns of 
stated dimensions or using 500 mg DIOL Bakerbond disposable cartridges. 
Carboxylic acid (CBA) column chromatography was pertormed using either 
Bakerbond CBA (40 J..Lm APD) packing material in glass columns of stated 
dimensions or using 500 mg CBA BondElut cartridges. Cyano column 
chromatography was pertormed using 500 mg cyano BondElut disposable 
cartridges. Amino column chromatography was performed using either 
Bakerbond amino (40 J..Lm APD) packing material in glass columns of stated 
dimensions or using 500 mg amino BondEiut disposable cartridges. Celite 
filtration and coating was performed using diatomaceous earth (Celite 
Corporation). LH-20 column chromatography was performed using pre-
swollen Sephadex LH-20 (Pharmacia Biotech AB) packing material in glass 
columns of stated dimensions. 
Thin Layer Chromatography 
The silica analytical TLC described in this thesis was pertormed using Merck 
silica gel 60 F254 plastic or aluminium-backed sheets, the silica 0.2 mm in 
thickness. DIOL analytical TLC was performed using Merck F254 glass-
backed plates of 0.2 mm thickness. Whatman MKC1sF TLC plates of 0.2 
mm thickness were used for analytical C18 TLC performed in this thesis. 
Cyano TLC was performed on Merck F254 glass-backed plates of 0.2 mm 
thickness. Amino analytical TLC was pertormed on Merck F254 glass-backed 
plates of 0.2 mm thickness. Silica TLC plates containing pateamine or the 
major fragment of pateamine were visualised with H2S04 in ethanol (1 :1). All 
Experimental - General Methods 124 
other silica and DIOL plates were visualised initially under short-wave (A. 254 
nm) light and subsequently with phosphomolybdic acid in ethanol spray (1 0 
% phosphomolybdic acid in ethanol w/v). 
Solvents 
Technical grade solvents were distilled and dried using standard procedures. 
Dry methanol was distilled from freshly prepared magnesium methoxide 
immediately before use. Hexane was prepared from petroleum ether (1 0 L, 
b.pt. 60-?00C), nitrated with a mixture of c. HNOs (1 L) and c. H2S04 (1 L) for 
two days. After this time, the nitrating mixture was removed and the organic 
layer washed with H20 (20 L), and dried over CaCI2 overnight. The resulting 
solution was filtered through activated alumina (Laporate, 100 mesh) and 
distilled. 
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Halisarca Sp. 
First Extraction (900P 18-1) 
Halisarca sp. (1 kg wet weight, HSV, ?; Hcyt 3+ (10, 4); PV1, ?; Pcyt, 4+, (4); 
P388, 4230 1 o·6 dil; no antimicrobial activity, see appendices for an 
explanation of the codes for the antiviral and antimicrobial assays performed 
at the University of Canterbury) was steeped in MeOH (1 L) overnight at 4·c. 
The MeOH was decanted off and the sponge was then homogenised with 
MeOH {2 L) in a Waring blender and extracted overnight at 4"C. The mat 
was re-homogenised in MeOH/CH2CI2 (3:1, 1 L), and again filtered through 
Celite. The solvents were removed in vacuo to yield a mobile yellow/green 
oil (40 g). The combined extracts were partitioned between H20 (2 x 200 
ml) and CH2CI2 (2 x 200 ml). The solvents were removed in vacuo to give 
a white friable powder (H20 fraction, 21.7 g, ICso >25000 ng/ml) and a 
green/yellow gum (CH2CI2 fraction, 18.6 g, 1597 ng/ml). 
Chemical screening was carried out as follows (full details of the current 
protocol can be found in Appendix 1): an aliquot (2 mg) of the active fraction 
was dissolved in 50:50 MeOH/H20 and loaded onto a reverse-phase C18 
cartridge. Four fractions (3 ml) were collected from a steep stepped 
gradient (F1, 50:50 MeOH/H20, 2697 1 o·6 dil; F2, 80:20 MeOH/H20, 
181 10·6 dil; F3, MeOH, <97.5 10-6 dil; F4, 10:90 CH2CI2/MeOH, <97.5 10-6 
dil). Another aliquot of the same active fraction (3 mg) was dissolved in 
benzene and loaded onto a DIOL cartridge. Five fractions (3 ml) were 
collected from a stepped gradient (benzene 0.3 mg, > 12500 ng/ml; hexane, 
0.3 mg, >12500 ng/ml; 5:95 CH2CI2/hexane , 1.0 mg, >12500 ng/ml; 
CH2CI2, 0.1 mg, >12500 ng/ml; MeOH, 1.4 mg, 109.9 ng/ml). Finally, 
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another aliquot of the same active fraction (1.7 mg) was dissolved in MeOH 
and loaded onto a CBA cartridge. Three fractions (3 ml) were collected from 
a "pH" gradient (MeOH, 1.9 mg, 134 ng/ml; MeOH/TFA (1 drop), 0.4 mg, 
134 ng/ml; MeOH/NH3 (1 drop), 0.3 mg, >12500 ng/ml). 
The CH2CI2 fraction was chromatographed on a C18 reverse-phase column 
(28 mm x 400 mm, 100 g). The CH2CI2 suspension of the fraction was 
mixed with C18 packing material to form a slurry and the solvents removed in 
vacuo. The coated C18 packing material was then dry packed onto the 
column that was equilibrated to 25:75 MeOH/H20. Seventeen fractions were 
collected from the column, which was eluted with a stepped gradient from 
25:75 MeOH/H20 through MeOH to 10:90 CH2Cl2/MeOH, then stripped with 
MeOH and CH2CI2. The active material was contained in fractions 6 through 
12 (F6, 70:30 MeOH/H20, 17.0 mg, 99.5 ng/ml; F7, 70:30 MeOH/H20, 
18.6 mg, 134.3 ng/ml; F8, 80:20 MeOH/H20, 38.9 mg, 51.9 ng/ml; F9, 
80:20 MeOH/H20, 11.4 mg, 20.0 ng/ml; F1 0, 90:10 MeOH/H20, 68.0 mg, 
>125 ng/ml; F11, 90:10 MeOH/H20, 111.9 mg, 60.3 ng/ml; F12, MeOH, 
375.8 mg, 200 ng/ml). 
Fractions 9, 10 and 11 were combined (191 mg) and chromatographed on a 
normal-phase DIOL column (12 mm x 300 mm, 12 g) equilibrated to CH2CI2. 
Nine fractions were collected from the column, which was eluted with a 
gradient from CH2CI2 through EtOAc to MeOH. The active material eluted 
early off the column (F1, CH2CI2, 46.6 mg, 22 ng/ml; F2, 20:80 
CH2Cl2/EtOAc, 40.4 mg, 232 ng/ml). Fractions 8 and 12 from the previous 
C18 column were combined (413 mg) and chromatographed on a larger 
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DIOL column (28 mm x 200 mm, 20 g) equilibrated to benzene. Ten 
fractions were collected from the column, which was eluted with a gradient 
from benzene through CH2CI2 to MeOH. The active material was contained 
in fractions 3 through 8 (F3, 25:75 benzene/CH2CI2, 24.2 mg, 27 ng/ml; F4, 
50:50 benzene/CH2CI2, 34.1 mg, 49.4 ng/ml; F5, 25:75 benzene/CH2CI2, 
20.6 mg, 63.4 ng/ml; F6, CH2CI2, 15.4 mg, 66.6 ng/ml; F7, 50:50 
MeOH/CH2CI2, 8 mg, 221 ng/ml; F8, 25:75 MeOH/CH2CI2, 71.2 mg, 
49 ng/ml). 
Fraction 8 from the latter DIOL column was used in an attempt to develop the 
chemical screening technique using amino and strong anion exchange (SAX) 
cartridges. The 4 amino cartridges and 1 SAX cartridge were loaded with 
equal aliquots of fraction 8 from the latter DIOL column and prepared and 
eluted with different schemes. The amino cartridge 1 was prepared with 
MeOH followed by 0.01 % TFA in MeOH and eluted with MeOH, 2 % 
NH40H/MeOH, 2% TFNMeOH; amino cartridge 2 was prepared with MeOH 
followed by 2 % NH40H/MeOH and eluted with MeOH, 0.01 % TFA/MeOH, 
2% NH40H/MeOH; amino cartridge 3 was prepared with MeOH and eluted 
with MeOH, 2 % NH40H/MeOH, 0.01 % TFA/MeOH; amino cartridge 4, a 
previously used column, was prepared by MeOH followed by 0.01 % TFA in 
MeOH, eluted with MeOH, 2 % NH40H/MeOH, 0.01 % TFA/MeOH. All 
amino cartridges destroyed or retained the activity. The SAX cartridge 
(1 00 mg) was prepared with MeOH and eluted with MeOH, 2 % NHs in 
MeOH and 0.01 % TFA in MeOH. All the activity was contained in fraction 1 
(F1, MeOH, MeOH, 5.1 mg, 97.5 ng/ml) 
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The active fractions from the earlier DIOL column were chromatographed on 
two identical LH-20 gel permeation columns (16 mm x 300 mm, 20 g). The 
first column is described, but the results were identical for both. The active 
fraction (40 mg) was dissolved in MeOH and loaded onto the LH-20 column, 
which was eluted with MeOH. Eighty three fractions (20 mL) were collected 
after the void volume with the activity diffused throughout the first 29 
fractions. All fractions from both columns showing activity were combined 
(43.4 mg). Analysis of this fraction by 1 H NMR revealed contamination by 
plasticiser. 
The contaminated active material from both LH-20 columns was 
chromatographed on a normal-phase DIOL column (1 0 mm x 200 mm, 7 g) 
equilibrated to benzene. Eight fractions were collected from the column, 
which was eluted with a gradient from benzene through CH2CI2 to MeOH. 
The active material eluted in fractions 4 through 7 (F4, CH2CI2, 1.5 mg, 
14.8 ng/mL; F5, 25:75 MeOH/CH2CI2, 9.0 mg, <97.5 ng/mL; F6, 50:50 
MeOH/CH2CI2, 7.8 mg, 99.4 ng/mL; F7, 50:50 MeOH/CH2CI2, 16.7 mg, 
54.6 ng/mL). 
Significant activity was lost in further attempts to develop the chemical 
screening technique using amino and CBA cartridges. The active fractions 
were combined and equal aliquots loaded onto an amino and a CBA 
cartridge. The amino cartridge was prepared with MeOH followed by 0.1 % 
TFA in MeOH, then eluted with MeOH, followed by 2% NH40H/MeOH, and 
2% TFA!MeOH. The CBA cartridge was prepared with MeOH followed by 
0.1 % TFA in MeOH, then eluted with MeOH, 2 % NH40H/MeOH. The 
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amino cartridge returned activity early (F1, MeOH, 1.5 mg, 97.5 ng/mL) and 
the CBA cartridge returned activity late (F2, 2% NH40H/MeOH, 3.9 mg, 200 
ng/mL). 
Second Extraction of Halisarca (900P 19-4} 
Halisarca sp. (740 g wet weight, HSV, ?; Hcyt 3+ (1 0, 4); PV1, ?; Pcyt, 3+, 
(4); P388, 5432 1 o·6 dil; no antimicrobial activity) was sonicated in distilled 
H20 (1 L), to remove the mucous material permeating the sponge, the 
resulting solution drained off and the sample re-sonicated (1 L). The two 
H20 solutions were combined and freeze dried. The sponge was then 
homogenised with MeOH (2 L) in a Waring blender with Celite {400 g), and 
extracted overnight at 4·c. The resulting homogenate was filtered through 
Celite to give a yellow coloured filtrate. The mat was re-homogenised in 
CH2CI2 (1 L) then again filtered through Celite. The solvents were removed 
in vacuo to yield a light brown crusty powder (16.1 g), a yellow/brown gum 
(14.0 g) and a brown gum respectively (1.1 g). Assays revealed that the 
cytotoxic material was contained in the MeOH soluble extract (H20 soluble 
extract, IC50 > 12500 1 o·6 dil; MeOH soluble extract, IC50 2980 1 o·6 dil; 
CH2CI2 soluble extract, ICso >12500 10"6 dil). 
The MeOH fraction (14.0 g) was concentrated, which resulted in formation of 
a precipitate that was resolubilised with the addition of CH2CI2. The 
MeOH/CH2CI2 suspension of the fraction was mixed with Celite to form a 
slurry and the solvents removed in vacuo. The coated Celite was then dry-
packed onto a C18 reverse-phase column {28 mm x 400 mm, 100 g), 
equilibrated to 25:75 MeOH/H20. Twelve fractions were collected from the 
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column, which was eluted with a stepped gradient from 25:75 MeOH/H20 
through MeOH to CH2CI2 then back to MeOH. The active material was 
contained in fractions 5 through 10 (F5, 85:15 MeOH/H20, 101.0 mg, 
518 ng/ml; F6, 90:10 MeOH/H20, 59.8 mg, 424 ng/ml; F7, MeOH, 73.2 mg, 
275 ng/ml; F8, 90:10 MeOH/CH2CI2, 133.4 mg, 773 ng/ml; F9, 80:20 
MeOH/CH2CI2, 612.8 mg, 172 ng/ml; F10, 80:20 MeOH/CH2CI2, 667.3 mg, 
347 ng/ml). 
Fractions 5, 6, 7, 8, and 9 (978 mg) were combined and partitioned between 
H20 and CH2CI2. All the activity was in the organic phase (518.4 mg, 
898 ng/ml). The active material was chromatographed on an LH-20 gel 
permeation column (16 mm x 300 mm, 20 g). Forty one fractions were 
collected after the void volume, with no activity detectable in any fraction. 
Fraction 1 0 was chromatographed on a normal-phase D IOL column ( 12 mm 
x 300 mm, 12 g) equilibrated to hexane. Nine fractions were collected from 
the column, which was eluted with a stepped gradient from hexane through 
CH2CI2 to MeOH. The active material was contained solely in fraction 5 (F5, 
CH2CI2, 14.4 mg, 127 ng/ml, 8.9 % recovery of activity). 
Various HPLC profiles were used in an attempt to further purify the active 
component, however these attempts were unsuccessful, and the entire 
14 mg of active material was consumed. 
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Third Extraction of Halisarca (91 OP 28-2) 
Halisarca sp. (800 g wet weight, no antiviral activity; P388, 81 03 1 o-6 dil; no 
antimicrobial activity) was sonicated in distilled H20 (1 L), the resulting 
solution drained off and the sample re-sonicated (1 L). The two H20 
solutions were combined and freeze dried. The sponge was then 
homogenised with MeOH (2 L) in a Waring blender with Celite (400 g), and 
extracted overnight at 4°C. The resulting homogenate was filtered through 
Celite to give a yellow coloured filtrate. The residue was re-homogenised in 
CH2CI2 (1 L) then again filtered through Celite. The solvents were removed 
in vacuo to yield a white crusty powder (15.3 g), a yellow/brown gum (8.6 g) 
and a brown gum respectively (1.4 g). Assays revealed that the cytotoxic 
material was contained mainly in the MeOH soluble extract (H20 soluble 
extract, ICso 4914 ng/mL; MeOH soluble extract, ICso <97.5 ng/mL; CH2CI2 
soluble extract, IC5 o 1480 ng/mL). The MeOH extract was partitioned 
between H20 (2 x 100 mL) and CH2CI2 (2 x 100 mL). The solvents were 
removed in vacuo to give a brown friable powder (H20 fraction, 7.81 g, ICso 
13394 ng/mL) and a green/yellow gum (CH2CI2 fraction, 370 mg, 121 
ng/mL). TLC showed a large amount of sterols present (Silica gel, 95:5 
CH2CI2/MeOH, phosphomolybdic acid spray, Rt 0.75). 
The active fraction (361 mg) was chromatographed on a C18 reverse-phase 
column (18 mm x 270 mm, 15 g). The MeOH/CH2CI2 suspension of the 
fraction was mixed with Celite to form a slurry, and the solvents removed in 
vacuo. The coated Celite was then dry packed onto the column, and 
equilibrated to 50:50 MeOH/H20. Thirteen fractions were collected from the 
column, which was eluted with a stepped gradient from 50:50 MeOH/H20 
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through MeOH to 5:95 CH2CI2/MeOH, and then stripped with MeOH and 
CH2CI2. The active material was contained in fractions 7, 8, 9, and 10 (F7, 
90:10 MeOH/H20, 15.8 mg, <97.5 ng/mL; F8, MeOH, 15.2 mg, 134 ng/mL; 
F9, MeOH, 35.8 mg, 190 ng/mL; F1 0, MeOH, 67.7 mg, 200 ng/mL). 
Fractions 7,8,9 and 10 were combined (130 mg), and then chromatographed 
on a normal-phase DIOL column (1 0 mm x 200 mm, 7 g) equilibrated to 
hexane. Sixteen fractions were collected from the column, which was eluted 
with a gradient from hexane through CH2CI2 to MeOH. The active material 
eluted late off the column (F14, CH2CI2, 32.0 mg, 17.7 ng/mL; F15, 50:50 
CH2CI2/MeOH, 65.8 mg, 35 ng/mL; F16, MeOH, 4.4 mg, 281 ng/mL). 
F15 was re-chromatographed on a DIOL cartridge, with four fractions being 
collected (F1, 50:50 hexane, 24.0 mg, 89 ng/mL; F2, CH2CI2, 12.4 mg, 56 
ng/mL; F3, 50:50 CH2CI2/MeOH, 17.3 mg, 1122 ng/mL; F4, MeOH, 0.3 mg, 
1122 ng/mL). 
F14 was further chromatographed on an amino cartridge, with three fractions 
being eluted using a stepped gradient from CH2CI2 through EtOAc to MeOH. 
Only slight activity was recovered (F1, CH2CI2, 1.7 mg, 125 ng/mL; F2, 
EtOAc, 4.1 mg, 354 ng/mL; F3, MeOH, 4.7 mg, 2511 ng/mL). With this 
result, and the other failed attempts at using this sorbent, amino was 
discounted for further purification of the active material. 
The three active fractions from the DIOL cartridge and the two remaining 
active fractions from the DIOL column were combined (17.4 mg, 100 ng/mL). 
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This was dissolved in MeOH/acetonitrile/H20 (1 :1:1, 500 Jll), filtered, and 
injected onto a reverse-phase C18 preparative HPLC column (Rainin 
Dynamax-60A, 250 mm x 21.4 mm, 55:45 ACN/H20, 5 ml/minute, UV 
detection at 200 nm). Six fractions were collected, then the column was 
stripped. The combined weight of the six fractions (4.7 mg) and the strip (3.8 
mg) only accounted for 50 % of the mass. Assays revealed no activity 
remained. 
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Pateamine 
4S-Hydroxy-2-pentanone (29) 
Baker's yeast (25 g, Bluebird Foods) and table sugar (1 0 g) were mixed with 
tap water ( 140 ml) and stirred for 5 minutes by a magnetic follower. 
Acetylacetone (1.4 ml) was added, and the reaction mix isolated from the 
atmosphere by a non-return water trap. The mix was stirred for 5 days at 
room temperature. The suspension was centrifuged (4000 rpm, 15 minutes), 
and the supernatant decanted from the pellet. The aqueous solution was 
extracted with CH2CI2 (3 x 100 ml), then freeze-dried to approximately half 
the original volume and re-extracted with CH2CI2 (1 00 ml). All the CH2CI2 
extracts were combined, and the solvent evaporated to give a viscous dark 
brown tar (0.5 ml). Simple vacuum distillation to dryness (20 mm Hg) of the 
tar gave 4S-hydroxy-2-pentanone (29) (1 07 mg), a colourless viscous oil; 1 H 
NMR 8H: 4.22 (m, 1 H, H4), 2.62 (dd, 1 H, J=3.4, 17.5 Hz, H3s), 2.52 (dd, 1 H, 
J=8.5, 17.5 Hz, H3R), 2.15 (s, 3H, H1), 1.16 (d, 3H, J=6.4 Hz, H5) ppm. 
Racemic 4-Hydroxy-2-pentanone (30) 
Acetaldehyde (11 g, 0.25 mol) was passed as a vapour in a stream of dry 
nitrogen into a 250 ml round bottom flask containing acetone (94 ml), 
MeOH (6 ml), and potassium hydroxide (0.34 g) during 1.5 hours. Oxalic 
acid was added to neutralise the product, the precipitate was removed by 
vacuum filtration, and the residue was fractionally distilled, collecting the 
fraction with b. p. 65-75°C at 20 mm Hg to give racemic 4-hydroxy-2-
pentanone (30) (20 ml), a colourless viscous oil. 
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Chiral Gas Chromatography on 4-Hydroxy-2-pentanone {29, 30) 
4S-Hydroxy-2-pentanone (29) was analysed by chiral gas chromatography 
(Carlo-Erba/Kratos, MSC500 HRGC, injector; 1 oo·c) using a 30 m x 0.32 
mm Cyclodex-8 column (J&W, 0.25 J.Lm film, 35"C isothermal), with He as the 
carrier gas and a mass spectrometer as a detector, to give a retention time of 
6 minutes 17 seconds. Injection of racemic 4-hydroxy-2-pentanone {30) 
allowed the assignment of the peak with the retention time of 6 minutes 11 
seconds as the (R) isomer. Racemic 4-hydroxy-2-pentanone (30) spiked 
with 45-hydroxy-2-pentanone (29) enhanced the latter peak confirming that 
the ( S) isomer was retained relative to the ( R) isomer. 
( 8)-a-Methoxy-a-(trifluoromethyl)phenylacetylchloride ((S)-MTPACI) 
The following is a representative synthesis of a number that were carried out. 
The reaction was scaled as necessary. 
(R)-a-Methoxy-a-(trifluoromethyl)phenylacetic acid ((R)-MTPA) was added 
as a CH2CI2 solution to a 1 mL Reactivial and taken to dryness. The (R)-
MTPA was dissolved in hexane (0.5 mL), then DMF (9 J.LL) and oxalyl 
chloride (5 J.LL) were added producing copious quantities of white precipitate 
and generating gases. After 40 minutes reaction time extra oxalyl chloride (5 
J.LL) was added. After a further 20 minutes the solution was filtered through 
an HPLC filter (0.45 J.Lm) into a 5 mL Reactivial. Hexane (2 x 0.5 mL) was 
used to rinse the reaction vessel. The Reactivial was placed under vacuum 
(1 mm Hg) for 1 hour to yield (S)-MTPACI in 95% yield (by 1 H NMR). 1 H 
NMR oH: 7.52 (m, 2H, phenyl), 7.46 (m, 3H, phenyl), 3.76 (q, 3H, F-HJs=1.9 
Hz) ppm. 
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(R)-a-Methoxy-a-(trifluoromethyl)phenylacetylchloride ((R)-MTPACI) 
(R)-MTPACI was formed in an identical manner to (8)-MTPACI. 
4S-((S)-MTPA)-2-pentanone (34) 
48-Hydroxy-2-pentanone (34) (1 0.2 mg), triethylamine (40 Jll) and 
N,N-dimethylaminopyridine (4.0 mg) were mixed and transferred in CH2CI2 
(2 x 500 Jll) to a 5 ml Reactivial containing (R)-MTPACI (28 mg). After 22 
hours the solution was blown to dryness under a stream of N2 and taken up 
in benzene (1 ml). This solution was chromatographed on silica (6 mm x 30 
mm, 2 g) equilibrated to benzene. Fraction 1 (F1, 5 ml benzene) gave 48-
(( 8)-MTPA)-2-pentanone (34) (5 mg) in 16 % yield. 1 H NMR 8H: 7.49 (m, 
2H, phenyl), 7.40 (m, 3H, phenyl), 5.56 (m, 1 H, H4), 3.51 (s, 3H, MTPA-
OCH3), 2.91 (dd, 1 H, J=8.3, 17.1 Hz, H3a), 2.60 (dd, 1 H, J=4.6, 17.1 Hz, 
H3b), 2.13 (s, 3H, H1), 1.31 (d, 3H, J=5.9 Hz, H5) ppm. 
(S)-MTPA Esters of Racemic Hydroxyketone (34,36) 
(S)-MTPA esters of racemic hydroxyketone (34,36) were formed in a similar 
but scaled down manner to 48((8)-MTPA)-2-pentanone (34) to give both 48-
((8)-MTPA)-2-pentanone (34) and 4R((8)-MTPA)-2-pentanone (36) (1.5 mg) 
in 47 % yield. 4R-((8)-MTPA)-2-pentanone (36) 1 H NMR 8H: 7.49 (m, 2H, 
phenyl), 7.40 (m, 3H, phenyl), 5.56 (m, 1 H, H4), 3.55 (s, 3H, MTPA-OCHs), 
2.85 (dd, 1 H, J=7.8, 17.1 Hz, H3a), 2.60 (dd, 1 H, J=5.1, 17.1 Hz, H3b), 2.04 
(s, 3H, H1 ), 1.39 (d, 3H, J=5.1 Hz, H5) ppm. 
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Extraction of 94FL04-12 
The following extraction procedure is a representative extraction of a number 
that were carried out. 150 mg of pateamine (3) was isolated in total. 
Frozen Myca/e sp. (2.2 kg wet weight) was thawed in MeOH (2 L) overnight 
and then homogenised in a Waring blender. The resultant homogenate was 
then filtered through Celite to give a dark brown filtrate. The mat was re-
homogenised in MeOH (1 L), re-filtered then re-homogenised and soaked 
overnight at 4°C with 33:66 CH2CI2/MeOH. The homogenate was then 
filtered, and the mat washed with MeOH (1 L). All filtrates were combined, 
concentrated and re-filtered through Celite. The solvents were removed in 
vacuo to give a green/brown gum (58.6 g). The gum was homogenised by 
sanification in MeOH (600 ml) and diluted to 50:50 MeOH/H20. This 
homogenate was loaded onto a reverse-phase C18 column (170 mm x 70 
mm, 1 kg). 14 fractions (1 L) were collected from the column, which was 
eluted with a stepped gradient from 50:50 MeOH/H20 to CH2CI2 and back to 
MeOH. Assays revealed that fractions 9 through 14 contained all of the 
activity (F9, 10:90 CH2CI2/MeOH, 1.16 g, <97.5 ng/ml; F1 0, 20:80 
CH2CI2/MeOH, 970 mg, <97.5 ng/ml; F11, 50:50 CH2CI2/MeOH, 400 mg, 
<97.5 ng/ml; F12, CH2CI2, 230 mg, <97.5 ng/ml; F13, 50:50 CH2CI2/MeOH, 
220 mg, <97.5 ng/ml; F14, MeOH, 1 g, <97.5 ng/ml). 
Fractions 9 through 14 were combined (4.23 g) and then chromatographed 
on a CBA column (28 x 300 mm, 100 g) equilibrated to 0.05 % trifluoroacetic 
acid (TFA)/MeOH. 32 fractions (20 ml) were collected from the column, 
which was eluted with a gradient from 0.05 % TFNMeOH through MeOH, 
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and then with 0.05 % NH40H/MeOH, to 2 % NH40H/MeOH. Assays 
revealed that fractions 3 through 15 were active, as was the final fraction. 
Silica TLC (2% NH40H/MeOH, 50:50 c. H2S04fEtOH, heat) showed that all 
the active fractions contained yellow spots at Rt 0.2 and 0.3. These yellow 
charring spots have previously been found to correspond to the pateamine 
family of compounds.9° Fraction 32 (84.6 mg) showed much pateamine 
character (by 1 H NMR) and was dissolved in MeOH (1 mL) then 
chromatographed on an amino cartridge (500 mg) equilibrated to MeOH. 
Two fractions (5 mL) were collected, with the yellow charring material 
occuring in fraction 1 (MeOH, 68 mg). 
Fraction 1 was dissolved in CH2CI2 (1 mL) and chromatographed on a 
normal-phase DIOL column (1 0 x 230 mm, 8 g) equilibrated to CH2CI2. Four 
fractions were collected from the column, which was eluted with a gradient 
from CH2CI2 to acetone containing a trace of TFA. The yellow charring 
material was contained in fraction 3 (MeOH, 38 mg). 
Fraction 3 was dissolved in MeOH (1 mL) and re-chromatographed on a CBA 
column (20 mm x 40 mm, 5 g) equilibrated to MeOH. Two fractions were 
collected, with the yellow charring material eluting off in fraction 2 (2 % 
NH40H/MeOH, 25.4 mg). Fraction 2 was not totally soluble in CH2CI2, so 
the material was filtered through an HPLC filter (0.45 !lm) to give pateamine 
(3) (22 mg). 
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24S-Hydroxydienoate (37) 
Pateamine (3, 10 mg) was added to a sodium methoxide solution (5 mL; Na 
(0.86 g) in dry MeOH (20 mL)) at room temperature. After 4 hours, the 
solution was diluted with H20 (10 mL), neutralised by the addition of TFA and 
the products trapped onto a reverse-phase C18 cartridge (AIItech; 200 mg} 
equilibrated to H20. The C18 phase was washed with H20 (1 0 mL), before 
being stripped with MeOH (2 mL). The MeOH was removed under a stream 
of N2, and the resultant yellow gum triturated with CH2CI2 to give crude 248-
hydroxydienoate (37). Crude 248-hydroxydienoate (37) was further purified 
by passage through a CBA cartridge (Analytichem; 300 mg) in MeOH in 
order to remove traces of unreacted pateamine (3), to give (37) (2.2 mg) in 
67% yield and a trace (by 1H NMR) of (38). 1 H NMR (37) DH: 7.23 (br d, 1 H, 
J=11.7 Hz, H4), 6.88 (t, 1 H, J=11.7 Hz, H3), 5.63 (d, 1 H, J=11.7 Hz, H2), 
4.02 (m, 1 H, H7), 3.72 (s, 3H, OCHs), 2.32 (d, 2H, J=6.3 Hz, H6), 1.89 (d, 
3H, J=1.4 Hz, H9), 1.23 (d, 3H, J=6.3 Hz, HS) ppm; 1 H NMR (38) bH: 7.57 
(dd, 1 H, J=11.2, 11.7 Hz, H3), 6.06 (br d, 1 H, J=11.7 Hz, H4), 5.83 (d, 1 H, 
J=15.6 Hz, H2), 4.03 (m, 1 H, H7), 3.75 (s, 3H, OCHs), 2.27 (d, 2H, J=6.8 Hz, 
H6), 1.93 (d, 3H, J=1.4 Hz, H9), 1.22 (d, 3H, J=5.3 Hz, H8) ppm. 
Attempt at Osmylation of ( S)-Hydroxydienoate (37) 
A CH2CI2 solution of (8)-hydroxydienoate (1 mg) was taken to dryness in a 1 
mL Reactivial and dissolved in ether (100 J..LL). Os04 (2 mg) was transferred 
to the Reactivial in ether (40 J..LL), then pyridine (30 J.LL) was added, the 
reaction capped with a septa, and left for 3 hours at RT. A solution of 
Na2820s (9 mg in 260 J.LL H20) was added, and the resulting mix extracted 
with CH2CI2 (3 x 1 mL) and the solvent removed. Nai04 (5 mg in 200 J.LL 
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H20) was added, a triangular magnetic follower placed in the Reactivial and 
the reaction left stirring for 48 hours. The solution was extracted with CH2CI2 
(3 x 500 f.LL). 1 H NMR spectra showed no (S)-hydroxydienoate or 4S-
hydroxy-2-pentanone. 
24S((R)-MTPA)-hydroxydienoate (Synthetic) (39) 
24S-Hydroxydienoate (3 7) (1 mg), triethylamine (4 f.LL) and 
N,N-dimethylaminopyridine (approx. 0.1 mg) were mixed and transferred in 
CH2CI2 (2 x 100 f.LL) to a 1 ml Reactivial containing (S)-MTPACI. After 1 
hour the solution was blown to dryness under a stream of N2 and taken up in 
benzene (200 f.LL). This solution was chromatographed on silica (6 mm x 20 
mm, 1.5 g) equilibrated to benzene. Fraction 1 and 2 (F1, 1 ml benzene, 0.5 
mg; F2, 1 ml CH2CI2, 0.8 mg) were combined to give 24S((R)-MTPA)-
hydroxydienoate (39) in 57 % yield. 1 H NMR (pateamine numbering) OH: 
7.49 (m, 2H, phenyl), 7.36 (m, 3H, phenyl), 7.14 (d, 1H, J=11.7 Hz, H21), 
6.76 (t, 1 H, J=11.7 Hz, H20), 5.60 (d, 1 H, J=11.7 Hz, H19), 5.37 (m, 1 H, 
H24), 3.70 (s, 3H, OCHs), 3.53 (d, 3H, J=1.0 Hz, MTPA-OCHs), 2.52 (dd, 
1 H, J=7.8, 13.7 Hz, H23a), 2.36 (dd, 1 H, J=5.6, 13.9 Hz, H23b), 1.77 (bs, 
3H, H31), 1.36 (d, 3H, J=6.4 Hz, H25) ppm. 
24S((R)-MTPA)-hydroxydienoate (Pateamine Derived) (39) 
24S((R)-MTPA)-hydroxydienoate (39) derived from pateamine was formed in 
an identical manner to synthetic 24S((R)-MTPA)-hydroxydienoate (39) in 24 
%yield (0.9 mg). 1 H NMR (pateamine numbering) OH: 7.49 (m, 2H, phenyl), 
7.36 (m, 3H, phenyl), 7.14 (d, 1H, J=12.2 Hz, H21), 6.76 (t, 1H, J=11.5 Hz, 
H20), 5.60 (d, 1 H, J=11.7 Hz, H19), 5.37 (m, 1 H, H24), 3.70 (s, 3H, OCHs), 
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3.53 (d, 3H, J=1.0 Hz, MTPA-OCH3), 2.52 (dd, 1 H, J=8.0, 14.0 Hz, H23a), 
2.36 (dd, 1 H, J=5.1, 14.0 Hz, H23b), 1.77 (d, 3H, J=1.0 Hz, H31 ), 1.36 (d, 
3H, J=6.3 Hz, H25) ppm. 
24S((S)-MTPA)-hydroxydienoate (synthetic) (40) 
Synthetic 24S-hydroxydienoate (37) (1.0 mg) was reacted with (R)-MTPACI 
in an identical manner to (S)-MTPACI, as previously described, to give 
24S((S)-MTPA)-hydroxydienoate (40) (0.9 mg) in 41 % yield. 1 H NMR 
(pateamine numbering) DH: 7.49 (m, 2H, phenyl), 7.36 (m, 3H, phenyl), 7.23 
(d, 1 H, J=11.7 Hz, H21 ), 6.84 (t, 1 H, J=11.5 Hz, H20), 5.64 (d, 1 H, J=11.2 
Hz, H19), 5.38 (m, 1 H, H24), 3.71 (s, 3H, OCH3), 3.53 (d, 3H, J=1.5 Hz, 
MTPA-OCH3), 2.59 (dd, 1 H, J=8.0, 14.0 Hz, H23a), 2.40 (dd, 1 H, J=5.4, 14.0 
Hz, H23b), 1.87 (d, 3H, J=1.5 Hz, H31 ), 1.28 (d, 3H, J=6.4 Hz, H25) ppm. 
3((R)-MTPA)-pateamine (41) 
A CH2CI2 solution of pateamine (3) (1.4 mg) was placed in a 1 ml Reactivial 
and taken to dryness. 1-Hydroxybenzotriazole (HOBT) (0.5 mg, in CH2CI2, 2 
x 250 Ill), and (R)-MTPA (4 mg, in CH2CI2, 2 x 250 Ill) were transferred to 
the Reactivial. The solution was stirred with a magnetic follower and the vial 
cooled in an ice/water bath. N,N'-dicyclohexylcarbodiimide (DCC) (0.8 mg) 
was added, and the reaction was allowed to return to room temperature as 
the ice melted (12 hours). MeOH (3 ml) was added to the reaction mix, and 
the solution was chromatographed on a CBA cartridge. The cartridge was 
washed with MeOH and stripped with 2 % NH40H/MeOH. Fraction 2 
contained (by 1 H NMR) 3((R)-MTPA)-pateamine (41) (1.5 mg) in 80% yield. 
1 H NMR DH: 7.51 (m, 2H, phenyl), 7.38 (m, 3H, phenyl), 7.00 (d, 1 H, J=11.5 
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Hz, H21 ), 6.85 (d, 1 H, J=7.2 Hz, NH), 6.80 (s, 1 H, H7), 6.69 (t, 1 H, J=12.0 
Hz, H20), 6.40 (d, 1H, J=15.9 Hz, H14), 6.26 (m, 1H, H10), 6.22 (d, 1H, 
J=15.9 Hz, H13), 5.64 (t, 1H, J=7.6 Hz, H16), 5.54 (d, 1H, J=9.0 Hz, H11), 
5.45 (d, 1 H, J=11.7 Hz, H19), 5.05 (m, 1 H, H24), 3.67 (m, 1 H, H3), 3.39 (m, 
3H, MTPA-OCHs), 3.20 (d, 1 H, J=3.8 Hz, H9), 3.05 (d, 1 H, J=7.3 Hz, H17), 
2.89 (m, 1 H, H5), 2.65 (dd, 1 H, J=11.3, 16.6 Hz, H2a), 2.36 (dd, 1 H, J=3.8, 
16.6 Hz, H2b), 2.29 (dd, 1 H, J=2.9, 13.3 Hz, H23a), 2.24 (s, 3H, H29), 2.24 
(s, 3H, H30), 2.12 (d, 1 H, J=13.3 Hz, H23b), 1.99 (d, 3H, J=1.1 Hz, H27), 
1.97 (m, 2H, H4), 1.80 (d, 3H, J=0.97 Hz, H28), 1.79 (d, 3H, J=1.2 Hz, H31), 
1.23 (d, 3H, J=6.7 Hz, H25), 1.23 (d, 3H, J=6.7 Hz, H26) ppm; 13C NMR 8c: 
170.1 (C1 ), 140.8 (C20), 132.5 (C14), 131.5 (C13), 129.3 (C16), 128.4 
(phenyl), 128.1 (phenyl), 126.2 (C11 ), 124.1 (C21 ), 115.2 (C19), 113.7 (C7), 
69.0 (C1 0), 67.8 (C24), 56.3 (C17), 54.9 (MTPA-OCH3), 47.5 (C23), 46.6 
(C3), 44.1 (C29), 44.1 (C30), 42.0 (C4), 38.8 (C2), 38.7 (C9), 33.7 (C5), 22.0 
(C26), 20.7 (C25), 17.3 (C31), 13.4 (C27), 12.8 (C28) ppm; HRFABMS 
(Lewis Pannell, NIDDK, NIH, U.S.A.) MH+ 772.3622 (C41 HssFsNs06S calc. 
772.3607). 
3((S}-MTPA)-pateamine (42) 
Pateamine (3) (1.0 mg) was reacted with (S)-MTPA, HOBT and DCC in an 
identical manner to (R)-MTPA, as described above, to give 3((S)-MTPA)-
pateamine (42) (1.0 mg) in 72 % yield. 1 H NMR 8H: 7.56 (m, 2H, phenyl), 
7.39 (m, 3H, phenyl), 6.97 (d, 1 H, J=11.7 Hz, H21), 6.83 (d, 1 H, J=8.6 Hz, 
NH), 6.72 (s, 1 H, H7), 6.67 (t, 1 H, J=11.2 Hz, H20), 6.37 (d, 1 H, J=16.7 Hz, 
H14), 6.23 (m, 1 H, H10), 6.22 (d, 1 H, J=16.7 Hz, H13), 5.64 (t, 1 H, J=6.7 Hz, 
H16), 5.53 (d, 1H, J=9.0 Hz, H11), 5.41 (d, 1H, J=11.2 Hz, H19), 5.02 (m, 
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1 H, H24), 3.70 (m, 1 H, H3), 3.36 (m, 3H, MTPA-OCHs), 3.23 (dd, 1 H, J=3.4, 
14.5 Hz, H9a), 3.14 (dd, 1H, J=10.4, 14.5 Hz, H9b), 3.11 (d, 2H, J=8.7 Hz, 
H17), 2.80 (m, 1H, H5), 2.58 (dd, 1H, J=11.2, 16.6 Hz, H2a), 2.40 (dd, 1H, 
J=3.8, 16.6 Hz, H2b), 2.27 (s, 3H, H30), 2.27 (s, 3H, H29), 2.00 (d, 3H, J=1.2 
Hz, H27), 1.98 (m, 2H, H4), 1.81 (d, 3H, J=1.0 Hz, H28), 1.79 (d, 3H, J=1.0 
Hz, H31), 1.27 (d, 3H, J=7.2 Hz, H26), 1.15 (d, 3H, J=6.6 Hz, H25) ppm; 
HRFABMS (Lewis Pannell, NIDDK, NIH, U.S.A.) MH+ 772.3605 
(C41 HssFsNs06S calc. 772.3607). 
3((S)-MPA)-pateamine (44) 
A CH2CI2 solution of pateamine (3) (1 0 mg) was placed in a 5 ml Reactivial 
and taken to dryness. HOBT (2.6 mg, in N,N-dimethylformamide (DMF), 2 x 
100 ~-tL), and (S)-a-methoxyphenylacetic acid ((S)-MPA), (3.2 mg, in CH2CI2, 
2 x 150 ~-tL) were transferred to the Reactivial. The solution was stirred with 
a magnetic follower, and the vial cooled in an ice/water bath. DCC (4 mg) 
was added, and the reaction allowed to return to room temperature as the ice 
melted (9 hours). MeOH (3 ml) was added to the reaction mix, and the 
solution was chromatographed on a CBA cartridge. The cartridge was 
washed with MeOH and stripped with 2 % NH40H/MeOH. Fraction 2 
contained (by 1 H NMR) 3((S)-MPA)-pateamine (44) (8.3 mg) in 66 %yield. 
1 H NMR 8H: 7.35 (m, 5H, phenyl), 6.99 (d, 1 H, J=11.5 Hz, H21 ), 6.81 (s, 1 H, 
H7), 6.81 (d, 1 H, J=7.2 Hz, NH), 6.69 (t, 1 H, J=11.5 Hz, H20), 6.37 (d, 1 H, 
J=15.5 Hz, H14), 6.24 (d, 1 H, J=15.5 Hz, H13), 6.24 (m, 1 H, H1 0), 5.64 (t, 
1 H, J=7.1 Hz, H16), 5.55 (d, 1 H, J=8.9 Hz, H11 ), 5.44 (d, 1 H, J=11.5 Hz, 
H19), 4.95 (m, 1 H, H24), 4.56 (s, 1 H, MPA-H), 3.65 (m, 1 H, H3), 3.34 (s, 3H, 
MPA-OCHs), 3.24 (m, 2H, H17), 3.15 (m, 2H, H9), 2.83 (m, 1 H, H5), 2.61 
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(dd, 1 H, J=1 0, 16 Hz, H2a), 2.34 (dd, 1 H, J=3, 16 Hz, H2b), 2.31 (s, 3H, 
H29), 2.31 (s, 3H, H30), 2.20 (t, 1 H, J=11.3 Hz, H23a), 2.04 (d, 1 H, J=14.4 
Hz, H23b), 1.99 (s, 3H, H27), 1.96 (bt, 2H, J=5.7 Hz, H4), 1.82 (s, 3H, H28), 
1.78 (s, 3H, H31 ), 1.21 (d, 3H, J=6.9 Hz, H26), 1.19 (d, 3H, J=6.5 Hz, H25) 
ppm; HRFABMS MH+ 704.3750 (C4oH54NaOaS calc. 704.3733). 
3((R)-MPA)-pateamine (43) 
Pateamine (3) (1 0.0 mg) was reacted with (R)-MPA, HOST and DCC in an 
identical manner to (S)-MPA described above, to give 3((R)-MPA)-pateamine 
(43) (5.7 mg) in 45% yield. 1 H NMR BH: 7.35 (m, 5H, phenyl), 7.01 (dd, 1 H, 
J=1.0, 10 Hz, H21 ), 6.76 (d, 1 H, J=5.8 Hz, NH}, 6.72 (s, 1 H, H7), 6.72 (t, 1 H, 
J=11.5 Hz, H20), 6.37 (d, 1H, J=14 Hz, H14), 6.25 (d, 1H, J=16 Hz, H13), 
6.24 (m, 1H, H10), 5.66 (dt, 1H, J=1.0, 7Hz, H16), 5.57 (d, 1H, J=10 Hz, 
H11 ), 5.46 (d, 1 H, J=12 Hz, H19), 5.07 (m, 1 H, H24), 4.55 (s, 1 H, MPA-H), 
3.69 (m, 1 H, H3), 3.32 (s, 3H, MPA-OCHa), 3.19 (m, 2H, H9), 3.19 (m, 2H, 
H17), 2.81 (m, 1 H, H5), 2.49 (dd, 1 H, J=12, 16Hz, H2a}, 2.34 (s, 3H, H29), 
2.34 (s, 3H, H30), 2.30 (t, 1 H, J=12.5 Hz, H23a), 2.29 (d, 1 H, J=12 Hz, H2b), 
2.12 (d, 1H, J=i6.6 Hz, H23b), 2.00 {s, 3H, H27), 1.94 {m, 2H, H4}, 1.92 (s, 
3H, H28), 1.82 (s, 3H, H31), 1.21 (d, 3H, J=6.2 Hz, H25), 1.20 (d, 3H, J=6 
Hz, H26) ppm; 13C NMR Be: 170.4 (C1), 165.3 (C8), 161.0 (C6), 145.5 
(C22), 140.9 (C20), 138.0 (C12), 137.3 (CiS), 133.7 (C14), 129.1 (C13), 
128.9 (C11), 128.5 (phenyl), 128.3 (C16), 127.2 (phenyl), 123.9 (C21}, 115.1 
(C19), 113.2 (C7), 83.8 (MPA-CH), 68.9 (C1 0), 67.6 (C24), 56.9 (C17), 56.4 
{MPA-OCH3 ), 47.6 (C23), 46.0 (C3), 44.5 (C29), 44.5 (C30), 41.4 (C2), 41.3 
(C4), 38.8 (C9), 33.8 (C5), 22.3 (C26), 20.9 (C25), 17.1 (C31), 13.4 (C27}, 
12.8 (C28) ppm; HRFABMS MH+ 704.3748 (C4oH54NaOaS calc. 704.3733). 
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3((S)-MPA)-pateamine Major Fragment (49) 
3((S)-MPA)-pateamine (44) (8.3 mg) was dissolved in dry MeOH (200 !J,L) 
and placed in a dry 1 mL Reactivial. Sodium methoxide solution (500 !J,L; Na 
(0.120 g) in dry MeOH (3 mL)) was added to the 3((S)-MPA)-pateamine (44) 
at room temperature. After 2.5 hours the MeOH solution was 
chromatographed on an LH-20 gel permeation column (5 mm x 200 mm, 800 
mg) equilibrated to MeOH. 1 H NMR revealed fractions 2 and 3 contained the 
major fragment. 
Fractions 2 and 3 were combined, dissolved in MeOH (5 mL) and 
chromatographed on a CBA cartridge equilibrated to MeOH. Fraction 2 (2 % 
NH40H/MeOH) contained (49) (5.4 mg) in 78% yield. 1 H NMR OH: 7.34 (m, 
5H, phenyl), 7.13 (d, 1 H, J=9 Hz, NH), 6.89 (s, 1 H, H7), 6.29 (d, 1 H, J=16 
Hz, H14), 6.21 (d, 1 H, J=16 Hz, H13), 5.62 (m, 1 H, H16), 5.57 (d, 1 H, J=6.1 
Hz, H11 ), 4.94 (dt, 1 H, J=5.9, 8.3 Hz, H1 0), 4.57 (s, 1 H, MPA-H), 4.07 (m, 
1 H, H3), 3.55 (s, 3H, ester-OCHs), 3.35 (s, 3H, MPA-OCHs), 3.11 (d, 2H, 
J=5.8 Hz, H9), 3.05 (d, 2H, J=6.2 Hz, H17), 2.98 (m, 1 H, H5), 2.43 (d, 2H, 
J=6.5 Hz, H2), 2.24 (s, 3H, H29), 2.24 (s, 3H, H30), 1.92 (m, 2H, H4), 1.84 
(d, 3H, J=1.2 Hz, H27), 1.79 (d, 3H, J=1.0 Hz, H28), 1.30 (d, 3H, J=7.0 Hz, 
H26) ppm; HRFABMS MH+ 584.3156 (Cs2H45Ns05S calc. 584.3158). 
3((R)-MPA)-pateamine Major Fragment (48) 
3((R)-MPA)-pateamine (43) (5.7 mg) was reacted with NaOMe/MeOH in an 
identical manner to 3((S)-MPA)-pateamine, as previously described, to give 
3((R)-MPA)-pateamine fragment (48) (1.9 mg) in 40 % yield. 1 H NMR OH: 
7.38 (m, 5H, phenyl), 7.14 (d, 1 H, J=9.5 Hz, NH), 6.30 (s, 1 H, H7), 6.28 (d, 
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1 H, J=8.7 Hz, H14), 6.23 (d, 1 H, J=8.7 Hz, H13), 5.64 (d, 1 H, J=7.5 Hz, 
H16), 5.57 (d, 1 H, J=6.6 Hz, H11 ), 4.90 (m, 1 H, H1 0), 4.57 (s, 1 H, MPA-H), 
3.98 (m, 1 H, H3), 3.66 (s, 3H, ester-OCHs), 3.38 (s, 3H, MPA-OCHs), 3.13 
(d, 2H, J=7.5 Hz, H17), 3.06 (dd, 2H, J=1.5, 6.8 Hz, H9), 2.75 (m, 1 H, HS), 
2.53 (dd, 1H, J=5.3, 15.8 Hz, H2a), 2.48 (dd, 1H, J=5.3, 15.8 Hz, H2b), 2.29 
(s, 3H, H29), 2.29 (s, 3H, H30), 1.94 (m, 2H, H4), 1.82 (d, 3H, J=1.2 Hz, 
H27), 1.80 (d, 3H, J=1.0 Hz, H28), 1.21 (d, 3H, J=6.5 Hz, H26) ppm; 
HRFABMS MH+ 584.3145 (Cs2H45NsOsS calc. 584.3158). 
3( ( S)-MPA)-1 0( ( S)-MTPA)-pateamine Major Fragment (51) 
A CH2CI2 solution of 3(( 8)-MPA)-pateamine major fragment (49) (2.4 mg) 
was taken to dryness in a 1 ml Reactivial. (R)-MTPACI (11 mg) was 
transferred into the Reactivial in pyridine (3 x 10 ~L). The solution was 
cooled in an ice/water bath, and allowed to react for 20 minutes. H20 (1 ml) 
was added to the solution, and the products trapped onto a reverse-phase 
C18 cartridge equilibrated to H20. The column was stripped with MeOH. 
The stripped fraction contained 3((8)-MPA)-10((8)-MTPA)-pateamine major 
fragment (51) in 50% yield (1.6 mg). 1H NMR 8H: 7.67 (m, 2H, phenyl), 7.33 
(m, 3H, phenyl), 7.14 (d, 1 H, J=9.2 Hz, NH), 6.86 (s, 1 H, H7), 6.29 (d, 1 H, 
J=14.2 Hz, H1 0), 6.27 (s, 1 H, H13), 6.27 (s, 1 H, H14), 5.62 (m, 1 H, H16), 
5.54 (d, 1 H, J=9.3 Hz, H11 ), 4.57 (s, 1 H, MPA-H), 4.05 (m, 1 H, H3), 3.72 (d, 
2H, J=7.7 Hz, H17), 3.58 (s, 3H, MTPA-OCHs), 3.54 (s, 3H, ester-OCHs), 
3.41 (dd, 1 H, J=14.4, 5.0 Hz, H9a), 3.34 (s, 3H, MPA-OC.!:!s), 3.23 (dd, 1 H, 
J=14.4, 5.0 Hz, H9b), 2.94 (m, 1 H, HS), 2.69 (s, 3H, H29), 2.69 (s, 3H, H30), 
2.42 (d, 2H, J=5.5 Hz, H2), 2.40 (d, 2H, J=4.0 Hz, H4), 1.86 (s, 3H, H28), 
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1.83 (s, 3H, H27), 1.26 (d, 3H, J=7.5 Hz, H26) ppm; HRFABMS MH+ 
800.3545 (C42H5sFsNs07S calc. 800.3556). 
3( ( S)-MPA)-1 0( (R)-MTPA)-pateamine Major Fragment (50) 
3((S)-MPA)-pateamine major fragment (49) (5.7 mg) was reacted with (S)-
MTPACI in pyridine and chromatographed in an identical manner to that 
previously described to give 3((S)-MPA)-10((R)-MTPA)-pateamine major 
fragment (50). 1 H NMR ()H: 7.68 (m, 2H, phenyl), 7.33 (m, 3H, phenyl), 6.90 
(s, 1 H, H7), 6.28 (m, 1 H, H1 0), 5.39 (d, 1 H, J=9.6 Hz, H11 ), 4.05 (m, 1 H, 
H3), 3.45 (dd, 1H, J=15.2, 7.3 Hz, H9a), 3.26 (dd, 1H, J=15.2, 5.9 Hz, H9b), 
2.96 (m, 1 H, H5), 2.69 (s, 3H, H29), 2.69 (s, 3H, H30), 1.90 (m, 2H, H4), 1.26 
(s, 3H, H26) ppm. 
Attempt at Crystallisation of Pateamine (3) with ZnCI2 
Pateamine (3) (1 0 mg) was dissolved in MeOH (0.5 mL). ZnCI2 (9.8 mg) 
was dissolved in MeOH (1 0 mL), and c. HCI added until the pH was 
approximately 5. The vial was covered with a plastic film and stored at room 
temperature in the dark for 5 days. After this time, some solution was 
removed (5 mL) and placed in another vial without any cover, and the original 
vial was resealed with a perforated plastic film. After 1 month, both solutions 
had dried to a brown gum which showed no crystalline character, and 
attempts made to recover the pateamine (3) were unsuccessful. 
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Attempt at Crystallisation of Pateamine (3) with NaPF6 
Pateamine (3) (1 0 mg) was dissolved in MeOH (5 mL). NaPF6 (12 mg) was 
dissolved in MeOH (5 mL), and TFA added until the pH was approximately 5. 
The vial was covered with a plastic film and stored at room temperature in 
the dark for 5 days. After this time, an aliquot of solution was removed (5 
mL) and placed in another vial without any cover, and the original vial was 
resealed with a perforated plastic film. After 1 month, both solutions had 
dried to a brown gum which showed no crystalline character, and attempts 
made to recover the pateamine (3) were unsuccessful. 
3(N-Acetyl)-pateamine (52) 
Pateamine (3) (1 0.0 mg) was reacted with acetic acid (1.3 mg), HOB! and 
DCC, as previously described with the MPA enantiomers, to give 3(N-acetyl)-
pateamine (52) (4.8 mg) in 45 %yield. 1 H NMR OH: 7.05 (d, 1 H, 1 H, J=11.5 
Hz, H21 ), 6.76 (t, 1 H, J=11.5 Hz, H20), 6.38 (s, 1 H, H7), 6.38 (s, 1 H, H13), 
6.38 (s, 1H, H14), 6.22 (m, 1H, H10), 5.66 (t, 1H, J=7.7 Hz, H16), 5.65 (d, 
1 H, J=8.2 Hz, H11 ), 5.54 (d, 1 H, J=11.1 Hz, H19), 5.10 (m, 1 H, H24), 3.80 
(d, 2H, J=7.6 Hz, H17), 3.72 (m, 1H, H3), 3.20 (d, 2H, J=6.6 Hz, H9), 3.03 
(m, 1 H, H5), 2.79 (s, 3H, H29), 2.79 (s, 3H, H30), 1.99 (s, 3H, H27), 1.91 (s, 
3H, N-acetyl), 1.89 (s, 3H, H28), 1.85 (s, 3H, H31 ), 1.26 (d, 3H, J=7.1 Hz, 
H26), 1.24 (d, 3H, J=6.4 Hz, H25) ppm; HRFABMS (Lewis Pannell, NIDDK, 
NIH, U.S.A.) MH+ 598.3306 (CssH4sNs05S calc. 598.3314). 
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Attempted Methanolysis of 3(N-Acetyl)-pateamine (52) 
3( N-Acetyl)-pateamine (52) was reacted with NaOMe/MeOH in an identical 
manner to 3((S)-MPA)-pateamine, as previously described, except for the 
method of attempted isolation. The methanolysis was quenched by addition 
of 25 ml of H20 and 10 ~L TFA. The organic material was then trapped on 
a C18 cartridge and washed with 10 ml of H20. The trapped material was 
eluted with MeOH (3 ml) to give a complex reaction mixture (by 1 H NMR). 
Further chromatography on a CBA cartridge yielded no 3(N-acetyl)-
pateamine major fragment (53) or starting material. 
3(N-p-bromobenzoyl)-pateamine (54) 
Pateamine (3) (2.2 mg) was reacted with p-bromobenzoic acid (p-BBA) (0.9 
mg), HOBT and DCC, as previously described, with the MPA enantiomers to 
give 3(N-p-BBA)-pateamine (54) (0.6 mg) in 21 %yield. 1H NMR OH: 7.61 (d, 
3H, J=8.6 Hz, phenyl), 7.54 (d, 2H, J=8.6 Hz, phenyl), 7.05 (d, 1 H, J=11.5 
Hz, H21 ), 6.84 (s, 1 H, H7), 6.71 (t, 1 H, J=11.5 Hz, H20), 6.39 (d, 1 H, J=16 
Hz, H13), 6.30 (d, 1 H, J=6 Hz, NH), 6.27 (d, 1 H, J=16 Hz, H14), 6.20 (m, 1 H, 
H1 0), 5.68 (t, 1 H, J=7.2 Hz, H16), 5.57 (d, 1 H, J=8.7 Hz, H11), 5.54 (d, 1 H, 
J=11.5 Hz, H19), 5.05 (m, 1 H, H24), 3.89 (m, 1 H, H3), 3.33 (d, 1 H, J=7.5 Hz, 
H17), 3.19 (d, 1H, J=5.6 Hz, H9), 3.03 (m, 1H, H5), 2.61 (dd, 1H, J=10.5, 
15.6 Hz, H2a), 2.43 (s, 3H, H29), 2.43 (s, 3H, H30), 2.41 (d, 1 H, J=12.7 Hz, 
H2b), 2.29 (dd, 1H, J=10.5, 17Hz, H23a), 2.11 (d, 1H, J=14 Hz, H23b), 2.09 
(m, 2H, H4), 1.97 (s, 3H, H27), 1.83 (s, 3H, H28), 1.79 (s, 3H, H31 ), 1.28 (d, 
3H, J=7 Hz, H26), 1.16 (d, 3H, J=6.3 Hz, H25) ppm; HRFABMS MH+ 
738.2582 (C3sH49N305SBr calc. 738.2576). 
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Extraction of Aplysia parvula (92K11-04) 
Isolation of Thyrsiferol (70} 
150 
Thirty nine Aplysia parvula (300 g wet weight) were washed in acetone (500 
ml) and allowed to drain. The purple fluid exuded by the animals after 
capture was assayed (<97.5 ng/ml) then passed down a C18 cartridge to 
trap any organic material. The activity was found solely in the H20 wash of 
the C18 column (262 mg, <97.5 ng/ml) and none in the C18-trapped 
material (7.7 mg, >12500 ng/ml). Due to the lack of organic soluble activity, 
attention was focused on the bodies and excised digestive glands. 
The digestive glands were excised (200 g) from the bodies (1 00 g) and the 
latter were extracted with MeOH and CH2CI2. The solvents were removed in 
vacuo to yield a yellow gum (7.8 g, 79621 ng/ml, slight antimicrobial activity). 
The gum was dissolved in MeOH and CH2CI2, and coated onto Celite. The 
coated Celite was dry-packed onto a C18 reverse-phase column. Eleven 
fractions were collected from the column, which was eluted with a stepped 
gradient from 20:80 MeOH/H20 through MeOH to CH2CI2. The slight 
antimicrobial activity was contained in fractions 3 to 6, but no P388 activity 
was observed. 
The excised digestive glands were homogenised in H20 (1 00 ml) with a 
Virtis (super 30, Gardner) and filtered through Celite (50 g). The mat was 
washed with H20 (2 x 250 ml), MeOH (2 x 100 ml), and then CH2CI2 (2 x 
100 ml). The MeOH and CH2CI2 extracts were combined. The solvents 
were removed in vacuo to yield a brown friable powder (1 0.8 g) and a yellow 
gum (2.17 g) respectively. Activity was found solely in the combined 
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MeOH/CH2CI2 extract (1 0.8 g, 79621 ng/ml in the P388 assay, some 
antimicrobial activity against B. sub, C. alb and C. res). 
The organic-soluble material was chromatographed on a reverse-phase C18 
column (25 mm x 300 mm, 1 00 g) equilibrated to 20:80 MeOH/H20. The 
organic-soluble material was dissolved in MeOH/CH2CI2, coated onto Celite 
(5 g) and then dry packed onto the column. Nine fractions were collected 
from the column, which was eluted with a stepped gradient from 20:80 
MeOH/H20 to 5:95 MeOH/CH2CI2. 
The most active fraction (F6, 1 0:90 H20/MeOH, 16146 ng/mL, 450 mg) was 
dissolved in benzene (1 ml) and loaded onto a DIOL column (18 mm x 200 
mm, 10 g). Twelve fractions were collected from the column, which was 
eluted with a stepped gradient from 30:70 benzene/hexane through CH2CI2 
to 20:80 MeOH/CH2CI2. Analysis of the fractions by 1 H NMR revealed 
thyrsiferol (70) in fractions F8, CH2CI2, 40.1 mg; F9, 1:99 MeOH/CH2CI2, 
27.8 mg; F11, 10:90, MeOH/CH2CI2, 43.1 mg) were combined (111 mg) and 
re-chromatographed on the same DIOL column. Ten fractions were 
collected from the column, which was eluted using a gradient elution from 
hexane through CH2CI2 to EtOAc. Fraction 6 (90:10 CH2CI2/hexane) gave 
pure thyrsiferol (70) (16.7 mg) 1 H NMR 3H: 3.89 (dd, 1 H, J=4, 12 Hz, H3), 
3.76 (dd, 1 H, J=6, 9 Hz, H22), 3.69 (m, 1 H, H14), 3.56 (dd, 1 H, J=7, 11 Hz, 
H11 ), 3.44 (dd, 1 H, J=2, 10 Hz, H18), 3.04 (dd, 1 H, J=3, 9 Hz, H7), 2.24 (dq, 
1 H, J=4, 13, 13, 13 Hz, H4R), 2.07 (m, 1 H, H4s), 2.07 (m, 1 H, H20s), 1.87 
(m, 1 H, H12s), 1.82 (m, 1 H, H13s), 1.81 (m, 1 H, H16a), 1.81 (m, 2H, 
H21 R&s), 1.78 (m, 1 H, H5s), 1.76 (m, 1 H, H9R), 1.71 (m, 1 H, H8R), 1.67 (m, 
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1 H, H13R), 1.57 (m, 1 H, H20R), 1.55 (m, 1 H, H17a), 1.51 (m, 1 H, H5R), 1.51 
(m, 1 H, H9s), 1.47 (m, 1 H, H12R), 1.46 (m, 1 H, H17b), 1.40 (m, 1 H, H8s), 
1.39 (s, 3H, CHs-1), 1.37 (m, 1 H, H16b), 1.26 (s, 3H, CHs-25), 1.20 (s, 3H, 
CHs-30), 1.19 (s, 3H, CHs-26), 1.17 (s, 3H, CHs-27), 1.15 (s, 3H, CHs-29), 
1.12 (s, 3H, CH3-24), 1.09 (s, 3H, CH3-28) ppm; 13C NMR oc: 87.4 (C22), 
86.5 (C7), 86.01 (C19), 77.6 (C18), 76.3 (C11 ), 76.1 (C14), 74.9 (C2), 74.3 
(C6), 73.2 (C15), 71.9 (C1 0), 58.9 (C3), 38.5 (C9), 37.0 (C5), 33.5 (C16), 
32.3 (C20), 31.0 (C25), 28.2 (C4), 27.2 (C30), 26.6 (C21), 25.4 (C17), 23.7 
(C1 ), 23.4 (C29), 23.0 (C8), 22.8 (C28), 21.4 (C27), 21.1 (C12), 20.7 (C13), 
20.0 (C26) ppm. Thyrsiferol (70) returned an IC50 value of 1222 ng/ml in the 
P388 assay. 
GCMS Analysis of Digestive Glands 
The organic fraction of the extraction of the digestive glands was analysed by 
GCMS (Carlo-Erba/Kratos, MSC500 HRGC, injector; 260°C) using a 30 m x 
0.25 mm DB-1 column (J&W, 0.25 ~m film, 50°C initial column temperature, 
held for 1 minute, then SOC minute-1 to 250°C), with He as the carrier gas. 
Eleven peaks were visible in the total ion count chromatographic trace. The 
mass spectra of these peaks revealed that the compounds present were C-
12 mono-, and C14 di-unsaturated hydrocarbons, and a series of C-13, C-15, 
C-17, and C-19 fatty acid methyl esters with various methyl substitution 
patterns. 
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Extraction of Egg Masses 
Approximately 50 A. parvula were collected from April to June 1996. These 
were placed into a 200 litre tank with several kilograms of fresh Laurencia 
thyrsifera. Fresh sea water was run through the tank continuously. Every 
two weeks the tank was searched for egg masses, which were removed and 
stored at -18°C until required. Newly found wild Aplysia were added after the 
tank was cleaned and fresh algae added. At the end of June no wild L. 
thyrsifera could be found, and the A. parvula were kept until all had starved, 
by which time 260 g of egg masses had been collected. The frozen eggs 
were steeped in MeOH (600 mL) until thawed, then sonicated for 30 minutes. 
The eggs and solution were homogenised in a Waring blender, and the 
resultant homogenate filtered through Celite. The mat was rehomogenised 
with CH2CI2 in the Waring blender and refiltered. All extracts were combined 
and the solvent removed in vacuo to yield an orange viscous oil (12.5 g). 
The extract was taken up in CH2CI2 and MeOH, and dried onto Celite, then 
packed onto a C18 reverse-phase column (28 mm x 400 mm, 100 g) 
equilibrated to 80:20 H20/MeOH. Eleven factions were collected from the 
column, which was eluted with a gradient from H20/MeOH (80:20) to MeOH 
(F1, 80:20 H20/MeOH, 7.6 g; F2, 80:20 H20/MeOH, 2.9 g; F3, 50:50 
H20/MeOH, 75.4 mg; F4, 40:60 H20/MeOH, 16.6 mg; F5, 30:70 H20/MeOH, 
43.9 mg; F6, 20:80 H20/MeOH, 45.9 mg; F7, 10:90 H20/MeOH, 67.6 mg; 
F8, 5:95 H20/MeOH, 78 mg; F9, MeOH, 178.5 mg; F1 0, 5:95 CH2CI2/MeOH, 
137.7 mg), then stripped with CH2CI2 and MeOH (605 mg). Fractions 3-5 
showed strong antiviral activity (Herpes simplex type 1 virus (ATCC VR 733} 
and Polio virus type 1 (Pfiser vaccine strain)) and some antimicrobial activity 
(against Bacillus subtilis and three species of fungi). 
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Comparison by TLC of the fractions from the C18 column with a genuine 
sample of thyrsiferol (70) revealed that fraction 3 had material at a similar Rt 
(Rt ""'0.4, silica, 95:5 CH2CI2/MeOH). Fraction 3 (75.4 mg) was partitioned 
between CH2CI2 (1 ml) and H20 (2 ml), and the solvents removed in vacuo 
to yield a yellow oil (4 mg). 1 H NMR analysis revealed no thyrsiferol (70) in 
the organic phase. 
The remaining active fractions (52.9 mg) were combined and dissolved in 
petroleum ether (500 j..tl) and MeOH (one drop) and loaded onto a DIOL 
column (1 0 mm x 140 mm, 10 g). Nine fractions were collected from the 
column, which was eluted with a stepped gradient from pet ether through 
EtOAc and CH2CI2 to MeOH (F3, 50:50 pet ether/CH2CI2, 0.4 mg; F4, 70:30 
pet ether/CH2CI2, 3.1 mg; F5, 90:10 pet ether/CH2CI2, 1.8 mg; F6, CH2CI2, 
1.4 mg; F7, 20:80 EtOAc/CH2CI2, 2.1 mg; F8, 50:50 EtOAc/CH2CI2, 2.2 mg; 
F9, MeOH, 25.9 mg). 1 H NMR analysis of fractions 4-9 from this column 
overwhelmingly displayed the characteristic signals for triglycerides. 
Fractions 3-9 all had antimicrobial activity suggesting that the active 
compound was at a very low level. The minute masses of the material 
remaining after the fractions were assayed precluded further work in this 
area. 
1 H NMR analysis of all fractions from all columns showed no thyrsiferol (70) 
was present in any sample. 
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GCMS Analysis of Selected Fractions 
Selected fractions from the extraction of the egg masses were analysed by 
GCMS (Carlo-Erba/Kratos, MSC500 HRGC, injector; 260.C) using a 30 m x 
0.25 mm DB-1 column (J&W, 0.25 J.Lm film, 5o·c initial column temperature, 
held for 1 minute, then 5·c minute-1 to 250.C), with He as the carrier gas. 
No chromatographic peaks of any fraction displayed any bromine isotopic 
splitting patterns in the mass spectrum. 
Culturing of Microorganisms 
Fresh Aplysia egg masses were located and removed from the substrate with 
sterile tweezers. The egg masses were then rinsed in sterile sea water and 
wiped over three sterile salt water agar plates (16.5 g 'Bacto' agar, 0.5 g 
peptone, 0.5 g yeast extract, 750 ml filtered sea water, mixed then 
autoclaved for 15 minutes at 121 ·c). The egg masses were then 
homogenised with a sterile tissue grinder and a drop of the homogenate 
thinly spread over three more salt water agar plates. The microorganisms 
were cultured until sizeable colonies formed, then restreaked over fresh 
plates. This process was carried out until the colonies were a monoculture. 
Nine distinct species were isolated. The isolated colonies were bulked up on 
several agar plates until approximately 200 J.LL of microorganisms were 
collected. These were diluted with MeOH (200 J.LL), then placed into small 
vials (1 ml) and sonicated for 10 minutes. The resultant solution was filtered 
through a syringe filter (AIItech, 0.22 J.Lm) prior to mixing with P388 (murine 
leukaemia) cells in a standard assay. Four colonies of interest, i.e. those in 
which the P388 cells metabolized the MTT stain to a level less than 5 % of 
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the controls, were cultured on slants and forwarded to PharmaMar (Spain) 
and the Abbott Chemical Company (U.S.A.) for further study. Initial testing at 
both these establishments revealed no samples were deemed, by these 
companies requirements, to warrant further work. 
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Appendices 
Appendix I - Summary of Assays 
' Marine Chemistry Group University of Canterbury 
Summary of assays currently in use. 
THE ANTIMICROBIAL ASSAYS. 
Bacteria or fungi at a known concentration are mixed with Mueller Hinton or Potato 
dextrose agar and poured into petri dishes so that after incubation a 'lawn' of 
bacteria/fungi will grow over the dish 
Samples of interest are pipetted onto 6 millimetre diameter filter paper disks and their 
solvents evaporated. 
These are then placed onto the above prepared seeded agar dishes (with appropriate 
solvent and positive controls) and incubated. 
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If the samples show any activity against the bacteria/fungi (i.e. are antimicrobial) there 
will be zones of inhibition outside the disk. This is measured in millimetres as the radius 
of inhibition and is recorded for each bacteria/fungi. A"-" in the column means no 
inhibition (antimicrobial activity) was detected for that bacteria/fungi. 
The six organisms we currently test against are: 
Bacteria-Escherichia coli (G-ve), Bacillus subtilis (G+ve), Pseudomonas aeruginosa 
(G-ve). 
Fungi-Candida albicans, Trichophyton mentagrophytes, Cladosporium resinae. 
B. subtilis and T. mentagrophytes are our most sensitive organisms. 
THE ANTIVIRAL ASSAY 
Samples of interest are pipetted onto 6 millimetre diameter filter paper disks and their 
solvents evaporated. 
These are then placed directly onto BSC-1 cells (African Green Monkey kidney), infected 
with either Herpes simplex type 1 virus (ATCC VR 733) or Polio virus type 1 (Pfiser 
vaccine strain), then incubated. 
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Assays are examined after 24 hours, using an inverted microscope, for the size of 
antiviral (ie viral inhibition) and or cytotoxic zones, and the type of cytotoxicity. 
The following scale is used for the antiviral (HSV and PV) and cytotoxicity (zone, Hcyt 
and Pcyt) results for Herpes simplex type 1 virus or Polio virus type 1 respectively. eg 
HSV,? (Unknown due to cytotoxicity); Hcyt 3+ (1 0, 4 (type)); PV1, ?; Pcyt, 4+, (4). 
? Unknown antiviral activity due to cytotoxicity 
ND no discernible antiviral or cytotoxic effects 
+- minor effects located under the disc 
+ antiviral or cytotoxic zone 1-2 mm excess radius from the disc (25 % zone) 
2+ antiviral or cytotoxic zone 2-4 mm excess radius from the disc (50% zone) 
3+ antiviral or cytotoxic zone 4-6 mm excess radius from the disc (75% zone) 
4+ antiviral or cytotoxic zone over the whole well (1 00% zone) 
As you can imagine, sometimes it is very difficult to interpret the results when both 
cytotoxicity and viral effects are present in the same test well in which case a "?" is 
noted. 
THE ANTITUMOUR ASSAY (P388) 
The antitumour assay is our most sensitive assay for cytotoxicity, being up to 100 times 
more sensitive than the BSC-1 cells used in the antiviral assay. 
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For the antitumour assay a 2 fold dilution series of the sample of interest is incubated for 
72 hours with P388 (Murine Leukaemia) cells. The concentration of sample required to 
reduce the P388 cell growth by 50% (comparative to control cells) is determined using 
the absorbance values obtained when the yellow dye MTT tetrazolium is reduced by 
healthy cells to the purple colour MTT formazan. 
The result is expressed as an 1c50, in ng/mL if a sample concentration has been supplied 
or as dilution factor 
(*1 o-6) if a sample concentration has not been supplied. Results containing a < or> sign 
indicate the result is off scale and the sample needs to be retested at a lower or higher 
concentration. 
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SAMPLES FOR ASSAY 
Please supply samples well labelled, in screw capped vials, either dried or in solution, 
with weights or concentrations listed, with solvents soluble in or the solvent used listed. 
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Marine samples are normally tested at 2 mg/mL, whereas some plant extracts need to be 
tested at 1 00 mg/mL. 
A few samples may need to be tried to find the appropriate levels to test at. 
Antimicrobial assays require a minimum of 360 J!L for testing against all 6 organisms, 
antiviral assays require 80 J!L, and antitumour assays require 40 f.!L 
Therefore a minimum of 500 ~-tL at the preferred concentration is required for testing in 
all our assays. 
1 mL or equivalent weight would be preferable to allow extra sample if assays need to be 
repeated etc. 
For more information or to send samples please contact me. 
G. Barns 
Chemistry Department 
University of Canterbury 
Private Bag 
Christchurch 1 
New Zealand 
Phone: (03) 3667001 ext 7 416 
Fax: (03) 3642110 
March 92, Gill Barns 
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PROTOCOLS 
for 
CHEMICAL SCREENING 
MHGMunro 
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Currently on leave from the University of Canterbury at the Laboratory for Drug 
Discovery, Research and Development (LDDRD), NCI, Frederick MD, USA. 
PREAMBLE 
Just as certain criteria have to be met before an extract is judged active in the initial 
screening, those same extracts should, in turn, be critically examined from a 
chemical perspective before selection for further study. Chemical screening is the 
chemical equivalent of biological screening and describes the process by which the 
physical, chromatographic and stability properties of an extract can be assessed. 
Chemical screening (CS) has been used routinely and very successfully for the 
dereplication of aqueous extracts. 37 Every effort should be made to keep procedures 
as simple as possible 
INTRODUCTION 
The POLARITY, CHARGE and SIZE of an active component in an extract can be 
explored by selecting sorbent phases such as C18 or DIOL, CBA or PEI and LH-20 
or G-25. Depending on the choice these phases can be used with organic extracts, or 
with71if the selection used was Cl8, CBA and LH-20 then it would be possible to 
dispense directly from a solution of the crude extract in methanoL This avoids 
coating of the crude extract onto Celite with a considerable saving of time. In a 
similar vein, use of C18, CBA or PEl and G-25 could be used directly with aqueous 
solutions. 
GENERAL PROCEDURE 
I. Organic Samples 
Preparation of Primary Standard 
About 50 mg of extract are weighed out precisely and made up to 1000 J.LL in 
methanol. Withdraw 200 J.LL as the primary standard. 
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Preparation of Cartridges 
Each cartridge needs to be pre-equilibrated with an appropriate solvent. For C18 and 
CBA this is by first passing 3 column volumes (3 mL) of methanol through the 
cartridge followed by 10 mL of the initial eluting solvent (see below). This 
preparation can be done under vacuum using the "Vac-Elut" system, but do not 
allow the cartridges to dry out. The size separation cartridges contain LH-20 and are 
prepared by adding 1.5 g of LH-20 to a blank cartridge, adding 4 mL of methanol, 
capping and shaking for a minute of two. A frit can be inserted under the liquid and 
pushed into place on top of the column with a glass rod. Do not trap air under the 
frit. Allow to drain under gravity into a vial. Wash with at least another 5 mL of 
methanol. Do not let the gel permeation cartridges dry out once prepared. 
Loading of Cartridges 
1. Carefully pipette 200 J..LL of the prepared solution on to the frits of the 
prepared LH-20 cartridge. Allow the solvent to drain under gravity for the 
LH-20 into the vial for the first fraction from that cartridge. 
2. For the C18 first add the 200 J..LL of water followed by a "dollop" (~50 mg) of 
Celite and the 200 J..LL of the solution. Allow the solvent to drain under 
gravity into the vial for the first fraction. 
3. For CBA add 200 J..LL of the solution followed rapidly by 80 J..LL of 0.05 M 
ammonium acetate. Allow the mixture to drain under gravity into the vial for 
the first fraction. 
Elution of Cartridges 
Add 3 mLs of the initial eluting solvent (see below) for the C18 and CBA cartridges 
and pull the solvent gently through the cartridge into fresh 7.4 mL vials in the "Vac-
Elut". Allow the vacuum to pull the last solvent off the cartridge, but do not allow 
the cartridge to dry out. Repeat with each of the required solvent systems (see 
below) using fresh vials for each solvent change. As ion-exchange cartridges do not 
equilibrate as rapidly as the other types the slow passage of solvent is essential. 
Vo in the LH-20 size separation cartridge is about 2 mL. When adding the solvent, 
especially if you do not have a frit in place, try not to disturb the surface of the LH-
20. Collect the first sample starting from the addition of the 200 J..LL aliquot to the 
top of the column. Collect 3.3 mL. (The best method is to add the sample, allow it 
to go on to the column, gently wash it on with 2 x 200 J..LL of methanol and then add 
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the balance of the methanol for the first fraction (2.7 mL)). The second fraction is 
1.0 mL and the third is 4 mL. Even at this point there may still be colour (material?) 
eluting off the column. Collect a 4th fraction of 4 mL if necessary. Collect all 
fractions under gravity, not vacuum. 
Solvent Systems 
C18: 1:1 methanol/water, methanol, 1:1 CH2Ch/methanol. 
CBA: 
LH-20: 
4:1 methanol/ aqueous 0.05M ammonium acetate, 4:1 methanol/ 2% 
aqueous ammonia, 4:1 methanol/ aqueous 0.05% TFA. 
methanol. 
Alternative Phases 
Alternative, or additional cartridges that could be used are DIOL and Amino. For 
the DIOL cartridge the system is activated with CH2Cl2 and eluted with CH2Cb, 
ethyl acetate and methanoL For the amino or PEl column activate with methanol as 
for CBA. Use the same initial solvent (4:1 methanol/ aqueous O.OSM ammonium 
acetate) and simply reverse the elution order of the ammonia and TF A containing 
solvent systems. 
Removal of Solvents 
Fractions can be evaporated to dryness under a stream of N2, on a rotary evaporator, 
or, if available, on a vacuum concentrator (preferable). Note it is desirable to 
neutralise the methanolic 0.1% TF A solution by the addition of an aliquot of the 
methanolic 2% ammonia solution BEFORE concentration. 
Preparation for Analysis 
Each fraction is dissolved in 200 J.LL of methanol and assayed along with the primary 
standard. Suggested solvents are: Cl8/1; CBA/1; CBN2; CBN3 and LH-20/1 in 
70% MeOH/water: C18/2; C18/3; LH-20/2 and LH-20/3 in MeOH. Store balance 
of fractions for subsequent analysis (see below). 
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Analysis of Results 
At the LDDRD laboratory at the NCI a protocol has been developed for testing of 
CS fractions for anti-HIV activity. In this assay 2 J.LL of each fraction is submitted 
along with the standard in a "Sarstedt" vial. The 9 fractions and the primary 
standard are assayed on 1 plate over a 7 x 1:2 dilution range following an initial 
1:200 dilution. This gives a top concentration of 250 J.Lg/J.LL for the primary 
standard and as each sample has been made back up to 200 J.LL the "equivalent" 
concentration is used for each of the fractions. Dilutions are made directly into the 
submission vial. The results are scored by the assay lab by visual observation after a 
6 day incubation and cytopathic effects as well as protection are noted using a++,+ 
scoring system. 
Alternatively, each CS fraction could be analysed in the regular 2-dmgs/plate assay. 
If this option is used then for each fraction that offers protection in the anti-HN 
screen (ECso was reached) record a +ve result. For those fractions where there was 
protection, but the ECso was not reached, the result could be recorded as+-. For no 
protection note a -ve result. 
Calculation of the recovery of activity in each fraction could be as follows: 
% Recovery in fraction X = 100 x ECso for primary standard 
ECso for fraction X 
At the University of Canterbury, each fraction is submitted to the P388 (murine 
leukaemia) assay as outlined in Appendix I. 
II. Aqueous Chemical Screening 
The following procedure is additional to the initial aqueous chemical screening 
carried out by LDDRD in the dereplication of aqueous extracts.37 The initial 
procedure uses C18, a wide-pore C4 and G-25 to explore POLARITY and SIZE. The 
following procedure repeats the C18 chromatography and explores CHARGE by using 
CBA and NH2 phases. 
Preparation of Primary Standard 
About 50 mg of extract are weighed out precisely and made up to 1,000 J.LL in water. 
Withdraw 200 J.LL as the primary standard. 
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Preparation of Cartridges 
Each cartridge needs to be pre-equilibrated with an appropriate solvent. For C18, 
CBA and NH2 this is done by first passing 3 column volumes (3 mL) of methanol 
through the cartridge followed by 10 mL of the initial eluting solvent (see below). 
This preparation can be done under vacuum using the "Vac-Elut" system, but do not 
allow the cartridges to dry out. 
Loading of Cartridges 
1. For the C18 first add 200 ML of the solution. Allow the solvent to drain under 
gravity into the vial for the first fraction. 
2. For both CBA and NH2 add 200 f.LL of the solution followed rapidly by 80 f.LL 
of 0.05 M ammonium acetate. Allow the mixture to drain under gravity into 
the vial for the first fraction. 
Elution of Cartridges 
Add 3 mLs of the initial eluting solvent (see below) for the C18 (aq.), CBA and NH2 
cartridges and EITHER let the solvent drain through under gravity OR pull the 
solvent gently through the cartridge into fresh 7.4 mL vials in the "Vac-Elut". Allow 
the vacuum to pull the last solvent off the cartridge, but do not allow the cartridge to 
dry out. Repeat with each of the required solvent systems (see below) using fresh 
vials for each solvent change. As ion-exchange cartridges do not equilibrate as 
rapidly as the other types the slow passage of solvent is essential. 
Solvent Systems 
C18: water, 1:1 water/methanol, methanol. 
CBA: 0.05M ammonium acetate, 2% aqueous ammonia, 1:1 methanol/.05% 
aqueous TF A. 
0.05M ammonium acetate, aqueous 0.05% TFA, 1:1 methanol/.05% 
aqueous TF A. 
Alternative Phases 
Alternative, or additional cartridges that could be used are PEL Activate with 
methanol as for NH2. Use the same initial solvent and use the same solvents as for 
NH2. 
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Removal of Solvents 
Fractions can be evaporated to dryness under a stream of N 2, by freeze-drying, on a 
rotary evaporator or if available on a vacuum concentrator (preferable). Note it is 
desirable to neutralise the methanolic 0.1% TFA solution by the addition of an 
aliquot of the methanolic 2% ammonia solution BEFORE concentration. 
Preparation for Analysis 
Each fraction is re-dissolved in 200 J.LL of an appropriate solvent and assayed along 
with the primary standard. Suggested solvents are: C18/1, CBN1, and NH2/1 in 
water; C18/2, C18/3, NH2/2, NH2/3, CBA/2 and CBN3 in MeOH:water (1:1). 
Store balance of fractions for other, subsequent analyses. Each fraction and the 
primary standard are submitted as a 200 J.LL solution in a "Sarstadt" vial and assayed 
as noted for the organic protocol. 
Analysis of Results 
As for Organic Chemical Screening. 
Interpretation of Results 
The bioactivity data from chemical screening is most conveniently displayed as a 
matrix. For example: 
C18 CBA LH-20 
I + 
II + + 
III 
This profile established that the bioactivity was retained during chromatography and 
processing. Furthermore, the bioactive component(s) were cationic (retained on 
CBA, fraction II), of medium polarity (eluted off C18 in fraction II) and with MW 
>750 (fraction I off LH-20). This profile immediately indicates the best methods to 
approach isolation work on this extract as well as giving an insight into the chemical 
properties of the bioactive compound. 
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As a dereplication tool this combination of techniques is simple and relatively quick. 
Although it is ideally suited to compounds with distinctive chromophores, it can still 
be applied to situations where end-absorption only is observed. 
An example is given below and is based on the bioactive sponge Lamellonwrpha 
strongylata, worked on at the University of Canterbury. The plots shown are 
isoplots of the HPLC traces of the bioactive fractions from the chemical screening 
experiment on the extract from Lamellomorpha strongylata. 
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By examining the isoplots the active components (ie the components in common to 
all active fractions) can be located at around 300 and 600 seconds. The UVprofiles 
are shown as is the "normal" HPLC presentation for the active fraction of the LH-20 
cartridge. The UV profile allowed the active components to be quickly 
characterised. 
Secondary Chemical Screening 
In the first instance chemical screening establishes something of the 
chromatographic properties of a crude extract and the stability of the active(s). As 
shown above: 
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C18 CBA LH-20 
I + 
II + + 
III 
A variation on the chemical screening approach (secondary chemical screening) 
makes further use of the information given by the "matrix". The refinement is to 
passage one or more of the "active" fractions through the appropriate cartridges as 
indicated below. 
Take an ACTIVE fraction, say C18/2 and passage it through the CBA and then take 
the appropriate cut (CBN2) and passage that in turn through LH-20. 
CBA/1 
CI8/2 -------;..,.. CBA( CB~ 
~ CBA/3 
/ LH20/l 
LH20 ""' LH20/2 
"" LH20/3 
The derived fraction (LH-20/1) should be considerably "purer" and more amenable 
to HPLC analysis (see above). Further purification, to rapidly obtain small 
quantities of the active material, at a sufficient state of purity for further biological 
evaluation, is a distinct possibility. 
Once a peak in the HPLC of an extract has been identified as the likely bioactive 
compound, LC/MS can be used to garner molecular weight and molecular formula 
data. 
The emphasis at this point is NOT purification of a compound for structural 
elucidation, but purification to a sufficient state of purity to allow decisions to be 
made on the biological uniqueness of the active component. 
